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Abstract 
In general, this thesis describes the design, synthesis, oligomerization and biophysical 
studies of novel PNA monomers.  
Our initial aim was to develop an efficient and inexpensive route for the synthesis of a 
series of novel alkyne PNA monomers bearing thymine, cytosine, adenine and guanine 
nucleobases suitable for Fmoc solid phase PNA synthesis strategy. These novel 
monomers allow functionalising the PNA sequences with alkyne functions at their N-
terminus during solid phase synthesis. These novel monomers can be exploited in the 
click reaction applications such as a click ligation of PNA and conjugation of PNA with 
different substrates such as nucleic acids and proteins. As an application for ligation 
PNA sequences, the alkyne thymine PNA monomer was incorporated successfully into 
the target PNA oligomers during oligomerization.  
Mimicking the click (CuAAC) reaction linkers of the ligation of PNA oligomers, three 
novel 1,2,3-triazole functionalised building blocks were designed and prepared suitable 
for the Fmoc solid phase PNA synthesis strategy. Furthermore, synthesis of these 
building blocks specifically that is bearing thymine base represents an attempt for 
modification the original PNA oligomers in order to improve their drawbacks such as 
poor water solubility and cellular uptake or to enhance their hybridization properties. 
Our approach to synthesise these monomers is the Click (CuAAC) reaction which is not 
analogous for the routes that are used for the synthesis of the modified or unmodified 
PNA monomers. To investigate their effect on the biophysical properties of PNA 
oligomers, a single monomeric unit of these monomers was incorporated successfully 
into a series of mixed purine-pyrimidine 8-mer PNA sequences following the standard 
Fmoc-solid phase PNA synthesis conditions.  
In general, The Tm experiments-UV spectroscopy showed that the modified PNA 
oligomers containing these modified monomers still have a binding affinity with 
complementary sequences of DNA and RNA. The Tm values indicated that the 
incorporation of the 1,2,3-triazole functionalised monomers maintained or slightly 
reduced the thermal stability of the PNA/DNA duplexes, whereas the PNA/RNA 
duplexes resulted in a significantly reduced thermal stability. All of them are compared 
to the corresponding unmodified PNA/DNA duplexes. 
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1.1 Motivation
The recognition of natural oligonucleotides sequences by a complementary 
sequence is a fundamental feature in biological systems and is essential for 
hybridisation-based therapeutic and diagnostic applications.1,2,3 This principle 
underpins a possible consideration of antisense or antigene-based inhibition of gene 
expression, as a practical approach to therapeutics. The mechanism of this 
recognition depends on Watson-Crick base-pairing between the heterocyclic bases 
of the antisense oligonucleotide and their complementary nucleobases on the 
target RNA sequence to form a duplex. Or alternatively, via Hoogsteen base-pairing 
between an antigene oligonucleotide and its complementary sequence of double-
stranded DNA, allowing the third strand antigene to bind around the duplex to form 
a triplex. These two hybridization mechanisms are only possible through relatively 
weak hydrogen bond interactions, resulting in highly variable hybridisation 
efficiencies depending on the number of the nucleotides in each strand sequence. 
Currently, DNA and RNA oligonucleotides have found only limited applications in 
hybridisation based therapeutics owing to their poor permeability and low stability 
in vivo, due predominantly to the susceptibility of their phosphodiester backbone to 
undergo enzymatic cleavage by the cellular nucleases. Furthermore, they exhibit 
poor permeability into cells because they are negatively charged compounds. For 
these reasons, there is a lot of interest in the discovery and development of 
oligonucleotide analogues that have structural features which lead to improved 
pharmacological applications. Furthermore, these analogues should also have 
sufficient chemical and biological stability, and show a significant increase in the 
binding efficiency with the target oligonucleotide sequence in a high selectivity with 
lack of sequence restriction.  
Peptide nucleic acids (PNA) are one of the most successful examples of the DNA 
analogues, which have been applied as a biomolecular tool in the recognition of 
natural oligonucleotides. They, therefore, display promising potential applications 
such as antisense and antigene based therapeutics, and as such the synthesis and 
biophysical studies of PNA oligomers, are therefore, described throughout the 
remainder of this thesis.  
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However, before describing the experimental work performed it is important to 
discuss the fundamental oligonucleotides chemistry and how PNA, and other DNA 
analogues, mimic the structure and function of natural nucleic acids.   
1.2 Nucleic Acids: Chemical Structure 
Nucleic acids are biological macromolecules that store or transfer the genetic 
information for all living beings and were first described in 1869 by Friedrich 
Miescher.4,5 Subsequent studies have already revealed the fact that there are two 
nucleic acids differing in their structure and nature of their function, namely DNA 
(Deoxyribonucleic acid) and RNA (Ribonucleic acid). Structurally, nucleic acids are 
biopolymers composed of repeating monomeric units called nucleotides (Figure 
1.1). 
Figure 1.1: Nucleotide structure of DNA and RNA. 
Each nucleotide is made up of a pucker-shaped pentose sugar attached at C1 to a 
nucleobase through a β-glycosidic bond, and at C5 to a phosphate group via a 
phosphoester linkage. The most substantial difference between DNA and RNA is the 
nature of the sugar unit. DNA contains a 2-deoxyribose moiety as opposed to the 
ribose in RNA. Thus, RNA can be distinguished chemically from DNA by its greater 
instability in alkaline solutions owing to the potential for the additional hydroxyl 
group on the sugar moiety to be deprotonated then causing hydrolysis of RNA 
strand.6 Initial chemical analysis of nucleotides proved that the nucleobases that are 
attached to the sugar moiety belong either to the pyrimidine or purine families 
(Figure 1.2). Pyrimidines have a heterocyclic single-ring structure 1 to which they 
are attached at the N1-position to the sugar unit, whereas the purines are hetero 
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aromatic bicyclic compounds such as 5 which are connected to the sugar moiety at 
the N9-position.7
Figure 1.2: Structure of the common pyrimidine and purine nucleobases. 
Further, more advanced, chemical investigations have revealed another difference 
between DNA and RNA which is in the finer structure of the nucleobases. There are 
four common bases in both DNA and RNA, in DNA these are thymine (T) 2, cytosine 
(C) 3, adenine (A) 6, and guanine (G) 7, whereas, in the RNA structure, the thymine 
base is replaced with uracil base (U) 4. This difference, although subtle, is highly 
important in error checking during DNA replication. Cytosine can undergo 
spontaneous deamination to uracil which could result in an undesired mutation. 
However, because thymine is expected in DNA, not uracil, the DNA repair enzyme 
uracil-DNA glycosylase can remove these mutations and repair the sequence.8
In both DNA and RNA, the nucleotide monomers are linked by phosphodiester 
linkages, which are formed between the 5'-phosphate group of one nucleotide and 
the 3'-hydroxyl of the sugar of the next nucleotide. Consequently, the terminus of 
the formed oligonucleotide chain is carrying the free 3'-hydroxyl group called the 3'-
end while the other terminus is bearing the 5'-phosphate known as the 5'-end. 
Therefore, their sequences are conventionally depicted from the 5'-end (left hand) 
to the 3'-end (right hand). Structurally, RNA is a single-stranded polynucleotide folds 
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upon itself via intramolecular hydrogen bonding into the characteristic secondary 
and tertiary structures that are essential for the RNA molecule to perform its 
biological roles.9,10 In the folded region, most of the nucleobases are 
complementary and joined together by hydrogen bonds according to Watson-Crick 
base paring to form a helical structure. This structure helps in the stability of the 
RNA molecule. Inside living cells, RNA exists in many forms that differ in their size 
and function. The major classes of RNA in eukaryotic organisms are messenger RNA 
(mRNA) as a DNA copy, transfer RNA (tRNA) as a coupler between the genetic code 
and the protein building blocks, and ribosomal RNA (rRNA) as a structural 
component of ribosomes.  
Functionally, RNA plays a key role in the synthesis of protein by transmitting genetic 
information encoded in DNA and converting it into a variety of different proteins 
depending on the original DNA sequence. mRNA is transcribed from a DNA source 
sequence, and in turn transmits this sequence information to the ribosome, where 
it is ‘read’ in the blocks of three nucleobases known as codons. Then tRNA carries a 
specific amino acid, to the site of protein production according to the codon 
sequence. Moving along the mRNA strand, this combination of functions results in 
the production of a long chain polypeptides and protein.9,10
DNA is the genetic material existing mainly in the nucleus of the cell, but can be 
found in other cell structures of eukaryotes such as the mitochondria and freely 
moving around the cytoplasm of prokaryotes. DNA acts as a template and store of 
the genetic instructions that are used in the development, functioning and 
replication of all known living organisms (except RNA viruses). Furthermore, DNA 
controls the synthesis of RNA in the cell.  
Inside living cells, DNA almost always consists of two complementary strands of poly 
nucleotides that are twisted about one another in a spiral (Figure 1.3) to form the 
famous double-helix structure that was first described in 1953 by Watson and 
Crick.11 This helix structure gives the DNA molecule the chemical stability and the 
ability to copy the information it contains that are necessary to accomplish its 
functions, by not containing any additional sequence modifying moieties.  
Chapter One                                                                                                        Introduction  
6 
Figure 1.3: An example schematic of the helix of DNA. 
Further research into the DNA double helix led to important information about how 
the strands are held together. The two strands are antiparallel, meaning, from any 
fixed position; one strand is oriented in the 5' to 3' direction and the other in the 3' 
to 5' direction. These two strands of DNA are held together by two types of non-
covalent binding interactions including the lipophilic interactions between the 
adjacent bases and the hydrogen bonding between the complementary nucleobases 
on the opposite strand.   
In addition, it has been proven that the thymine base in one strand always pairs 
only to the adenine base in the other strand via two hydrogen bonds, and similarly, 
the cytosine base always pairs to the guanine base by three hydrogen bonds. As a 
consequent, thymine and adenine always have the same concentration, and the 
amount of cytosine is always equivalent to the amount of guanine.12 This base 
pairing is known as Watson-Crick base pairing as shown in Figure 1.4.  
Figure 1.4: Watson-Crick base pairing. 
One more feature of the double helix structure is that the two DNA strands are 
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arranged in such a way to present their sugar-phosphate backbones on the outside 
of the helix, and their bases are in the centre. This is important as the hydrophobic 
nature of the nucleobase keeps them on the inside of the double helix of DNA, away 
from water content in cells. Meanwhile, the phosphate backbone is hydrophilic and 
retains the backbone on the outside.11 Consequently, the DNA double helix is 
stabilised by the fact that the base pairs are stacked one on top of another, which 
allow for π-π stacking interactions between the heterocyclic rings.      
A careful examination of a space-filling model of a double helix of DNA reveals the 
presence of two types of grooves on its exterior surface between the deoxyribose-
phosphate chains. Due to the asymmetry of the sugar moiety and the structurally 
distinct nature of the upper surface of a base-pair relative from the bottom surface, 
these grooves are not equal in their size (Figure 1.3). Therefore, they are termed the 
major groove (ca. 12 Å wide) and the minor groove (ca. 6 Å wide).13 Practically, 
DNA-binding proteins use these grooves to interact with a specific DNA sequence 
without disrupting the base-pairing of the ds-DNA molecule.14,15 Also, the minor 
grooves contain water molecules that interact with the keto and amino groups of 
the nucleobases.16,17
Furthermore, the nucleobases have displayed another important alternative base 
pairing mechanism to Watson-Crick base paring, termed Hoogsteen base pairing 
which is used to form a triplex.18,19 In Hoogsteen base pairing, each nucleobase pairs 
with the complementary nucleobase through two hydrogen bonds. However, acid 
conditions are required for protonation of the cytosine base, enabling it to form two 
hydrogen bonds with guanine as shown in Figure 1.5.   
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Figure 1.5: Hoogsteen base pairing. 
These features of the structure of the double helix are highly important for DNA to 
achieve its biological activity which allow it to take part in a number of molecular 
interactions 20 through intercalation, electrostatic, and groove binding mechanisms 
not only with itself and other nucleic acids but also with other molecules such as 
proteins,21,22 drugs,23 metal ions,24,25 etc.  
1.2.1 Nucleic acids modifications 
DNA and RNA oligonucleotides have been used as a tool for antisense and antigene 
investigations that are helped molecular biologists to discover new gene functions 
and as a base for future gene therapy applications. However, for in vivo
applications, there are some problems such as a low biological stability against 
nucleases, cellular uptake problems and weak DNA binding affinity, which imped 
their use in certain applications. To overcome these drawbacks, many chemical 
modifications have been targeted to each of the nucleotide sections, the phosphate 
backbone, the sugar moiety or the nucleobase.  
As the negatively charged phosphodiester linkage of the backbone is readily cleaved 
by nuclease or protease action,26 a large number of modifications have been 
extensively investigated in order to improve its enzymatic stability. These 
modifications involved altering this linkage partly or wholly to produce neutral, 
anionic and cationic alternatives. The most common phosphodiester analogues are 
the phosphorothioate 8, methyl phosphonates 9, phosphoramidite 10 and 
hydroxymethyl phosphonium 11 in which one phosphate oxygen is replaced with a 
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sulphur atom, methyl, alkyl amine and hydroxymethyl groups, respectively as shown 
in Figure 1.6.26-31 
Figure 1.6: Structure of common modifications in antisense oligonucleotides. 
In RNA, several interesting modifications have been introduced by replacing the 
hydroxyl group at the position C2 of the ribose with different groups to enhance its 
chemical and nuclease stability. The most important analogues at this position are 
2’-deoxy-2’-fluorooligoribonucleotide 12, 2’-deoxy-2’-amine oligoribonucleotide 13, 
2’-O-methyl oligoribonucleotide 14 and 2’-deoxy-2’-C-alkyl oligoribonucleotide 15 as 
shown in Figure 1.6.31
In general, these sugar-phosphate modifications have been examined for antisense 
applications. Although these modifications displayed an increased resistance to the 
enzymatic degradation, some associated drawbacks has been resulted such as a 
lower RNA binding affinity and lower water solubility and lack the binding 
specifically to proteins than the natural oligonucleotides.26,30,31 Therefore, further 
improvements in the design of antisense oligonucleotides need to be made in order 
to arrive at more ideal therapeutics. 
A promising class of nucleic acid modifcations, termed locked nucleic acid (LNA) 
such as 16 (Figure 1.7), has also been introduced when the ribose sugar of RNA is 
locked through a bridging methylene group, between the C4 atom and the oxygen 
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of the hydroxyl group at C2, resulting in a bicyclic RNA analogue.32,33,34  LNA 
oligonucleotides have displayed remarkable properties such as resistance to 
enzymatic degradation, high affinity and excellent specificity toward their 
complementary DNA or RNA oligonucleotides, with increased thermal stability of 
their duplexes. These unique properties make this modification to be a promising 
drug platform for therapeutic applications based upon gene expression.35,36,37
Figure 1.7: Structure of locked nucleic acid LNA 16. 
For more investigations, one more chemically advanced modifications of nucleic 
acids was reported when the phosphodiester linkage of nucleic acids was replaced 
with a 1,2,3-triazole ring such as 17 (Figure 1.8).  
Figure 1.8: Structure of triazole modified DNA oligonucleotide 17.  
Very promising results were reported for the triazole DNA analogues when Isobe et 
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al. in particular found that a polythymidine triazole analogue showed a higher 
affinity towards polyadenosine oligonucleotides compared to the unmodified 
DNA.38
Currently, one of the most divergent modifications of nucleic acids is one that has 
wholly replaced the polyanionic sugar-phosphate backbone with a neutral 
polyamide backbone to make an oligonucleotide analogue called peptide nucleic 
acid 18 which is abbreviated PNA (Figure 1.9). 
Figure 1.9: Structure of peptide nucleic acid (PNA) 18. 
The astonishing discovery that this polyamide bearing nucleobases can bind with 
higher affinity and specificity to complementary sequences of nucleic acids obeying 
Watson-Crick base-pairing rules and has a high resistance to nucleases resulted in 
the rapid development of a new branch of research focused on diagnostic and 
therapeutic applications of this highly interesting class of compounds. Thus, the 
next section is dedicated to peptide nucleic acid (PNA). 
1.3 Peptide Nucleic Acid (PNA)
1.3.1 Structure and properties of PNA  
Peptide nucleic acid (PNA) is a single strand of nucleobases, was first introduced  by 
Nielsen and his colleagues in 199139 as a ligand to bind ds-DNA in the DNA major 
grooves to form a triplex oligonucleotide. In the PNA sequence, the natural 
negatively charged sugar-phosphate backbone of nucleic acids was replaced with a 
neutral achiral polyamide backbone. This new backbone is consisted of repeating 
units of N-(2-aminoethyl) glycine (AEG) linked together by amide bonds in a similar 
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way to that is used in polypeptides. Therefore, PNAs are also depicted with the N-
terminus at the left hand and the C-terminus at the right hand. Mimicking DNA, the 
four common nucleobases thymine 2, cytosine 3, adenine 6 and guanine 7 (Figure 
1.3) are retained and attached to the secondary amine of this backbone via a 
methylene carbonyl linkage.  
Structurally, the original N-(2-aminoethyl) glycine PNA monomer backbone was 
designed to keep the distance between the nucleobases along the PNA oligomer to 
six bonds (Blue bonds), and three bonds (Red bonds) from the nucleobase to the 
PNA backbone as shown in Figure 1.10. This maintains the same internuclear 
distances that are found in the natural oligonucleotides. 
Figure 1.10: Structure of DNA and PNA, B: Nucleobase. 
Characteristically, unlike DNA and RNA which are degraded in a depurination 
reaction, PNAs are fully resistant towards strong acids including HF and even weak 
bases such as ammonia and piperidine. For this reason, PNA oligomers can be 
prepared under these conditions.40 Furthermore, PNAs are also stable in a wide 
range of temperatures. As PNAs are achiral compounds, they are synthesised 
without requiring any stereo-selective pathway. In contrast to the nucleic acids, 
PNAs are particularly more stable in both human serum and cellular extracts as a 
result of high resistance to biological degradation by nucleases and proteases.41
Because of PNA’s neutral backbone, the electrostatic repulsion between PNA 
oligomers and the nucleic acids is reduced. Consequently, PNA sequences have a 
high binding affinity towards complementary sequences of nucleic acids with 
increased thermal stability of their complexes giving rise to different important 
applications in molecular biology. An interesting feature, PNA oligomers also display 
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a greater specificity in binding to complementary DNAs, and also have a high 
sequence selectivity resulting in the fact that a mismatch in a PNA/DNA and 
PNA/RNA duplexes is consider more destabilising than a mismatch in a DNA/DNA 
duplexes.42
On the other hand, PNA oligomers are uncharged compounds and hence have some 
drawbacks such as lower water solubility compared with DNA and RNA with 
comparable length and purine: pyrimidine ratio and poor cellular uptake. PNA 
oligomers tend to be  aggregated depending on the sequence of the oligomer,                  
G-rich oligomers being the worst.43,44
1.3.2 PNA-Nucleic acids hybridizations 
1.3.2.1 Duplex formation with complementary ss-DNA and RNA  
PNA sequences have a high affinity and sequence selectivity to bind to 
complementary sequences of single-stranded DNA or RNA obeying Watson-Crick 
base pairing.45,46 In contrast to DNA/DNA and DNA/RNA hybridisations that are 
always antiparallel, the PNA strand can hybridise to the target sequences of ss-DNA 
or RNA in both parallel and antiparallel orientations to make the corresponding 
PNA/DNA and PNA/RNA duplexes. In antiparallel hybridisations, the N-terminus of 
the PNA oligomer pairs to the 3’ end of DNA or RNA strand, and to the 5’ end in the 
case of the parallel hybridisation (Figure 1.11).  
Figure 1.11: PNA/DNA and PNA/RNA duplexes binding orientations. 
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Similar to DNA/DNA and DNA/RNA duplexes, the hybridization properties of 
PNA/DNA  and PNA/RNA can be assessed with different biophysical techniques such 
as DSC,47,48 UV,49,50 and CD 51,52 through studying the thermal melting temperature 
(Tm). The Tm is defined as a temperature at which equal amounts of base paired 
duplex and unpaired single strands are in equilibrium when the free energy change 
is zero. Interestingly, the thermal studies have demonstrated that the antiparallel 
hybridisations always show a higher stability than the corresponding parallel 
hybridisations, and PNA/RNA duplexes are always more stable than PNA/DNA 
duplexes. More importantly, all these duplexes are much more stable than the 
corresponding natural oligonucleotide duplexes.53 The hybridization experiments 
also have revealed that the Tm values depend on the length of the molecule and the 
particular nucleotide sequence.54,45
Unlike DNA/DNA or DNA/RNA duplexes that are highly dependent on the ionic 
strength, the thermal stability studies on the effect of NaCl on PNA/DNA and 
PNA/RNA duplexes practically showed no a significant effect as a result of the 
uncharged PNA backbone.55,56 This feature can be exploited when targeting DNA or 
RNA sequences involved in secondary structures, which are destabilized by low ionic 
strength. 
1.3.2.2 PNA/double-stranded DNA hybridizations 
The PNA oligomers were first designed to interact with double-stranded DNA via 
major groove recognition, through Hoogsteen hydrogen bonding to form a PNA/ds-
DNA triplex with strand displacement.39 However, it has been found that PNA 
sequence can bind the ds-DNA in a variety of important mechanisms.  
Thus, under certain circumstances, a homopyrimidine PNA strand can bind to the 
complementary strand of double-stranded DNA in the DNA major grooves without 
displacement of the second strand of DNA to form a conventional triplex formation 
of PNA/ds-DNA. In this mechanism, the PNA strand is bound to the complementary 
strand of ds-DNA through Hoogsteen hydrogen bonds, whereas the Watson-Crick 
hydrogen bonds between two strands of DNA are preserved (Figure 1.12).30,57
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Figure 1.12: PNA/ds-DNA triplex formation, dashed lines are Hoogsteen base pairs. 
The stability of the formed triplex PNA/ds-DNA is dependent on the length of PNA 
oligomers where it has been shown that the melting temperature increases with                   
1 °C per base. However, this mechanism of hybridization has only been 
demonstrated in specific cases involving a homo-pyrimidine PNA strand with high 
cytosine content. Furthermore, triplex formation only happens when the cytosine 
nucleobase can be protonated at the N3-position under acidic conditions. This 
protonation makes the cytosine nucleobase able to form a hydrogen bonding that is 
required for triplex formation, specifically with the N7-position of the guanine 
nucleobase in the target strand of double-stranded DNA.57,58
Since then it has been found that PNA binding to ds-DNA could be accomplished in 
an alternative mechanism than was described for triplex formation. This alternative 
is called strand invasion; a mechanism that involves the dissociation of ds-DNA 
locally into two exposed strands. Then one or both of DNA strands will be targeted 
by the complementary PNA sequence. This is so called invasion pathway is not 
limited to one single binding mode, however, as different modes exist such as 
triplex invasion, duplex invasion and double-duplex invasion. 
Due to the increased stability of the resulting hybrid, the triplex invasion mode is 
the most preferred than the classical PNA/ds-DNA hybridization. Triplex invasion 
occurs between two homo-pyrimidine PNA strands and ds-DNA in two steps; one 
PNA strand is hybridised to the complementary DNA strand by Watson-Crick 
hydrogen bonds, and the other PNA strand by Hoogsteen hydrogen bonds via strand 
invasion. This forms an internal PNA/DNA:PNA hybrid. The second strand of DNA, 
which is not complementary to the tow PNA strands, is displaced and left as a 
single-strand (Figure 1.13).59-62
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Figure 1.13: PNA/ds-DNA triplex invasion, dashed lines are Hoogsteen base pair. 
Since Hoogsteen hydrogen bonds formation requires a protonation of the cytosine 
nucleobase, a modified base, pseudoisocytosine (J) (Figure 1.14), that carries a 
permanent proton at the N3-position was used rather than cytosine in the PNA 
strand aimed for Hoogsteen hydrogen bond.63 This alternative greatly facilitated the 
formation of triplex by the invasion mechanism, independently of pH.62
Although the stability of the complex that formed via triplex invasion depends on 
the salt concentration and the length of the PNA oligomers, the complex is 
extremely stable once triplex invasion is complete. For this reason, binding can be 
considered irreversible under most experimental conditions. 
Figure 1.14: Hydrogen bonds in the triplex invasion. 
Another binding mode for targeting ds-DNA, is through a duplex invasion 
mechanism, this time in which only one PNA strand targets the complementary 
sequence of ds-DNA. In this mode of a strand invasion mechanism, the hybridization 
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is obeying Watson-Crick base pairing with displacement of the DNA strand non-
complementary to PNA (Figure 1.15).  
Figure 1.15:  Duplex invasion mode of PNA-dsDNA.  
In principle, this mechanism of PNA/ds-DNA hybridisation is a very attractive 
binding mode because it only relies on Watson-Crick base pairing and therefore 
should not be sequence restricted. The mechanism was first described for a single 
homopurine PNA targeted to a homopyrimidine ds-DNA sequence.64 Unfortunately, 
however this complex is typically much less stable than triplex-invasion complexes 
although these complexes can exhibit greater stability if the DNA target is negatively 
supercoiled or if the PNA employed is conjugated to a cationic peptide. 
Interestingly, PNA has displayed another binding mode for targeting ds-DNA 
through double-duplex invasion mechanism. In this hybridization mode, however, a 
double-stranded DNA can be invaded by two complementary PNA strands through 
Watson-Crick base pairing, and thus that ds-DNA is locally denatured (Figure 
1.16).65-67 This mechanism of strand invasion is very important because it overcomes 
the sequence limitations that are associated with triplex and duplex invasion 
mechanisms. However, there is a drawback with this mechanism in that, due to 
their neutral backbone, the two complementary PNA strands prefer to hybridise to 
each other rather than performing strand invasion into the ds-DNA. 
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Figure 1.16: Double duplex invasion mode of PNA/ds-DNA hybridisations. 
The only way to achieve this mode of hybridisation is by using PNA containing 
modified nucleobases, such as the 2, 6-diaminopurine (D) and 2-thiouracil (sU) bases 
in place of adenine and thymine, respectively (Figure 1.17).68,65 Hybridisation of 
these bases with each other is restricted by a steric clash between the 2-amino 
group of the 2,6-diaminopurine and the thio group of 2- thiouracil. Consequently, 
this modification will prevent or destabilise the interaction between the two PNA 
strands.  
Figure 1.17: Binding of pseudo-complementary bases. 
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1.3.3 Peptide Nucleic Acids (PNA) as antisense and antigene agents 
DNA is the carrier of all the genetic material and directs the protein synthesis 
through transcription into the messenger RNA (mRNA) which is subsequently 
translated into proteins. Thus, the gene regulation can occur on an antisense level 
through blocking the translation process of mRNA into proteins, and on an antigene 
level through preventing the transcription of DNA into mRNA.  
In general, the ability of PNA to bind with high sequence specificity to the 
complementary DNA or RNA targets has provided a new tool for studying the 
recognition of nucleic acids and gene regulation. Owing to this ability to interact 
with the high sequence specificity to a chosen target in gene sequences and their 
unique physicochemical properties, there has been significant interest in PNA for 
medicinal and biotechnological applications including therapeutics, diagnostics, and 
molecular biology. As such PNAs have successfully been used as a tool for antigene 
or antisense therapeutics strategies, based on strand invasion of double-stranded 
DNA and duplex formation of single strand RNA, respectively.69
One key process in the regulation of gene expression by duplex formation between 
the PNA antisense, used as an antisense and the complementary mRNA strand via 
Watson-Crick base pairing is shown in Figure 1.18. Ideally, this mechanism is based 
on the steric blocking of mRNA sequences thereby inhibiting translation of the 
target gene.70,71
Figure 1.18:  General scheme of PNA as antisense agent. 
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Several examples of PNA-antisense induced downregulation of gene expression 
have been reported. The mechanism of the antisense effect of conventional 
oligonucleotides is based on the activation of Ribonuclease H (RNase H) which is 
essential to cleave the RNA portion of the heteroduplex. Since a PNA/RNA duplex is 
not a substrate for RNase H, the PNA antisense effect is based on the steric blocking 
of either mRNA processing, transport into cytoplasm or translation. The efficiency of 
PNA-based gene silencing, therefore, depends on the stability of the resulting 
RNA/PNA hybrid.72,73 In addition, the inhibition of any gene can take place by two 
different mechanisms. The first mechanism of inhibition involves the mRNA/DNA 
duplex. Inside the nucleus, mRNA is synthesised according to the initial sequence of 
DNA from which it is transcribed. Then, the RNaseH enzyme moves in to remove the 
mRNA strand by degradation, which allows the complementary DNA base pairs to 
be added to this newly formed strand, thus providing a double-stranded DNA. 
However, if oligodeoxynucleotides (ODN’s) are present in the nucleus, then they will 
bind to the mRNA and prevent it from forming the new single stranded DNA. This 
type of mechanism has the advantage that a single ODN can target many mRNA, 
thus the therapeutic amount of this drug would be very small. 
As an antigene agent, PNAs can recognise and hybridise to a complementary 
sequence of double-stranded DNA in a particular gene as shown in Figure 1.19.  
Figure 1.19: General scheme of PNA as antigene agent. 
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In an antigene application, PNAs are capable of interfering and inhibiting the 
transcription process of that particular gene through the formation of a stable 
triplex complex via strand invasion or strand displacement with the double-stranded 
DNA.69 Therefore, when PNA binds to DNA to form the triplex complex, the RNA 
polymerase cannot bind DNA, and so is unable to generate mRNA which in turn 
prevents the creation of protein.74 In vivo, PNA has also displayed an ability to block 
plasmid DNA replication,75 and several studies have confirmed the ability of PNAs to 
inhibit DNA replication via a triplex structure formation. In short, the PNA2/DNA 
triplex arrests transcription in vitro and so is, therefore, capable of acting as an 
antigene-agent. 
1.3.4 Solid phase PNA synthesis 
The concept of solid phase synthesis (SPS) was developed by Merrifield in 1963 
when the first efficient production of a tetrapeptide on a solid support (matrix) was 
reported.76 Later, this concept has become a fully established protocol in the 
chemical synthesis of biologically active oligomers like peptides and nucleic acids. 
The basic point of the solid phase synthesis methodology is that building blocks 
having two functional groups are used. One of these functional groups must be
temporary protected by a protective group. Therefore, for solid phase peptide 
synthesis, PNA monomers must have a suitably protected amino group, and their 
carboxylic functions are free thereby are able to accommodate two amide bonds 
during oligomerization. A feature that defines the chemistry of the solid phase PNA 
synthesis is the temporary protecting group of the N-terminal amino group of PNA 
monomers.  
Figure 1.20 shows a general scheme of solid phase synthesis cycle of PNA oligomers 
which involves a repetitive process of temporary deprotection of the primary amino 
group of growing chains, coupling the activated PNA monomer, and then capping 
any unreacted amino function via N-acylation reaction. Commonly used is acetic 
anhydride the presence of a base.  
Chapter One                                                                                                        Introduction  
22 
Figure 1.20: General scheme of SPS cycle of PNA oligomers. 
Historically, solid phase PNA synthesis was first realised using Boc-protected AEG 
thymine PNA monomer to give a homothymine sequence.39 Later, when the acid 
labile Carboxybenzyl group (Cbz) was employed for protecting the exocyclic amino 
groups of the bases C, A and G, a new Boc/Cbz strategy was introduced.77 This 
strategy quickly became the common protocol for producing mixed purine-
pyrimidine PNA oligomers. In this strategy, removal of the N-terminal Boc 
temporary group is carried out by trifluoroacetic acid (TFA), while the orthogonal 
protecting groups that are used to protect the exocyclic amino function of the 
nucleobases are removed using trifluoromethanesulfonic acid (TFMSA).  
However, the use of TFA in the removal of Boc group can lead to removing the acid 
labile protecting groups on the exocyclic amino groups on the nucleobase of the 
growing chains. This deprotection then leads to produce PNA oligomers impurities 
that are difficult to purify. In the final step, to cleave the PNA oligomer from the 
solid phase, a strong acid such as hydrogen fluoride (HF) is required. The use of such 
as strong acids in this process is one of the major drawbacks of this strategy.  
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To avoid the drawbacks that are associated with the Boc strategy, a milder method 
was developed and became the most commonly used solid phase PNA synthesis 
strategy. This approach depends on introducing a base labile fluorenyl 
methoxycarbonyl group (Fmoc) to protect the primary amino function of PNA 
monomers. In this strategy, the exocyclic amino function of the nucleobase must be 
protected with an acid labile protecting group such as Bhoc, Boc and Cbz that are 
quite stable under Fmoc-deprotection conditions, mostly a solution 20% of 
piperidine in different solvents such as NMP, DMF, and DCM.  
Regardless of the strategy that is used in the solid phase synthesis of  PNA 
oligomers, the carboxyl function of PNA monomers needs an activation. The most 
commonly used peptide coupling agents for in situ PNA monomers’ activation are 
the uronium reagents 78,79 such as HATU 19 and HBTU 20, and the phosphonium 
coupling reagents 78,80 such as PyBOP 21 and PyAOP 22 (Figure 1.21). The uronium 
reagents are less sensitive towards moisture, therefore are more easily handled in 
solid phase synthesis than the phosphonium reagents. Additionally, The popular 
carbodiimide condensation reagents such as DCC 23 and DIPCDI 24 (Figure 1.21) 
also can be used in the solid phase PNA synthesis, mostly in combination with 
additives such as HOBt and DHBtOH.80,81
On the other hand, one major drawback encountered the solid phase PNA synthesis 
is that the growing PNA oligomers have a tendency for aggregation by folding over 
upon themselves during the chain elongation. This aggregation can be formed by 
either intra- or intermolecular interactions thereby leading to a low peptide 
coupling efficiency. For this reason, PNA oligomers can only be prepared in a limited 
length of the nucleobases.  
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Figure 1.21: The common peptide coupling agents. 
1.3.3 Synthesis of PNA monomers 
Since PNA’s invention, different AEG PNA monomers have been prepared and used 
in the solid phase PNA synthesis. These monomers differ from each other in the 
type of orthogonal protecting groups that are used to protect the exocyclic amino 
function on the nucleobase and the primary amino function of their backbone. 
Although some PNA monomers are commercially available, they can be synthesised 
by relatively easy and inexpensive routes. 
The key step of the synthesis of PNA monomers such as 27, involves the coupling of 
the appropriate nucleobase acetic acid derivative such as 26 to the secondary amine 
of the protected backbone such as 25, in the presence of a coupling agent as 
outlined in Scheme 1.1. The most commonly used coupling agents for synthesis of 
PNA monomers are the carbodiimides such as DCC 23 and DIPCDI 24 (Figure 1.21), 
often in the presence of HOBt and DHBtOH.80
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Scheme 1.1: General scheme for the synthesis of AEG PNA monomer. 
In some cases, the carboxylic group of the PNA monomer backbone requires a 
temporary masking group in order to avoid unwanted side reactions such amide 
bond formation during synthesis of PNA monomers. This masking group will be 
removed later producing a PNA monomer that is ready for solid phase synthesis 
procedure. 
The AEG PNA monomer backbone is composed of a glycine with a 2-aminoethyl 
group extension from the amine. There are three efficient retrosynthetic routes 
have been used routinely for the synthesis of the protected N-(2-aminoethyl) 
glycine PNA monomer backbone, such as 25 as outlined in Scheme 1.2. The most 
common and inexpensive way is the SN2 N-alkylation of 1,2-diaminoethane (or its 
mono-protected derivative) 28 with α-haloacetic acid or its esters derivatives 29. 
Reductive amination is also a relatively straightforward route for the synthesis of 
the desired AEG backbone 25, either using protected amino acetaldehyde 30 with 
glycine esters 3182,83 or compound 28 with glyoxalic acid or its ester derivatives 32.84
A few further reaction steps give the desired N-protected PNA backbone in a 
relatively high yield. In order to protect the primary amino function of the AEG PNA 
monomer backbone, different temporary protecting groups have been used such as 
Boc,39,54 Mmt85 and Fmoc.86,87 Whereas the secondary amino function of this 
backbone to which the nucleobase acetic acid derivatives can be coupled, is left 
free. 
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Scheme 1.2: Retrosynthetic analysis of the PNA monomer. 
Synthesis of the nucleobase acetic acid derivatives such as 26 involves a selective N-
alkylation reaction of the pyrimidines or purines bases at N1- and N9-positions, 
respectively. This is performed using α-haloacetic acid, or its ester derivatives in the 
presence of different basic reagents such as sodium hydride,88 and potassium 
carbonate.86,89
In order to avoid undesired reactions such as an amide bond formation during the 
syntheis of PNA monomers or through the solid phase PNA synthesis, the 
nucleophilic exocyclic amino functionalities of adenine, cytosine and guanine must 
be orthogonally protected during the solid phase synthesis. For this purpose, 
various groups have been reported using a selection of protection groups such as 
Boc,90 Bhoc,91 and Cbz.86 Futhermore, this protection increases the solubility of PNA 
monomers in the most common organic solvents.   
1.3.5 PNA backbone modifications  
Since their invention in 1991,39 there is an increasing interest in solving the 
problems that are associated with using the AEG PNA oligomers, such as poor 
membrane permeability thus limiting its applications for antigene or antisense 
therapies, low water solubility and self-aggregation. In an attempt to overcome 
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these drawbacks, many research groups have focused their attention on developing 
new PNA monomers through backbone and nucleobase modifications.92 For the 
work that was performed in this thesis, two series novel PNA monomers consisting 
of a modified backbone were prepared. We, therefore, present a short overview of 
PNA monomer backbone modifications in the coming section.  
In general, the original N-(2-aminoethyl) glycine PNA monomer backbone offers two 
moieties, namely, 2-aminoethyl and glycine moieties that can be exploited for 
extension or insertion of a cyclic structure. It also introduces further modification 
potential at α-, β- and γ-positions that can be used for attachment of a side group 
(Figure 1.22).  
Figure 1.22: The possible sites for modification the PNA monomer backbone. 
The earliest attempts to modify the AEG PNA monomers involved extending the 
original backbone by a methylene group.93,94 This extra methylene group was 
introduced into the glycine moiety of AEG PNA monomer backbone by replacing the 
original N-(2-aminoethyl) glycine backbone with N-(2-aminoethyl)-β-alanine as 
outlined in Scheme 1.3. This modification involved hydroamination of methyl 
acrylate with mono Boc-protected ethylenediamine 33 to produce the extended 
backbone methyl ester 34 followed by coupling with an acetic acid derivative of 
thymine. The resultant thymine PNA monomer methyl ester 35 was then hydrolysed 
to obtain the target thymine PNA monomer 36 (Scheme 1.3). 
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Scheme 1.3: Synthesis of an extended thymine PNA monomer at glycine moiety.   
To further investigate the extension effect, the extra methylene group was also 
introduced into the 2-aminoethyl moiety of the original N-(2-aminoethyl) glycine 
PNA monomer backbone.93,94 This modifcation was achieved by using 1,3-
diaminopropane rather than 1,2-diaminoethane as outlined in Scheme 1.4. Thus, 
the 1,3-diaminopropane 37 was alkylated with chloroacetic acid, followed by 
esterification with methanol to give the precursor backbone  38. The priamry amino 
group of 38  was then protected with a Boc group by using tert-butyl 4-nitrophenyl 
carbonate. This protected modified backbone 39 was then coupled to thymin-1-yl 
acetic acid using DCC as a coupling agent in the presence of DHBtOH. A final 
hydrolysis reaction of the methyl masking group yields the target extended thymine 
PNA monomer 40 (Scheme 1.4).  
Chapter One                                                                                                        Introduction  
29 
Scheme 1.4: Synthesis of an extended thymine PNA monomer at 2-aminoethyl 
moiety. 
In order to investigate the effect of these extensions on the properties of PNA 
oligomers, a single monomeric of the extended PNA monomers 36 and 40, was 
incorporated into homo-thymine PNA oligomers during oligomerization following 
the Boc-solid phase synthesis procedure. Biophysical studies showed that the target 
homopyrimidine PNA oligomers resulted in a lowering of PNA binding affinity 
towards DNA with significantly reduced melting points (Tm) of PNA/DNA duplexes 
compare to those derived from unmodified PNA.94
In order to enhance the rigidity of the PNA structure, PNA monomers with a 
modified constrained, chiral, cyclic backbone were synthesised. This modification 
was done through the incorporation of a cyclic structure such as cyclopentyl 95,96 or 
cyclohexyl 97,98 into the 2-aminoethyl moiety of the original AEG backbone. Thus, 
inspired by the general synthetic route that is used in the synthesis of the original 
AEG PNA monomer backbone, Boc-protected 1,2-diamino cyclopentyl 41 or 
cyclohexyl 42 was N-alkylated with ethyl bromoacetate to produce the modified 
backbones 43 and 44, respectively. These modified backbones were then coupled to 
thymin-1-yl acetic acid, followed by hydrolysis under basic conditions to afford the 
corresponding thymine PNA monomers 47 and 48 (Scheme 1.5). 
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Scheme 1.5: Synthesis of PNA monomers containing a cyclic structure. 
To investigate the effect of this type of modification on the PNA properties, a single 
monomeric unit of 47 and 48 was incorporated into AEG PNA oligomers during Boc-
solid phase synthesis strategy. Thermodynamic studies showed that the modified 
PNA oligomer that is containing of cyclopentyl monomer 47 displayed an improved 
binding affinity toward DNA with higher thermal stability the corresponding 
PNA/DNA duplex than the unmodified PNA/DNA duplex. In contrast, the (R, R) 
isomer of 48 resulted in a drastic decrease in the thermal stability of the 
corresponding PNA/DNA or PNA/RNA complexes. The PNA oligomers with (S, S) 
orientated residues, however, were able to bind to complementary sequences of 
DNA or RNA with a little effect on the thermal stability depending on their number 
in the PNA sequence. 
For more investigations, a fully modified backbone containing a heterocyclic 
constrained unit was introduced rather than the original AEG PNA monomer 
backbone as outlined in Scheme 1.6.99,100 This modified backbone was prepared via 
condensation of N-Boc-glycine aldehyde 49 with L-cysteine methyl ester to give the 
target backbone in a mixture of anti and syn-isomer of 2-(Boc-aminomethyl) 
thiazolidine-4-carboxylic methyl ester 50. Both isomers were coupled to the 
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thymine nucleobase via a methylene carbonyl linkage through two steps to produce 
the intermediates compounds 51 and 52. Finally, a hydrolysis reaction with an 
aqueous solution of LiOH afforded the modified thymine PNA monomers anti 53 
and syn 54 (Scheme 1.6). 
Scheme 1.6: Synthesis of constrained PNA monomer: i) Cys-OMe, pyridine, MeOH; 
ii) ClCH2COCl, pyridine, CH2Cl2, -78 °C; iii) thymine, K2CO3, DMF; iv) 
LiOH, H2O/dioxane, v) KHSO4. 
To investigate the effect of these modifications on the properties of PNA oligomers, 
a single monomeric unit of heterocyclic constrained thymine PNA monomers 53 and 
54, was inserted into the middle of a 10-mer homothymine AEG PNA oligomer. UV 
melting experiments showed that the incorporation of these modified PNA 
monomers does not prevent the binding of the PNA with DNA but does however 
significantly decrease the stability of PNA/DNA and PNA/RNA triplexes relative to 
the corresponding unmodified PNA. 
A particularly interesting modification to improving the binding affinity, water 
solubility and cellular uptake of PNA oligomers involves the introduction of a 
stereogenic centre at the α-, β- and γ-positions of the the AEG PNA monomer 
backbone (Figure 1.22). Most commonly this is accomplished via the introduction of 
side chains belonging to proteinogenic amino acids. The most investigated class is 
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the α-chiral PNA backbone that is prepared by replacing the glycine moiety with an 
L- or D-chiral amino acid such as alanine, lysine, serine, glutamic acid, aspartic acid, 
isoleucine and arginine through an analogous synthetic route to that used for the 
synthesis of AEG PNA monomers.101,102 The α-chiral thymine PNA monomers such as 
58 were the first chiral PNA monomer and were introduced by Nielsen et al. in 
1994.101 This modified α-chiral thymine PNA monomer 58 was prepared by 
saponification reaction of the corresponding ester derivative 57 that was prepared 
via coupling of thymin-1-yl acetic acid to the precursor for the α-chiral PNA 
monomer backbone 56. This precursor backbone 56 was prepared via reductive 
amination of alanine methyl ester 55 and Boc-amino acetaldehyde 49 as outlined in 
Scheme 1.7.
Scheme 1.7: Synthesis of α-chiral PNA monomer. 
In general, biophysical studies of PNA/DNA duplexes showed that PNA oligomers 
carrying the α-chiral PNA monomers, derived from a D-amino acid, have a higher 
affinity towards complementary DNA than the corresponding L-monomers.102
Besides that, the PNA/DNA duplexes containing the D-form retained similar thermal 
stability to the corresponding unmodified duplexes. Whereas the incorporation of L-
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form monomers displayed reduced stability. Also, it was found that incorporation of 
α-chiral thymine monomers that were derived from negatively charged amino acids 
such as D-glutamic and L-aspartic acids into PNA oligomers such as H-
GTxAGATxCACTx-NH2 reduced the melting temperatures (Tm) of PNA/DNA 
complexes compared to the unmodified PNA/DNA duplex.102
Interestingly, the introduction of a chiral centre at the β-position is expected to 
influence the conformation and the binding properties of PNA toward DNA because 
this position corresponds to the C4 of the deoxyribose moiety of the DNA which is a 
chiral carbon. Although cyclic PNA monomers containing a chiral centre at the β-
position of their backbone were reported early, the first modified PNA backbone 
with a single substituent at the β-position of the original PNA backbone was 
reported by Sugiyama et al. in 2011.103  This β-modified backbone was prepared by 
using 1,2-diaminopropane in both S and R forms instead of 1,2-diaminoethane that 
is commonly used for the synthesis of the original PNA monomer backbone as 
outlined in Scheme 1.8. 
Scheme 1.8: Synthesis of β-chiral thymine PNA monomer. 
Thus, 1,2-diaminopropane 59 was selectively mono-protected on the amino group 
located at C1 with Cbz group using CbzOPh. The resulting intermediate compound 
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60 was then N-alkylated with methyl bromoacetate to produce a β-chiral modified 
PNA backbone methyl ester 61. This precursor Cbz-protected PNA monomer 
backbone methyl ester 61 was then coupled to thymin-1-yl acetic acid followed by 
hydrolysis reaction under basic conditions to yield a Cbz-protected β-chiral thymine 
PNA monomer 62. In the final reaction, the temporary protecting group (Cbz) was 
replaced with the Fmoc group to obtain Fmoc-protected β-chiral thymine PNA 
monomer 63 that is ready for solid phase PNA synthesis (Scheme 1.8).
Thermodynamic studies showed that incorporation of the S form of the β-chiral 
thymine PNA monomer into the PNA oligomers retained the binding affinity and 
thermal stability of the PNA/DNA duplexes, whereas the incorporation of the R form 
prevents the formation of PNA/DNA duplex.
Among all the PNA monomer backbone modifications, the introduction of a chiral 
centre at the γ-position is the most promising one to improve properties of PNA 
oligomers such as water solubility, binding affinity and thermal stability of PNA/DNA 
duplexes compared to unmodifed PNA.104,105 The crystal structure studies of a γ-
PNA/DNA duplex illustrates the unique characteristics of this modification, 
possessing conformational flexibility of PNA oligomers with maintaining sufficient 
structural integrity of the preferred conformation upon hybridization with single-
stranded DNA. Furthermore, the γ-PNA/DNA duplex is induced by the steric clash 
between and the nitrogen of the tertiary amide of the backbone and its γ-carbon 
and is stabilized by the sequential base stacking.106
Although the γ-modified PNA monomer backbone can be prepared by reductive 
amination of the Boc-protected amino acetaldehyde with glycine ester derivatives, 
it can be prepared alterantive way such as Mitsunobu-Fukuyama reaction.107,92 As 
an example for the introduction a guanidinium group at γ-position of the original 
PNA monomer backbone, Boc-protected lysine (guanidine-di-Cbz)-OH acid 49 was
first reduced to its alcoholic derivative 65, followed by coupling with ethyl 2-(2,4-
dinitrophenylsulfonamido) acetate to give the intermediated compound 66. To 
make the secondary amino function of the target backbone 67 is free, to which the 
nucleobase acetic acid derivatives can be coupled, the 2,4-dinitrophenylsulfonate
protecting group of 66 was removed using a mild base. This modified backbone 67
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was then coupled to an appropriate nucleobase acetic acid to give the intermediate 
a chiral γ-PNA monomer ethyl ester such as 68. A saponification reaction of 68
yielded the corresponding Boc-protected γ-chiral PNA monomer such as 69 as 
outlined in Scheme 1.9.  
Scheme 1.9: Synthesis of γ-chiral PNA monomers, R: (CH2)4NHC(NHCbz)(NCbz), B= 
nucleobase  
Thermodynamic studies showed that the incorporation of a single monomeric unit 
of γ-guanidine-modified PNA monomer into PNA sequences displayed a higher 
affinity for complementary DNA and RNA sequences than α-guanidine PNA 
oligomers.  
1.3.7 Ligation of PNA oligomers 
Peptide Nucleic Acid (PNA) is mimicking the behaviour of nucleic acids and bind to 
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complementary sequences of DNA or RNA with much higher affinity and greater 
recognition specificity. Due to these unique properties, PNA have been exploited to 
produce an attractive tool for gene targeting applications.108 In particular, when 
human natural oligonucleotide segments are targeted, usually oligonucleotides 
probes forming more than 16 base pairs are required to target a unique 
sequence.109 For example, PNA oligomers that are 18-20 nucleobases in length, 
however, have been used to monitor telomere dynamics,110 or to inhibit human 
telomerase.111 Unfortunately, SPPS has one major disadvantage which is the length 
limitation. Thus, the synthesis of PNA oligomers longer than 16 nucleobases by SPPS 
resulted in poor results.112 This length limitation can be attributed to that the 
growing PNA oligomers chains can be aggregated by formation of either intra- or 
intermolecular interactions thereby leading to low coupling efficiencies. Therefore, 
a different technique using ligation is considered as a promising route for the 
synthesis of the extended PNA sequences that are difficult to prepare by the 
standard solid phase methods. Native chemical ligation (NCL) has been developed 
for ligation of PNA with PNA or conjugation with DNA or peptide. Native chemical 
ligation allows the combination of two unprotected PNA segments by the reaction 
between the thiol group of the N-terminal cysteine of one PNA oligomers and the C-
terminal thioester of another PNA oligomer yielding modified PNA sequences.113-117
However, the efficient synthesis of C-terminal thioester PNA oligomers and the 
ability of a thiol group of cysteine at N-terminus to be oxidized to react with another 
thiol group making a disulfide causing a distorting in the PNA backbone remain 
limitations to use NCL as a ligation method for PNA sequences.  
The advent of the copper (I) catalysed azide-alkyne 1,3-dipolar cycloadditions 
(CuAAC) known as ‘click chemistry’ has provided a simple method to link together 
organic molecules generating 1,2,3-triazole products. This is can be achieved in high 
yields under mild conditions, and, in the presence of a diverse range of functional 
groups.118-120 Furthermore, the azide and alkyne functional groups are mostly inert 
towards other functional groups i.e. they react only with each other. Moreover, the 
formed 1,2,3-triazole moiety is of particularly high interest, especially in the area of 
biological applications, as it has been found to mimic amide bonds and is nearly 
Chapter One                                                                                                        Introduction  
37 
impossible to oxidize or reduce and is not toxic.121 Because of these unique 
features, it is interesting to consider the use of this click chemistry (CuAAC) in 
ligation of PNA oligomers via 1,2,3-triazole formation as a linkage.   
1.4 CuAAC ‘click’ reaction: 1,2,3-triazole formation
1.4.1 Historical background  
The formation of di-substituted triazole derivatives was first reported in 1893 by 
Arthur Michael as mentioned in the literature.122 However, the full synthetic study 
on the nature of this reaction was reported in 1961 by Rolf Huisgen, and 
determined to be a 1,3-dipolar cycloaddition reaction between the alkyne and azide 
functions.123 This study was revealed that this reaction is relatively slow, but could 
be achieved at high temperatures to give a reasonable yield, however with lack a 
regioselectivity and generate a mixture of 1,4- and 1,5-disubstituted triazoles 
(Scheme 1.10). 
Scheme 1.10: Azide–alkyne 1,3-dipolar cycloaddition reactions. 
In 1984, G. Labbe used copper as a catalyst for the synthesis of azidoallene complex 
and observed a Huisgen azide-alkyne 1,3-dipolar cycloaddition as a side reaction.124
However, this observation was left without any further investigations until 2001, 
when a renewed interest in 1,3-dipolar cycloaddition sparked a report by Sharpless 
and his co-worker when they published a seminal paper to introduce a new strategy 
for organic synthesis.118 They defined the term ‘‘click chemistry’’ and described the 
concept as being modular, broad in scope, giving high yields, generating only safe 
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by-products, stereospecific, and simple to perform. In 2002, the copper (I) species 
was reported as a catalyst for azide-alkyne cycloaddition independently by two 
groups: Sharpless in the US 119 and Meldal in Denmark.120 Both observed that this 
reaction exclusively gives the 1,4-disubstituted 1,2,3-triazole in high yield. 
Furthermore, CuAAC copper catalysed reaction can be described as a fast reaction, 
requiring low temperature, and can be used to covalently attach any fragment 
containing azide functionality to terminal alkynes, without being affected by the 
steric or electronics of the substrates.  
The generally accepted mechanism of the CuAAC reaction is shown in Figure 1.23. In 
this mechanism, the copper catalyzed azide-alkyne 1,3-dipolar cycloaddition 
(CuAAC) proceeds through the coordination between Cu(I) and the terminal alkyne 
to form an active copper acetylide such as (A). This intermediate in turn reacts with 
the azide component to generate the copper acetylide-azide complex (B). 
Figure 1.23: A general mechanism of Cu (I) catalysed azide-alkyne reaction.125 L 
stands for a ligand or a counter ion. The brackets around ‘’CuLn’’ 
symbolize that a bi or polynuclear Cu (I) species is involved in the 
reaction.  
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This complex (B) then cyclises to form a metallocycle intermediates such as (C), 
following by a rearrangement to form a cyclic compound such as (D). Finally, after 
protonation and dissociation, the reaction ends to produce the final products (E) 
regenerating the Cu (I) catalyst.  
The conventional sources of Cu (I) that can be used in this type of Cu (I)-catalyzed 
reaction are copper (I) iodide and copper (I) acetate. Furthermore, it was found that 
Cu (I) can be produced in situ from a Cu (II) salt, and the most common used is 
copper sulphate (CuSO4) in the presence of sodium ascorbate as a reducing agent.126
Although the standard CuAAC reaction solvent is tert-BuOH:H2O (1:1), it can be 
carried out in other solvents such as DMF, NMP, H2O, tert-BuOH, DMSO, CHCl3, 
MeOH, and DCM.126 In a subsequent investigation of the click reaction, it was found 
that the addition of some heterocyclic chelates could further accelerate CuAAC, and 
could largely decrease the amount of Cu (I) that is required which is very important 
in biological systems. For example, the stabilizing ligand tris-(benzyltriazolylmethyl) 
amine (TBTA) developed in the Sharpless group can protect Cu (I) from oxidation 
and disproportionation. As a result, the catalytic efficiency was accelerated by 106 
fold.127
1.4.2 1,2,3-Triazole ring as a bioisostere 
Since the copper (I) catalysed azide-alkyne 1,3-dipolar cycloaddition has made the 
preparation of the 1,2,3-triazole ring relatively easy, it is important to establish the 
bioisosteric potential of this moiety. The important concept was that the triazole 
group displays a structural similarity with the amide bond, mimicking a Z or an E-
form depending on its substitution pattern. The 1,4-disubstituted triazole moiety 
shows similarity with a Z-amide bond; where the lone pair of the N3 mimics one of 
lone pairs of the carbonyl oxygen of the amide bond and the polarized C (5)-H bond 
can act as a hydrogen bond donor like the amide N–H bond. The electrophilic and 
polarized C4 is electronically like the amide carbonyl carbon. Since the overall dipole 
moment of the triazole system is larger than that of the amide bond, its hydrogen 
bonding donor and acceptor properties are more marked than those of an amide 
bond, with an enhanced ability to mimic peptide.128,129
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Figure 1.24: Hypothesis of triazoles as a bioisostere of amides bond. 
Comparing the structure of a 1,2,3-triazole and an amide bond, some differences 
are present. For instance, the extra atom C5 in the triazole moiety leads to an 
increase in the distance between R1 and R2 by about 1.1 Å over the typical amide 
bond. Besides the potential of triazoles in mimicking the amide of the peptide bond, 
it has also been expected that triazoles might act as bioisosteres of the acyl-
phosphate and trans-olefinic moieties.  
1.4.3 Applications of ‘Click Chemistry’ in the field of PNA  
The copper (I) catalysed azide-alkyne 1,3-dipolar cycloaddition reaction known as 
the ‘click reaction’ has been become an established tool used for synthesis and 
developed for use with PNA. Thus, it is employed to conjugate PNA with DNA, to 
label PNA with certain groups such as fluorescent dyes and to ligate fragments of 
PNA.  
As an application of Cu (I) catalysed azide-alkyne cycloaddition reaction in the field 
of PNA, a DNA-templated, highly efficient and convenient method was developed by 
Xiaohua Peng et al. for the conjugation of PNA-DNA such as 73 via 1,2,3-triazole 
formation as a linker.130 The click reaction (CuAAC) was achieved between an alkyne 
functionalized PNA sequence such as 70 and an azide functionalised DNA sequence 
such as 71 using a DNA template such as 72. This reaction was performed in the 
presence of a water-soluble tris(3-hydroxypropyltriazolylmethyl) amine (THPTA) 
ligand to prevent DNA template degradation as outlined in Scheme 1.11.      
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Scheme 1.11: Conjugation of PNA with DNA by click reaction. 
Further investigations of this application showed that the efficiency of click 
conjugation of PNA sequence with DNA sequence depends on the duplex formation 
between the oligonucleotide starting materials and the DNA template. It was 
observed that a small yield of the click conjugation product was obtained with 
mismatched templates.  
For click (CuAAC) ligation of PNA-PNA, according to our knowledge, only one study 
has been reported describing a copper (I) catalysed azide-alkyne cycloaddition so 
far. As an useful application, Winssinger et al. were successful in ligation of two PNA 
oligomers via 1,2,3-triazole formation as a linkage by click chemistry.131 This study 
indicated that an azido functionalised PNA oligomer such as 74 and an alkyne 
functionalised PNA oligomer such as 75 were ligated together to give the ligation 
product 77 in an excellent yield using a complementary sequence of DNA as a 
template 76. The same conditions that described above for conjugation PNA with 
DNA were employed for ligation these PNA oligomers as outlined in Scheme 1.12.  
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Scheme 1.12: Ligation of PNA-PNA sequence by CuAAC reaction. 
Further investigations of this type of application revealed that the click ligation 
which was performed using an azido component with a single base pair mismatch 
also afforded the ligation product, however in a lower yield. In addition, no 
significant reaction yield was observed if the azide component was not 
complementary to the DNA template. These results are demonstrating the fact that 
the starting materials alkynoic and azide PNA oligomers must be bound to the DNA 
template for the click ligation to proceed successfully.    
On the other hand, an efficient common strategy to insert the 1,2,3-triazole moiety, 
into the structure of PNA oligomers, is based on performing the copper (I) catalysed 
azide-alkyne cycloaddition reaction on the solid support, termed CuAAC-SP.120,132,133
As an application for CuAAC-SP in the field of PNA, a new strategy was devised for 
the synthesis of modified PNA oligomers in which the amide link in their backbone is 
replaced partially or fully by 1,2,3-triazole ring.134 This approach involves first 
synthesising a modified alkyne functionalized PNA monomer, such as 80, as an 
alkyne component for the click reaction. Synthesis of this monomer involved SN2 N-
alkylation of mono Boc-protected ethylenediamine 33 with propargyl bromide to 
give a modified PNA monomer backbone 78. This modified backbone 78 was then 
reacted with α-chloroacetyl chloride to give the intermediate 79 that was coupled 
into the thymine nucleobase to afford the target PNA monomer 80 as outlined in 
Scheme 1.13.  
Chapter One                                                                                                        Introduction  
43 
Scheme 1.13: Synthesis of Boc-protected modified thymine PNA monomer. 
For performing the click chemistry on the solid support, the commercially available 
Boc-protected AEG thymine PNA monomer was first coupled into the solid support 
to give the growing PNA chains such as 81, followed by Boc-deprotection using TFA. 
Unlike the solid phase peptide synthesis procedure, the resulted unprotected N-
terminus was converted in situ into an azido group via an azido transfer protocol 
using triflyl azide (TfN3) and copper sulfate,135 generating azido functionalised 
growing PNA chains such as 82. The alkynoic thymine PNA monomer 80 was then 
coupled into these growing PNA chains via a click reaction using copper (I) iodide in 
the presence of DIPEA introducing the 1,2,3-triazole moiety into the growing PNA 
chain 83 as a linker instead of the amide bond formation as outlined in Scheme 
1.14. This click reaction step can be repeated at the desired position until the 
required sequence is formed. 
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Scheme 1.14: Synthesis of PNA oligomers bearing a 1,2,3-triazole ring. 
The hybridization of different triazolyl PNA oligomers with complementary DNA was 
studied by temperature-dependent UV absorbance measurements. UV-Tm studies 
showed an improved stability for the PNA2/DNA triplexes that derived from the 
modified triazole functionalised PNA oligomers than the corresponding unmodified 
triplexes.  
The scope of the CuAAC-SP strategy was explored as a key for the applications of 
PNA as electrochemical biosensors that are used to discriminate, and therefore 
detect, single-base mismatches DNA and RNA.136,137 For example, in order to 
achieve this goal, a facile method to covalently conjugate a metal complex such as 
ferrocene to a PNA strand is needed. Thus, for the conjugation of PNA oligomers 
with ferrocene derivatives via click reaction,138 the alkyne and azide functions were 
first introduced at the N-terminus of PNA oligomers, such as 85 and 86 respectively. 
Synthesis of these precursors was achieved by coupling of propynoic acid and azido 
acetic acid into a growing PNA chain 84 during solid phase PNA synthesis. The click 
reaction of these precursors 85 and 86 with azido ferrocene and ethynyl ferrocene 
produced ferrocene labelled PNA oligomers 87 and 88, respectively as outlined in 
Scheme 1.15.  
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Scheme 1.15:  Synthesis of Fc-PNA trimer conjugates. 
In another important application of the click (CuAAC) in the PNA field, the CuAAC-SP 
was used for the synthesis of PNA oligomers containing nucleobase surrogates.139 In 
this application, a azide functionalized building block 91 was prepared through 
coupling of 2-azido acetic acid to the Fmoc protected AEG PNA backbone allyl ester 
derivative 89 to form the intermediate 90. The ally temporary masking group of 90 
was removed by treatment with Pd(PPh3)4 in NMM to give the target building block 
91 that is ready for solid phase PNA synthesis as outlined in Scheme 1.16.  
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Scheme 1.16: Synthesis of azide-containing PNA monomer 91. 
The modified PNA monomer 91 was incorporated into a 7-mer sequence of PNA 
during solid phase synthesis. The resin-bound PNA chain with an internal azide 
residue 92 was then reacted with 2-ethynylfluorene and 1-ethynylpyrene to 
produce PNA-F 93 and PNA-P 94, respectively as outlined in Scheme 1.17.  
Scheme 1.17: Synthesis of PNA oligomers containing nucleobase surrogates. 
For study the effect of this application on the hybridization properties of PNA 
oligomers, UV-thermal melt analysis of duplexes that were derived from the 7-mers 
containing PNA-F 93, PNA-P 94, and an 11-mer complementary sequence of DNA 
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with a central abasic site displayed a lower Tm than expected for the corresponding 
unmodified duplexes. 
1.5 Hyaluronic acid
Hyaluronan (HA), 95 (Figure 1.25), also called hyaluronic acid is a member of the 
glycosaminoglycan family of extracellular matrix component,140 and can regulate a 
variety of physiological and pathological functions such as interacting with many 
receptors and proteins, cell proliferation, cell adhesion, migration and metastatic 
spread of tumour cells.141
HA is a macromolecule, multifunctional and non-sulfated linear glycosaminoglycan 
(GAG) distributed broadly through vertebrate organs, fluids, connective tissue, 
epithelial and natural tissue. Its chemical structure was determined in 1954 as a 
high molecular weight polymer of disaccharide that consists of D-glucuronic acid 
and N-Acetyl-D-glucosamine linked together via alternating β-1,4 and β-1,3
glycosidic bonds 140,141,142 as shown in Figure 1.25. Hyaluronan can be 25,000 
disaccharide repeats in length and the average of its molecular weight in the human 
synovial fluid is about 3×106 Da.143
Figure 1.25: Structure of Hyaluronan. 
Hyaluronan (HA) is synthesised biologically at the inner surface of the plasma 
membrane of the cell by three isoenzymes of hyaluronan synthase (HAS) in 
mammals termed as HAS1, HAS2 and HAS3 140,144,145 which consist of terminal 
transmembrane or membrane-associated domains flanking a large cytosolic 
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catalytic domain.146 In general, increased hyaluronan levels are often associated 
with elevated activities of growth factors and cytokines that are released in rapidly 
remodeling tissues as during embryonic development and wound healing or during 
certain pathological situations, such as inflammation, tumour progression, and 
vessel thickening.147 Although all these enzymes are equally capable of synthesising 
HA, HAS2 is considered the main HA synthase in polymerizing long hyaluronan chain 
of MW about 2×106 Da in adult mammalian tissues. 
There are data that suggested that natural antisense mRNA of HAS2 can regulate 
HAS2 mRNA levels and hyaluronan biosynthesis in a cell culture and may have a 
regulatory role in the control of the HA biosynthesis.141 Natural antisense RNA is an 
endogenous transcript that is complementary an mRNA sequence (sense sequence). 
Natural antisense RNA (AS) is capable of regulating gene expression in both 
prokaryotic and eukaryotic organisms. Natural antisense RNAs exert their regulatory 
effects at multiple levels including transcription, RNA editing, post-transcription, 
and translation.148,149  One of our aims in this thesis is looking at gene regulation of 
HAS2 through preventing the duplex formation inside the living cells between the 
mRNA of hyaluronic acid synthase (HAS2) and its natural antisense HAS2-AS. This 
blocking will then help investigating the effect of HAS2-AS on the translation 
process and protein synthesis, specifically production of HAS2. Our key to achieve 
this aim is based on using a long complementary sequence of PNA with 30 
nucleobases to bind the natural antisense HAS2-AS sequence via a stable duplex 
formation. HAS2 possesses a natural antisense transcript (NAT) named HAS2-AS1 
which is a part of long non-coding mRNA and has a crucial role in the modulation of 
gene transcription.
HAS2-AS1 is transcribed from the opposite DNA strand of the HAS2 gene localized at
8q24.13 on the minus strand of human chromosome 8 as shown in the literature 150
where the HAS2-AS1 exon 1 sequence lies within intron 1 of the HAS2 gene and the 
nucleotide sequences of HAS2-AS exons 3 and 4 are located upstream of HAS2. 
Furthermore, the second HAS2-AS1 exon is complementary to a portion of HAS2 
exon 1. 
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An alternative splicing can generate two HAS2-AS1 NAT isoforms, named long (L) 
HAS2-AS1 splice-variant, L-HAS2-AS1, which has 257 nucleotide in length and short 
(S), HAS2-AS1 alternatively-spliced product that has 174 nucleotides. These two 
isoforms of HAS2-AS1 are complementary sequences to the region starting 70 bp 
from the presumed transcription start site of human HAS2.151,152 This length 
variation involves a difference of 83 nucleotides of the HAS2- AS1 exon 2 sequence 
and thus changes the length of complementary sequence with HAS2. Furthermore, 
L-HAS2-AS1 shares 257 nucleotides with HAS2 exon 1, while S-HAS2-AS1 has a 
corresponding 174 nucleotide region of complementarity.152
Chapter Two
Design and Synthesis of Novel PNA monomers:
Results and discussion
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2.1 Introduction 
Peptide nucleic acid (PNA) has many advantages over nucleic acids including higher 
chemical and biological stability, greater mismatch sensitivity, and higher binding 
efficiency to complementary sequences of nucleic acids associated with higher 
thermal stability of their complexes. These unique properties make PNA an effective 
tool in the gene regulation applications. However, these applications are often 
hampered by inherent drawbacks, such as their limited length that is assembled by 
solid phase synthesis method, low solubility in water and poor cellular uptake. 
Therefore, there are considerable ongoing efforts to further improve properties of 
PNA for both fundamental science and practical applications.  
Due to their relatively simple structure, the chemical modifications of AEG PNA 
monomers have been studied extensively as an approach for improving their 
oligomers’ properties. It is hoped that through these modifications improved probes 
for nucleic acids recognition, and therapy based on gene regulation can be 
obtained. Furthermore, more importantly, modification of PNA monomers is 
necessary not only to overcome the drawbacks that are associated with PNA 
oligomers toward their DNA or RNA targets. This modification is also to enhance the 
binding affinity of unmodified PNA oligomers when it is not sufficient for a specific 
application, or when functionality needs to be used for a specific application. 
Several reviews have covered the literature concerning the design and biochemical 
testing of new chemically modified PNA monomers.153 As was mentioned in the 
introduction chapter, modification of PNA monomers can be performed via the N-
(2-aminoethyl) glycine backbone, the nucleobase and the acetyl linker. Often these 
changes are not mutually exclusive, and are not regularly used in combination to 
further tune and enhance the physical and biological properties of the PNA 
oligomers.  
The ease of altering the PNA backbone has encouraged the synthetic organic 
chemists to develop various PNA monomers as an attempt to improve their 
oligomers’ properties. A large number of chemical modifications of the original AEG 
PNA monomer backbone have targeted either the glycine unit, or the 2-aminoethyl 
moiety, or both.93,94,103 However, only a handful of these modifications appear to 
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display an advantage in practical biochemical and/or pharmaceutical applications.  
The use of Click reaction (CuAAC) within the realm of PNA chemistry has opened 
various opportunities to expand the applications of PNA in different fields. CuAAC 
reaction has been used in ligation, conjugation of PNA and insertion of a specific 
group into PNA sequence leading to the entry of PNA in new therapeutic and 
biosensor applications. In the current study, we are interested in using a click 
(CuAAC) reaction to extend PNA sequence as an antisense agent for blocking HAS2-
AS sequence that requires a long PNA sequence. 
The main results reported in this chapter are concerned with design and synthesis 
of two classes of novel PNA monomers consisting of modified PNA backbone units, 
ideally suitable for Fmoc-solid phase synthesis protocol. The first of these classes 
are alkynoic PNA monomers that allow functionalising the N-terminus of PNA 
sequences with an alkyne function that can be exploited in the click (CuAAC) 
reaction for ligation of PNA-PNA ligation as described in Chapter 3. Alternatively, 
synthesis of these modified PNA monomers also makes conjugation PNA with 
different substrates such as nucleic acid, ferrocene group, protein and sugar 
possible via click (CuAAC) reaction.  
The second class of these novel monomers are the 1,2,3-triazole functionalised 
building blocks that allow insertion of the 1,2,3-triazole moiety directly into the PNA 
sequence during oligomerization as an attempt to enhance their hybridization 
properties with nucleic acids. Furthermore, these modified monomers represent 
models that can be used to investigate the effect of the click ligation linkers on the 
PNA properties mimicking the reaction products from ligation of PNA sequences by 
click reaction (CuAAC) via 1,2,3-triazole formation as click ligation linkages. 
2.2 Results and Discussion 
2.2.1 Synthesis of novel alkyne functionalised PNA monomers  
When we began this project, our attention was turned to develop a new method to 
extend a specific PNA sequence by ligation of three PNA oligomers via 1,2,3-triazole 
formation as a biocompatible linker as an antisense agent for blocking HAS2-AS 
sequence that requires a long PNA sequence. Our approach to achieving this aim is 
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through a copper (I) catalysed azide-alkyne 1,3-dipolar cycloaddition reaction. 
Therefore, the correct precursors must be chosen to introduce the alkyne and azide 
functions at the N/C-terminals of PNA oligomers during solid phase synthesis. Thus, 
our work was first directed towards the synthesis of the azide-alkyne functionalised 
PNA oligomers. Although there are different commercially available chemicals, such 
as N-Fmoc-propargylglycine and propynoic acid, which can be used to introduce an 
alkyne function at the N-terminus of PNA oligomers during solid phase synthesis, we 
are particularly interested in the synthesis of a series of novel modified alkyne PNA 
monomers that allow introducing an alkyne function at the N-terminus of PNA 
sequences.  
Synthesis of these novel PNA monomers resulted in an important difference to the 
commercially available alkyne compounds. Specifically, when these novel 
monomers are used to introduce the target alkyne function at the N-terminus of 
PNA oligomers for achieving click (CuAAC) applications, it leads to construction of a 
linker unit bearing a nucleobase. Consequently, this click linker then will be as a 
modified PNA monomeric unit along the PNA sequence. In contrast, using the 
commercially available alkyne precursors to introduce an alkyne function at the N-
terminus of PNA oligomers generates a click reaction linker that is entirely 
independent of the PNA sequence. This unspecific linker will be as a spacer on the 
PNA sequence and is thought to negatively affect the PNA properties such as 
changing the conformation of PNA/DNA duplexes. In other words, the 
corresponding click ligation linkers of the target alkyne PNA monomers could help 
to avoid or reduce negative effects on the PNA properties compared to the 
commercially alkyne precursors. 
2.2.1.1 Retrosynthetic analysis of novel alkyne PNA monomer 
The synthetic route that has been adopted to synthesise the novel alkyne PNA 
monomers is inspired by the synthetic route that is commoenly used for the 
synthesis of standard AEG PNA monomer. Thus, this route is based on the 
conjugation of the nucleobase acetic acid derivatives to the designed alkyne 
functionalised PNA monomer backbone by coupling reaction through amide bond 
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formation. The retrosynthetic analysis suggests a convenient and efficient synthetic 
route for synthesising the target alkyne functionalised PNA monomers as described 
in Scheme 2.1.  
Scheme 2.1: A retrosynthetic route for N-alkynoic PNA monomers, n, m= 1, 2, 3. 
The first bond to be disconnected is the amide bond between the nucleobase acetic 
acid and the secondary amino function of the alkyne functionalised backbone. This  
yields the alkyne functionalised backbone and the nucleobase acetic acid derivative 
as synthons. The second bond disconnected is that between C1 of an alkynyl group 
and the amino function of the amino acid compound to give an alkyne group, which 
could come from an alkynyl halide and an amino compound that can be a 
proteinogenic amino acid or an alternative amino acid compound. 
2.2.1.2 Synthesis of modified alkyne PNA monomer backbone
In the present work, N-propargyl glycine ethyl ester was designed and synthesised 
as the precursor for the alkyne functionalised PNA monomer backbone in our 
synthetic pathway to synthesise the target PNA monomers. Starting from cheaply 
available glycine, a new, scalable and cheap route is reported for the synthesis of 
the target ester backbone as described in Scheme 2.2.  
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Scheme 2.2: Synthesis of N-propargyl glycine ethyl ester 99. 
To allow for two selective N-alkylation reactions, the carboxyl function of the glycine 
96 was first protected, by esterification with ethanol in the presence of 
trimethylchlorosilane (TMSCl) to obtain ethyl glycinate hydrochloride 97 in 99.9% 
yield. This reaction was achieved with relative simplicity through a slightly modified 
procedure to that was reported in the literature.154
The next proposed step of our synthetic route is the N-alkylation reaction of 97 with 
propragyl bromide. In the first attempt, an excess of K2CO3 was investigated as a 
reagent for carrying out this reaction in acetonitrile. However, the protonated 
primary amine group showed very low activity toward this N-alkylation reaction and 
failed to provide the target compound 99 under these conditions. To avoid this 
problem, a new step was devised, involving first deprotonating the amino function 
of compound 97 through treatment of a suspension of compound 97 in 
dichloromethane with triethylamine and subsequent work up to obtain ethyl 
glycinate 98 in a yield of 84%. However, as expected, it was noted that compound 
98 is particularly prone to undesired side reactions such as formation of 2,5-
diketopiperazine,155 and it cannot be stored for a long time. Consequently, the 
nitrogen atom of the primary amino group of compound 98 was alkylated 
immediately using propargyl bromide in the presence of the K2CO3 in acetonitrile. 
After work up and purification by column chromatography, the target alkynoic PNA 
monomer backbone 99 was obtained in 53% yield. Along with 99, a significant 
quantity of N,N-di-propargyl glycine ethyl ester side product was also obtained.  
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In order to synthesise adequate quantities of the four target PNA monomers, we 
investigated whether the yield of the required product 99 could be improved. Thus, 
the N-alkylation reaction was repeated using an excess of ethyl glycinate 98. The 
reaction gave only the desired product 99 in 78% as a yield. The highlightes of our 
new synthetic route are that it is a simple, high-yielding and gives a product 
requiring no further purification by column chromatography.  
The 1H NMR spectrum recorded for 99 using CDCl3 as a solvent showed the 
appearance of a narrow triplet peak at 2.20 ppm and a doublet peak at 3.44 that are 
corresponding to the terminal alkynyl proton coupling to the (CH2) of alkynyl group 
(CH≡CCH2) that is attached to the amino group of ethyl glycinate.  
2.2.1.3 Synthesis of nucleobase acetic acid derivatives 
Having made the precursor alkyne modified PNA backbone 99, we turned our 
attention to synthesise the N1- and N9-nucleobase acetic acid derivatives, 
particularly the N1-acetic acid derivatives of thymine and cytosine and the N9-acetic 
acid derivatives of adenine and guanine. A typical selective N-alkylation reaction is 
that of α-haloacetic acid or its ester derivatives, with the free nucleobase which 
could then be sequentially attached to the appropriate backbone, via amide 
coupling to construct the target PNA monomers.  
More importantly, for the synthesis of cytosine, adenine and guanine PNA 
monomers, the introduction of an orthogonal protecting group at the reactive 
exocyclic amino function of each nucleobase is necessary. This prevents an 
unwanted side reaction from amide bond formation at this position during the 
synthesis of PNA monomers or through the solid phase synthesis reaction such as 
coupling and capping reaction, further to improve the solubility of PNA monomers 
in most organic solvents. 
2.2.1.3.1 Synthesis of thymine-1-yl acetic acid  
Although the thymin-1-yl acetic acid 100 is commercially available, it can also be 
prepared by an inexpensive and straightforward method as described in the 
literature.156 Thus, the cheap commercially available thymine 2, was alkylated 
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selectively at the N1 position with 2-bromo acetic acid in the presence of potassium 
hydroxide as outlined in Scheme 2.3.  
Scheme 2.3: Synthesis of thymine-1-yl acetic acid 100.
This N1-alkylation reaction takes an advantage of that the amide group at the N1-
position, which is susceptible to deprotonation and is consider more nucleophilic 
than the amide group at the N3-position under these basic conditions. Thus, the 
controlled addition of chloroacetic acid to the reaction mixture is a key factor to 
maintain the pH of the reaction suitable for N1-alkylation product. The reaction 
mixture was worked up to obtain the desired compound 100 in 86% yield as white 
crystals. 
2.2.1.3.2 Synthesis of N4-benzhydryloxycarbonyl cytosine-1-yl acetic acid  
The first step in our synthetic route to synthesis the target compound is N1-
alkylation reaction. Many synthetic pathways have been reported in the literature 
to alkylate cytosine base with α-haloacetic acid ester derivatives.86,88,157,158 This N-
alkylation reaction takes advantage of the lower pKa of the amide group at N1-
position, which is more susceptible to deprotonation by a base and thus undergoes 
alkylation reaction more readily than the primary exocyclic amino group.159 In the 
current study, the N1-alkylation of cytosine was carried out using benzyl 
bromoacetate in the presence of K2CO3 in anhydrous DMF to give the desired 
compound 101 as shown in Scheme 2.4.  
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Scheme 2.4: Synthesis of N4-Bhoc protected- cytosine-1-yl acetic acid 103.
The acid labile benzhydryloxycarbonyl (Bhoc) group was chosen to protect the 
exocyclic amino function of 101 according to a simple modification of a procedure 
that was described in the literature.91 Thus, the alkylated cytosine 101 was treated 
with the 1,1-carbonyldiimidazole (CDI) in anhydrous DMF to generate a reactive 
intermediate isocyanate compound; which subsequently underwent nucleophilic 
attack with benzhydrol to install the Bhoc group generating the desired compound 
102. Importantly, it was noted that this reaction is very sensitive to moisture 
because CDI is hydrolysed readily to give imidazole, therefore, all attempts to 
perform this reaction in non-anhydrous DMF failed to provide the target compound. 
In the final reaction, the desired Bhoc-protected cytosiny-1-yl acetic acid 103 was 
obtained in an excellent yield, by hydrolysing compound 102 using an aqueous 
solution of LiOH. 
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2.2.1.3.3 Synthesis of N6-benzhydryloxycarbonyl adenine-9-yl acetic acid  
N6-benzhydryloxycarbonyl-9-adenyl acetic acid 106 was prepared by the same 
chemistry that was applied for the synthesis of Bhoc-protected cytosiny-1-yl acetic 
acid 103, starting from the commercially available adenine 6 as outlined in Scheme 
2.5.  
Scheme 2.5: Synthesis of N6-Bhoc-protected adenine-9-yl acetic acid 106. 
Many methods have also been described in the literature to alkylate adenine 
selectively at the N9-position with α-haloacetic acid ester derivatives.86,88,157,158 In 
the current project, N9-alkylation was carried out with ethyl bromoacetate using 
K2CO3 in anhydrous DMF, following new conditions and work up to obtain the 
desired compound 104 in an excellent yield. Similar to cytosine, this alkylation 
reaction also takes advantage of the lower pKa of the secondary amine at N9-
position, which is more susceptible to deprotonation by a base and thus undergoes 
alkylation more readily than the exocyclic amino function of adenine.159 As stated 
for compound 102, the exocyclic amine of alkylated adenine 104 was protected with 
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Bhoc group using 1,1-carbonyldiimidazole and benzhydrol in anhydrous DMF, to 
afford compound 105. This precursor was followed by hydrolysis with an aqueous 
solution of LiOH to afford the desired N6-Bhoc-protected adenine-9-yl acetic acid 
106 in an excellent yield (Scheme 2.5). 
2.2.1.3.4 Synthesis of N2-benzhydryloxycarbonyl guanine-9-yl acetic acid  
Because guanine has low solubility in most organic solvent and cannot be alkylated 
selectively at the N9-position,158,160 the commercially available 2-amino-6-
chloropurine 107 has been used as a precursor of the guanine nucleobase as 
outlined in Scheme 2.6.  
Scheme 2.6: Synthesis of N2-Bhoc-protected guanine-9-yl acetic acid 110.
Although numerous methods have been proposed for alkylation of 2-amino-6-
chloropurine 107,86,88,157 the selective N9-alkylation was achieved with benzyl 
bromoacetate  in the presence of K2CO3 in anhydrous DMF according to a modified 
procedure that was described in the literature 91 to give the desired compound 108
in excellent yield. Due to the exocyclic amino function of the alkylated compound 
108 displaying a lack of reactivity with CDI, the Bhoc group was installed at this 
amino group in a different route than that described for the exocyclic amino group 
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of compounds 103 and 106. In this way, triphosgene was used as the precursor to 
generate a reactive carbonyl intermediate compound, which underwent 
nucleophilic attack by benzhydrol to afford the desired compound 109. This reaction 
was also achieved according to the procedure that was  described in the literature.91
In the final reaction, a nucleophilic displacement of the chlorine atom of 109 was 
achieved by reaction with 3-hydroxypropionitrile in the presence of sodium hydride. 
Simultaneous removal of the benzyl ester moiety afforded the desired N2-Bhoc-
protected guanin-9-yl acetic acid 110 in a high yield.   
2.2.1.4 Synthesis of ethyl N-propargyl-N-(nucleobase-yl acetyl) glycinate  
Having made the intermediate alkyne-functionalised backbone 99 and nucleobases 
acetic acid derivatives 100, 103, 106 and 110, we then turned our efforts for 
combining them in a coupling reaction through amide bond formation. Inspired by 
the synthetic route that is used for synthesising AEG PNA monomers, we could 
synthesise the intermediate alkyne functionalised PNA monomers ethyl ester 111, 
112, 113 and 114 as described in Scheme 2.7. 
Scheme 2.7: Synthesis of ethyl N-propargyl-N-(nucleobase-yl acetyl) glycinate.  
To carry out this reaction, the carboxyl function of these nucleobase acetic acid 
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derivatives requires activation. Thus, a solution containing the modified backbone 
99 and the appropriate nucleobase acetic acid derivative in anhydrous DMF was 
treated with DCC in the presence of HOBt·H2O to give the precursors 111, 112, 113
and 114 that were worked up and purified by column chromatography to obtain 
yields of 74%, 76%, 82%, and 76%, respectively.  
The original PNA monomers 161 and N-alkyne-N-(Cbz-protected nucleobase-yl acetyl) 
glycine ethyl esters,162 showed the presence of two rotameric forms in solution. As 
had been found for these monomers, the 1H NMR and 13C NMR spectra that were 
recorded for the resultant Bhoc-protected N-propargyl PNA ethyl esters 111, 112, 
113 and 114 also showed splitting of some peaks, which indicates the presence of 
rotational isomers due to hindered rotation around the tertiary amide bond. This 
rotational restriction can be ascribed to a pseudo double bond, which means that 
this kind of monomer exists in two forms visible by the NMR spectroscopy, cis and 
trans rotamers. By comparing the integrations of the split peaks in the 1H NMR 
spectra, it was found that the two rotamers were present in a 1:1 ratio.  
At this point, the intermediate compounds 111, 112, 113 and 114 are not ready to 
be used in the solid phase synthesis strategies, as their carboxyl functions are still 
protected with an ethyl masking group. Consequently, they would be unable to 
form an amide bond during oligomerization. 
2.2.1.5 Synthesis of novel N-propargyl-N-(nucleobase-yl acetyl) glycine 
PNA monomers 
After completing the synthesis of the intermediate PNA monomers ethyl ester 111, 
112, 113 and 114, an efficient method was devised to remove the ethyl ester moiety 
thus, producing the novel alkyne PNA monomers that are ready to be used in the 
solid phase PNA synthesis. Our first attempt involved a saponification reaction of 
111, 112, 113 and 114 with an aqueous solution of NaOH (2 M) in THF. Subsequent 
extraction with ethyl acetate then gave the target alkyne PNA monomers 116, 117
and 118 in a low yield ranged from 30% to 40%, whereas the thymine monomer 115
was obtained in a slightly improved 60% yield as outlined in Scheme 2.8.  
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Scheme 2.8: Synthesis of novel alkynoic PNA monomers. 
The yields obtained with these conditions were not as high as expected. This is 
probably due to loss of the products during workup because of their limited 
solubility in ethyl acetate extraction solvent. The hydrolysis reaction was therefore 
repeated in 1,4-dioxane using an aqueous solution of NaOH (2 M). Interestingly, an 
acidification to pH 3 with an aqueous solution of citric acid (20% v/v), led to 
precipitation of the desired products. These products were then able to be collected 
directly by vacuum filtration, washed thoroughly with water and dried to afford the 
novel alkyne PNA monomers. The yields were greatly improved with thymine 115 in 
70%, cytosine 116 in 89% yield, adenine 117 in 90% yield and guanine 118 in 84%. 
All monomers were collected as pale white solids.  
As had been seen before, for the precursors 111, 112, 113 and 114, the 1H and 13C 
NMR spectra recorded for novel alkyne PNA monomers 115, 116, 117 and 118 still 
display splitting of some peaks due to the presence of rotational isomers that are 
described for their precursors.  
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As an application to use the novel alkyne PNA monomers in the solid phase PNA 
synthesis, and according to the PNA sequences that were chosen to be tested in the 
click chemistry ligation, the alkyne thymine PNA monomer 115 will be used in solid-
phase synthesis to introduce the required alkyne moiety at the N-terminus of 
selected PNA sequences as described in Chapter 3. Additionally, one of our aims is 
also to test the activity of all our novel alkyne PNA 115, 116, 117 and 118 monomers 
toward the click reaction (CuAAC) with a view of synthesising novel PNA monomers 
containing a 1,2,3-traizole moiety, further explained in the section 2.2.2. 
2.2.2 Synthesis of novel PNA monomers containing 1,2,3-triazole ring 
Currently, there is a desire to extend PNA sequences through click (CuAAC) reaction 
via 1,2,3-traizole formation, when the length of PNA that can be prepared by solid 
phase synthesis is not enough for a specific application. Thus, our motivation to 
design these novel 1,2,3-triazole functionalised PNA monomers arises from the 
possibility to obtain new PNA monomers which can be used to demonstrate the 
effect of 1,2,3-triazole modifications. An entirely different route than that is 
commonly used for the synthesis of the standard AEG or modified PNA monomers, 
was designed for the synthesis of these novel PNA monomers. This synthetic route 
is based on the click (CuAAC) reaction that was developed by Sharpless et al.119 to 
join an azide function with an alkyne terminus under mild conditions for formation 
1,2,3-triazole products. 
Herein, to make the target 1,2,3-functionalised building blocks can accommodate 
two amide bonds during the solid phase PNA synthesis protocols, the alkyne 
component of the click reaction was designed containing a carboxylic function. 
Whereas the azide component was designed to introduce an amino group 
functionality.  
2.2.2.1 Synthesis of 2-(Fmoc-amino) ethyl azide  
For the present project, the 2-aminoethyl azide was designed as an azide 
component for the click reaction. Choosing this compound takes advantage of that 
this precursor can be introduced at the C-terminus of a PNA sequence during 
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oligomerization using Azido Nova-Tag resin. Additionally, in order to avoid the 
undesired reactions that can occur on the primary amino function of the target 
monomers during oligomerization, the Fmoc group was chosen to protect the 
primary amino function of 2-aminoethyl azide. A simple and efficient route was 
devised for the synthesis of the target 2-(Fmoc-amino) ethyl azide 120. The key 
intermediate for the synthesis of the target compound 120 is 2-aminoethyl azide.
Several reviews have covered the literature concerning the introduction the azide 
function to organic compounds.163 Of these, however, the SN2 substitution of an 
alkyl bromide with sodium azide represents a straightforward reaction to introduce 
an azide function to organic molecules, where the bromide group is a good leaving 
group, as outlined in Scheme 2.9.  
Scheme 2.9: Synthesis of Fmoc-aminoethyl azide 120. 
The commercially available 2-bromoethylamine hydrobromide 119 and sodium 
azide were stirred in water at 80 °C for 24 hours, according to the procedure that 
was described in the literature.164 For the current work, isolation of the 
intermediate compound 2-aminoethyl azide is undesirable due to its relatively low 
boiling point and is unnecessary at this stage of this project.  
Thus, it was decided to remove this step through extraction of the reaction mixture 
with dichloromethane. The extraction solution that is containing the expected 
intermediate compound was then treated with the commercially available Fmoc-
succinimide ester in the presence of trimethylamine for two hours. Surprisingly on 
our first attempt, the primary amine function of the intermediate compound 2-
aminoethyl azide was protected successfully by Fmoc group in 80% yield. 
Consequently, our synthetic route highlighted a simple work up, higher-yielding 
strategy and required no further purification by column chromatography.  
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2.2.2.2 Synthesis of novel N-[(1-(2-Fmoc-aminoethyl)-1H-1,2,3-triazol-
4-yl) methyl]-N-(thyminyl-1-yl acetyl) glycine 121
Our first efforts focused on verifying that the click reaction could be applied to our 
novel alkyne PNA monomers 115, 116, 117 and 118. Each contains an alkyne 
component in CuAAC reaction for the synthesis of 1,2,3-triazole functionalised PNA 
monomers. Our efforts focused first on the synthesis of the modified thymine PNA 
monomer as outlined in Scheme 2.10.   
Scheme 2.10: Synthesis of monomer 121, i) CuSO4·5H2O, Na-ascorbate, 
           tert-butanol:H2O (2:1), 75% 
Our initial attempt involved the addition of monomer 115 and 2-(Fmoc-amino) ethyl 
azide 120 to a solution of (tert-butanol: water, 1:1 v/v) containing CuSO4·5H2O in 
the presence of sodium ascorbate. The latter of which as reducing agent to produce 
Cu (I) that is required to achieve CuAAC reaction. However, the starting materials 
115 and 120 displayed a limited solubility in the standard click solvent reaction 
mixture (tert-butanol:water, 1:1 v/v) at room temperature. Thus, this attempt 
proved unsuccessful in generating the desired product. Once the ratio of tert-
butanol:H2O was changed to 2:1 v/v, it was enough to dissolve both 115 and 120. 
The new solvent system was used with the same reaction constituent as before and 
left to stir at room temperature. The progress of the reaction was followed by TLC 
analysis. Although TLC analysis did not show formation a new product, a solid was 
seen to precipitate from the reaction mixture. Thus, the solid product was collected 
and characterised by 1H NMR which indicated that this solid is the target compound 
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121, formed in 20% yield. Since the yield was not optimal, we investigated whether 
the yield can be improved. Thus, the reaction mixture was heated up to 40 °C and 
left to stir for overnight, and this was enough to afford the desired product in a 75% 
yield. Our synthetic pathway highlighted that the product is separated, as a 
precipitate from the reaction mixture and can be collected by filtration without a 
further work up and was pure enough to not require column chromatography.   
1H NMR spectra recorded for this compound showed that all the signals are 
previously belonging to the starting materials combined with the correct integration 
of both starting material and product. However, the disappearance of the signal for 
the alkynyl proton of 115 at 3.44 and 3.26 ppm along with the appearance of the 
peaks that are belonging to the thymine moiety and azide component, indicated 
that 1,2,3-the target compound had been formed. This structure was also verified in 
the 13C NMR and mass spectra recorded for this compound, in additional to the IR 
spectrum that showed the disappearance of the peak for the azide group of 
compound 120.  
Encouraged by the results reported with the novel thymine PNA monomer 121, and 
the potential properties of any resulting oligomers, we were motivated to turn our 
attention to testing the reactivity of the other novel alkyne PNA monomers 116, 117 
and 118 towards the click reaction to obtain their corresponding novel 1,2,3-triazole 
functionalised PNA monomers. Starting, of course, with their potential in the click 
reaction, to obtain their corresponding novel 1,2,3-triazole functionalised PNA 
monomers. All reactions were performed under the same conditions that were used 
for synthesising monomer 121. 
Unfortunately, these compounds failed to give the desired PNA monomers, owing 
to the Bhoc protecting group on their exocyclic amino function displaying instability 
toward the click reaction conditions. The 1H NMR spectra, recorded for the 
resulting reaction products, confirmed disappearance of the protons belonging to 
the Bhoc group. In an attempt to overcome this problem modified routes using 
copper (I) acetate as rather than CuSO4·5H2O, or using DMF instead of tert-
butanol:H2O, were attempted but also failed to give the target compounds. Because 
it was deemed that these monomers were not really required at this stage of the 
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initial investigations, they were left without further investigations. 
2.2.2.3 Synthesis of novel 3-[1-(2-Fmoc-aminoethyl)-1H-1,2,3-triazol-4-
yl] propionic acid 123
For further investigation of the potential of the click reaction application in PNA, 
another novel Fmoc protected monomer 123 was designed and synthesised via a 
click reaction. This monomer was generated by reacting the synthesised compound 
120, and the commercially available 4-pentynoic acid 122. Choosing 4-pentynoic 
acid 122 as an alkyne component of click reaction for synthesis monomer 123, takes 
advantage of the fact that this compound 122 can be used to introduce an alkyne 
function at the N-terminus of PNA oligomers during solid phase synthesis for click 
reaction applications. 
Similar to the synthesis of monomer 121, the synthesised compound 120 was 
combined with 4-pentynoic acid 122 via the ‘click reaction’ using CuSO4·5H2O in the 
presence of sodium ascorbate as a reducing agent in tert-butanol:H2O (2:1) as 
outlined in Scheme 2.11. 
Scheme 2.11: Synthesis of monomer 123, i) CuSO4·5H2O, Na-ascorbate, 
                                     tert-butanol:H2O (2:1), 80%. 
In the first attempt, the resulting solution obtained was left to stir at room 
temperature. The progress of the reaction was monitored by TLC analysis. After a 
few hours, it was seen that a new product was formed beside the starting material. 
After 24 hours, the reaction was worked up and the crude sample obtained was 
purified, by column chromatography, to give the titled compound in 50% yield. As 
an attempt to improve this low yield, the reaction was heated up to 40 °C overnight; 
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after work up the desired compound 123 was obtained in 80% yield. The 1H NMR 
spectrum recorded for this compound 123 showed that all the previous signals 
belonging to the starting materials combined with the correct integration expected 
for the product and the starting material. However, the appearance of a new singlet 
at ppm and 7.77 ppm corresponding to the C (5) triazolyl proton, indicated that 
1,2,3-triazole ring had been formed. This structure also was verified in the 13C NMR 
and mass spectra recorded for this compound, and an additional IR spectrum 
showed the disappearance of the peak for the azide group of the compound. 
2.2.2.4 Synthesis of novel N-[(1-(2-Fmoc-aminoethyl)-1H-1,2,3-triazol-
4-yl) methyl]-N-(tert-butoxy carbonyl) glycine 126
For further investigations, another novel monomer suitable for Fmoc solid phase 
peptide synthesis was designed, mimicking the click ligation linker that can be 
constructed in the PNA sequence when the N-propargyl glycine was used to 
introduce the alkyne function at N-terminus of PNA oligomers. Choosing this type of 
click ligation linkers creates the advantage that this linker will introduce a secondary 
amino group into the extended PNA sequence. This amino function then will add a 
positive charge, and therefore will increase water solubility of PNA oligomers and 
may also increase its attraction to a DNA or RNA target.  
For this purpose and to make comparison with monomer 121, N-propargyl glycine 
was designed as an alkyne component for synthesis of the target novel monomer 
via click reaction. Again, to avoid undesired reactions during oligomerization, this 
secondary amino function must be protected orthogonally. Thus, the N-Boc-N-
propargyl glycine 125 that was reported previously by Wakselman et al.165 for a 
different aim, was chosen to be the precursor for the target N-propargyl glycine in 
our synthetic route. Our synthetic route to the precursor 125 is started from the 
amino acid glycine 96. Although the Boc-protected glycine 124 is commercial, it can 
be prepared in a straightforward and relatively inexpensive method according to 
the slightly modified procedure that was described in the literature166 as outlined in 
Scheme 2.12. 
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Scheme 2.12: Synthesis of N-Boc-protected glycine 124. 
The Boc group was installed on the amino function of glycine by the addition of di-
tert-butyl-dicarbonate in isopropanol, to a solution of glycine dissolve in an aqueous 
solution of NaOH (2 M). The reaction was accomplished under modified conditions 
and, following workup, the desired compound 124 was isolated in 88% yield and 
used in the next step without further purification by column chromatography.  
The biggest challenge was in N-alkylation of the nitrogen atom of the carbamate 
group with propargyl bromide, as this atom is much less reactive. However, the 
literature suggested the use of a stronger base i.e. sodium hydride 165 which did 
indeed lead to a successful reaction as outlined in Scheme 2.13. 
Scheme 2.13: Synthesis of N-Boc-N-propargyl glycine 125. 
To achieve this reaction successfully, anhydrous conditions are required during the 
time of reaction. Thus, a solution of 124 in anhydrous THF was cooled to 0 °C under 
nitrogen gas before being treated with propargyl bromide followed by sodium 
hydride. Following a simple modified work up, the target compound 125 was 
obtained in good yield, without requiring further purification by column 
chromatography.  
At this point, compound 125 can be used to introduce the alkyne function at the N-
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terminus of PNA oligomers during the Fmoc solid phase synthesis strategy. For this 
reason, we are interested in testing its reactivity toward CuAAC reaction in order to 
prepare the corresponding monomeric unit. We were then able to study the effect 
of this novel monomeric unit as seen in a PNA sequence that has been extended by 
the click reaction.  
The click reaction conditions that were investigated for the synthesis of monomers 
121 and 123 were used to synthesise the novel monomer 126 as shown in Scheme 
2.14.
Scheme 2.14: Synthesis of monomer 126, i) CuSO4·5H2O, Na-ascorbate,  
tert-butanol:H2O (2:1), 75%. 
Thus, compounds 125 and 120 were added sequentially to a solution containing 
CuSO4·5H2O and sodium ascorbate in a mixture of tert-butanol and water. The 
resulting reaction mixture was left to stir at 40 °C for overnight. After workup, the 
crude product was purified by column chromatography to obtain 126 in 75% yield. 
The 1H NMR spectra recorded for 126 showed a combination of all the signals from 
starting materials 120 and 125, in the correct integration. The disappearance of the 
signal for the alkynyl proton of 125 at 2.27 ppm along with the appearance of a new 
singlet 7.75 ppm corresponding to the C (5) triazolyl proton, indicated that 1,2,3- 
triazole ring had been formed. As it had been seen before, for compound 125, some 
of the signals from compound 126 were split in both 1H and 13C NMR spectra.  Once 
again, these implied two rotamers were present.  
2.3 Synthesis of Fmoc-protected AEG thymine PNA monomer 
Due to the need of obtaining a relatively large number of PNA oligomers during this 
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study, a large amount of the expensive commercially available Fmoc/Bhoc PNA 
monomers will be required. As the thymine acetic acid derivative 100 is already 
prepared for synthesising our novel PNA monomers 115 and 121 in addition to the 
relative simplicity of the synthesis thymine monomer, therefore, we tried to 
synthesise it in a relatively low-cost route.
The key intermediate for synthesising Fmoc-protected AEG thymine PNA monomer 
is the N-Fmoc-protected aminoethyl glycine benzyl ester (Fmoc-AEG-OBn). A simple 
and effective method was adopted to prepare this compound according to the 
modified procedure that was described in the literature87 as outlined in Scheme 
2.15. Thus, an excess of 1,2-diaminoethane was first mono Boc-protected to 33
using di-tert butyl carbonate in acetonitrile. Following removal of excess 1,2-
diaminoethane by a simple workup this gave pure compound 33 in a bit higher yield 
than reported previously. The primary amine function of 33 was alkylated with 
benzyl bromoacetate in the presence of triethylamine to afford benzyl N-(2-Boc-
aminoethyl) glycinate backbone 127 in 80% yield. 
Scheme 2.15: Synthesis of Fmoc protected PNA backbone 128, i) Boc2O in THF, 80%, 
ii) BrCH2COOBn, Et3N, MeCN, 83%, iii) TFA, DCM, iv) Fmoc-OSu, Et3N, 
DCM, 76%. 
For the synthesis of Fmoc-protected AEG thymine PNA monomer, the Boc 
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protecting group was first removed using TFA 95%. The TFA salt intermediate 
compound was treated with trimethylamine in dichloromethane followed by 
addition of Fmoc-OSu to produce the Fmoc-protected PNA monomer backbone 
128. After a simple workup, the target backbone was used in the next step without 
further purification by column chromatography.  
As was described for our compounds 111, 112, 113 and 114, the Fmoc protected 
backbone 128 was coupled to thymin-y-l acetic acid derivative 100 using DCC as a 
coupling agent in the presence of HOBt·H2O to give the intermediate Fmoc-
protected  thymine PNA benzyl ester derivative 129 in a good yield. Removal of the 
masking benzyl group was achieved by hydrogenation using Pd/C as a catalyst 
according to the procedure that was described in the literature 167 to afford the 
target Fmoc-protected AEG thymine PNA monomer 130 as outlined in Scheme 2.16.  
Scheme 2.16: Synthesis of Fmoc-protected AEG thymine PNA monomer 130. 
Chapter Three 
Design and Synthesis of Modified PNA Oligomers: 
Results and Discussion 
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3.1 Introduction
Click reaction (CuAAC) is now the method of choice for the conjugation of PNA 
sequences with nucleic acids and protein and represents a promising way to extend 
a PNA sequence via ligation through 1,2,3-triazole formation as a linkage. This 
triazole ring is, in fact, a mimic of the amide bond and a biocompatible group. In 
principle, it should keep the advantages of standard PNA with stability to 
degradation and an increased binding affinity toward nucleic acids. However, there 
are few publications that have demonstrated the effect of the 1,2,3-triazole moiety 
on the properties of PNA oligomers. 
Thus, this chapter will focus on the incorporation of the novel 1,2,3-triazole 
functionalised PNA monomers 121, 123 and 126, that were described in Chapter 2, 
into AEG PNA oligomers via the Fmoc solid phase peptide synthesis strategy. The 
resulting PNA oligomers will contain a single unit of these novel monomers. The 
modified PNA oligomers are then being used in binding studies to investigate the 
effect of these monomers on the hybridization properties of PNA oligomers. 
Specifically, their binding affinity and the thermal stability of their complexes with 
complementary sequences of nucleic acids. Comparisons of the binding properties 
of these PNA oligomers could then be made against the unmodified PNA oligomer 
of the same sequence or as an independent monomeric unit as described in Chapter 
4. In other words, the modified 1,2,3-triazole functionalised PNA oligomers will be 
used as models to demonstrate the effect of linkages that can be seen in the PNA 
sequences that are ligated or conjugated by click reaction. 
Further work that is reported in this chapter involves incorporating a novel alkyne 
functionalized thymine PNA monomer 115 into specific PNA sequences during Fmoc 
solid phase synthesis strategy in order to introduce an alkyne function at their N-
terminus. These alkyne functions can then be exploited in the application of the 
click reaction such as ligation of a PNA sequence. This formed the focus of our 
preliminary attempt to develop a new method to ligate the alkyne functionalized 
PNA oligomers with another sequence functionalized with an azide function via 
CuAAC reaction for a particular goal.  
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3.2 Solid phase PNA synthesis  
Peptide nucleic acid oligomers (PNAs) are polyamide compounds but not peptides 
because their building blocks are not proteinogenic amino acids. PNAs are synthetic 
oligonucleotides based upon a pseudo-peptide monomeric unit N-(2-aminoethyl) 
glycine. Therefore, PNA oligomers have been synthesised by the same procedures 
that are used for the synthesis of polypeptides, i.e. through either solid or solution 
phase synthesis. Synthesis of PNA is rather similar to that of peptides, in that it can 
be carried out either from the C or N termini. Most commonly, the synthesis of PNA 
oligomers is implemented via the automatic or manual solid phase peptide 
synthesis (SPPS) strategies. Regardless of the strategy chosen, the solid phase 
synthesis of PNA oligomers proceeds with the following standard synthetic steps: a 
temporary protecting group removal (deprotection step), a building block coupling 
(coupling step) and a blocking of the unreacted free amino functions (capping step), 
as outlined in Scheme 3.1. 
Scheme 3.1: General scheme of solid phase PNA synthesis cycle. 
Like polypeptides, the elongation of PNA oligomers takes place by deprotecting the 
N-terminus of the anchored PNA monomer and by coupling to it the activated next 
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N-protected PNA monomer. In general, solid phase synthesis has many striking 
advantages over conventional synthesis, including the utility of excess reagents 
which drives reactions to completion leading to improved yield. Reactions can be 
worked-up simply by washing the resin and filtering under vacuum, thereby 
removing the excess of the reagents and any soluble by-products. Practically, the 
solid phase PNA synthesis conditions are chosen considering the nature of the solid 
support (resin), and the type of orthogonal protecting groups that are used to 
protect the exocyclic amine protecting groups on nucleobases and the primary 
amino function of the PNA monomer backbone.  
A typical solid support used in SPPS is made up of an insoluble polymeric material, 
containing functional sites at which the growing polypeptide chain can be covalently 
attached. The ideal solid supports are an insoluble resin, with the minimum level of 
cross-linking to allow it to swell in a solvent while maintaining reasonable physical 
stability. The swelling opens the resin and thus allows reagents to penetrate its 
structure, which enables binding of the growing peptide chain at all possible active 
functional groups within the resin. There are a range of resins that are commercially 
available, and can be supplied in a functionalized form with a substrate fragment 
called a linker. The choice of the linker is highly dependent on the temporary 
protecting group strategy used. Functionalized polystyrene is among the most 
commonly used solid support.  
Although there are many synthetic strategies have been reported for solid phase 
PNA synthesis, in particular, it is carried out using one of two common standard 
strategies. The first makes use of Boc-protected PNA monomers and is referred to 
as the Boc strategy, while the other method involves the use of Fmoc protected PNA 
monomers, and is thus termed the Fmoc method. Although the basic premise for 
each method is essentially the same, different conditions are used throughout the 
two protocols.  
3.2.1 Fmoc Methodology   
The Fmoc/Bhoc and Fmoc/Boc combinations of protecting groups PNA monomers 
are the most widely employed in the synthesis of PNA oligomers. This is due to the 
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mild treatment needed for the cleavage of the oligomer from the resin, and removal 
of Bhoc and Boc groups simultaneously. Currently, the commercially available 
Fmoc/Bhoc PNA monomers (Figure 3.1) were used to build all the target novel 
modified PNA oligomers with incorporation of our novel PNA monomers at the 
desired positions.  
Figure 3.1: Structure of Fmoc/Bhoc protected PNA monomers. 
The Fmoc/Boc-protected lysine was incorporated into the target azide and alkyne 
functionalised PNA oligomers to enhance their water solubility. Furthermore, lysine 
moiety also was inserted into the synthesised 1,2,3-triazole functionalised PNA 
oligomers to prepare a model to study its effect on the binding properties of PNA 
oligomers in the presence of 1,2,3-triazole as click ligation linkage. For the current 
work, the commercially available Fmoc protected Rink Amide MBHA resin (Figure 
3.2) was chosen as a general solid support for synthesising the target PNA oligomers 
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with the exception of the PNA oligomers that required an azido group. This solid 
support is a type of Rink amide resins composed of a modified Rink amide linker 
attached to the (4-methyl benzhydryl amine) (MBHA) resin. This resin yields the PNA 
oligomers with C-terminal amides upon cleavage at the end of the synthesis using 
TFA. The C-terminal azide functionalised PNA oligomers terminus were synthesised 
on the specific Fmoc protected Azido-Nova Tag resin (N-Fmoc-N’-azido-PEG-
diamine-MPB-AM resin) which is a resin for C-terminus labelling of peptide. This 
solid support is one of the Nova Tag resins that are used for peptide labelling with a 
group for ligation such as the azido group that is stable under solid phase synthesis 
conditions such as piperidine and TFA solutions (Figure 3.2). This resin yields the 
PNA oligomers with C-terminal secondary amides substituted with ethyl azide upon 
cleavage at the end of the synthesis using TFA. For both these two resins, the 
polymer matrix is a copolymer (styrene + 1% divinyl benzene DVB). 
Figure 3.2: Chemical structure of resins that were used in SPS of PNA oligomers. 
The synthesis cycle of the target PNA oligomers was achieved manually following 
standard Fmoc solid phase synthesis strategy. The resins were initially swollen in an 
appropriate amount of NMP for two hours, then drained by filtration so that all 
active sites of the solid support were sterically accessible to reagents. In the Fmoc 
chemistry, the synthesis cycle is started with removal of the Fmoc group from the 
solid support (resin). For Fmoc removal, numerous procedures in the literature 
describe a variety of deprotection methods. Most of these pathways are based on 
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using piperidine and differ primarily in the final concentration of piperidine used 
which is prepared in different solvents. In the present work, a solution of piperidine 
(20% v/v) in NMP has proven efficient in removing the Fmoc group. Scheme 3.2 
illustrates the mechanism of the deprotection of the Fmoc group using piperidine.  
Scheme 3.2: Mechanism of Fmoc deprotection.168
When the soluble by-product of the deprotection step was removed by washing and 
filtration, the free amine group of the resin is ready for the peptide bond formation 
by a coupling reaction with the carboxyl function of the next monomer. However, 
prior to this, the carboxyl function of a monomeric unit needs an activation before it 
is able to couple to the amino function. In this project, the carboxylic acid group of 
PNA monomers was activated in situ by HATU in the presence of DIPEA and 2,6 
lutidine in NMP. When mixed, the reaction can be followed by the changing of the 
colour to a slight yellow. The activated monomer solution was then added to the 
resin and placed in the shaker for one hour at 25 °C. Scheme 3.3 is outlined the 
mechanism of activation and coupling of PNA monomers while assembling a PNA 
oligomer by solid phase synthesis.  
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Scheme 3.3: Mechanism of activation, and coupling of a PNA monomer.78
However, in the coupling reaction, some of the deprotected amino functions fail to 
react. These unreacted amino functions should be permanently blocked from 
further chain elongation, to prevent the formation of PNA oligomers with an 
internal deletion of monomers. This is important as these oligomeric impurities may 
be harder to separate from the desired product by HPLC. Thus, the resin-bound 
growing PNA chain was treated with a solution of acetic anhydride, in the presence 
of lutidine as a base in NMP for 10 min. This reagent rapidly reacts with the amino 
group via an acylation reaction. Scheme 3.4 illustrates the mechanism of the 
capping reaction.  
  Scheme 3.4: Mechanism of the capping reaction. 
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These four procedures of Fmoc-deprotection, activation, coupling and capping were 
repeated until the desired PNA sequences were completed. However, upon 
completion of the required sequence and after removal of the last N-terminal Fmoc 
group, the support-bound PNA chains remain fully protected. The exocyclic amino 
groups of the nucleobases remain protected with Bhoc groups, and a Boc group 
protects the side chain of lysine that had been coupled with the PNA sequences to 
enhance their water solubility.  
Therefore, the final step should involve removal of these protecting groups either 
before, or during cleavage the PNA sequence from the resin. As the Fmoc/Bhoc 
chemistry was used to synthesise the target PNA oligomers, the removal of Boc and 
Bhoc groups can be achieved simultaneously, during the release of the PNA 
oligomers from the resin, by treatment with TFA. Scheme 3.5 illustrates a proposed 
mechanism of cleavage PNA oligomer from MBHA Rink amide resin. In order to do 
this, the resin-bound PNA oligomers were swollen in a cleavage solution consisting 
of 95% TFA, 2.5% water, and 2.5% m-cresol.  The latter is a scavenger for the 
resultant benzhydryl, and tert-butyl cations that are generated from the 
deprotection of Bhoc protected the exocyclic amino group, and Boc-protected lysine 
side chain, respectively. After two hours, the solution containing the crude product 
was collected by filtration and concentrated under a flow of nitrogen gas.  
Scheme 3.5: A proposed mechanism of cleavage of PNA oligomers from MBHA Rink 
amide resin. 
The crude mixtures that comprises the desired PNA oligomer, the cleaved protective 
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groups and the capped PNA sequences were precipitated by addition of diethyl 
ether and centrifugation. All the target PNA oligomers were purified by reverse 
phase HPLC and characterised by mass spectrometry.   
3.3 Results and Discussion
In this project, a series of new modified PNA oligomers were prepared. Synthesise 
of these modified PNA was achieved by incorporating versatile novel monomers 
into a PNA sequence which may display the improved properties over standard PNA 
oligomers. Furthermore, an alternative application is synthesis of PNA oligomers 
with sufficient chemical reactivity to allow them to be converted into some 
desirable products. These protocols have several advantages for instance; synthesis 
of an oligomer containing a single modified versatile monomer could be used to 
study the application of click reaction on the PNA oligomers. Or the incorporation of 
some monomers could offer the possibility of making PNA containing a labile or 
chemically reactive conjugate.  
3.3.1 Rationale for synthesis of functionalised 1,2,3-triazole PNA oligomers  
Modification of the PNAs represent a promising way to enhance their properties 
such as nucleotide recognition, their water solubility, and cellular uptake or to 
present new functions into their structure for a specific application. In this research, 
mimicking the linkages that can be seen in extended PNA sequences via click 
reaction using the corresponding azide and alkyne precursors, three novel 
compounds 121, 123 and 126 (Figure 3.3) were designed and prepared suitable for 
Fmoc solid phase synthesis strategy as described in Chapter two.  
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Figure 3.3: Structure of synthesised modified PNA monomers 121, 123 and 126. 
Thus, once the task of synthesising these monomers was completed, the challenge 
of incorporating them into PNA sequences using SPS immediately followed. For this 
purpose, an 8-mer of a mixed pyrimidine-purine, PNA sequence (N-terminus G-A-C-
T-T-T-C-T C-terminus) was designed as a model to investigate the effect of these 
novel PNA monomers on the binding properties of their oligomers. Furthermore, 
this sequence represents a fragment of PNA sequence that is hoped to be extended 
by CuAAC reaction to produce a long complementary PNA sequence that is required 
for blocking the natural antisense sequence (AS) of the mRNA sequence of HAS2.  
Thus, based on this sequence, the unmodified 8-mer mixed PNA oligomer 131
(Figure 3.4) was synthesised as a control. Synthesis of this PNA oligomer 131 was 
carried out using the commercially available Fmoc/Bhoc protected AEG PNA 
monomers following the standard Fmoc solid phase synthesis strategy that was 
described in Section 3.2.1.  
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Figure 3.4: Chemical structure of the unmodified PNA oligomer 131. 
After cleavage from the resin, the crude PNA oligomer 131 was purified by RP-HPLC 
and characterised by LC-MS. Mass spectrometric analysis showed that there were 
peaks for various multiply-charged species of the target sequence 131 (Appendix 1). 
This PNA oligomer was used as a control sequence for comparing the hybridization 
properties of the 1,2,3-triazole functionalized PNA oligomers with complementary 
sequences of DNA and RNA.  
3.3.1.1 Solid phase PNA synthesis with incorporation of monomer 121
In order to devise the optimised conditions to incorporate our novel monomers into 
PNA oligomers, our efforts first focused on the incorporation of the novel Fmoc-
protected 1,2,3-triazole functionalised thymine PNA monomer 121 into the 
unmodified PNA sequence 131 (Figure 3.4).  
Thus, this monomer 121 is a key precursor for the synthesis of the internally 
functionalised 1,2,3-triazole PNA oligomers 132 (Figure 3.5). Synthesis of this 
modified PNA oligomer 132 was achieved by incorporation of a single monomeric 
unit of 121 rather than the Fmoc-protected AEG thymine PNA monomer at position 
4 of the unmodified PNA oligomer 131 (Figure 3.4). This was done using the 
standard Fmoc solid phase strategy that was described in Section 3.2.1.  
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Figure 3.5: Structure of modified PNA oligomer 132. 
Incorporation of the triazole functionalised thymine PNA monomer 121 into the 
PNA sequence 132 (Figure 3.5) has two important benefits. Firstly, it represents an 
attempt at modifying PNA oligomers in order to improve their properties such as a 
binding affinity and thermal stability. Therefore, if this novel monomer could 
support these goals, it would result in a novel method for modification of PNA 
oligomers with improved properties.  
Secondly, incorporation of monomer 121 into the PNA oligomer 132 can simulate 
the expected triazole monomeric unit that would be seen in the structure of a PNA 
oligomer that was extended through copper (I) azido-alkyne reaction. This PNA 
oligomer was produced using a PNA oligomer terminated with an alkyne function by 
coupling the novel alkyne PNA monomer 115.  Thus, PNA oligomer 132 will be used 
as a model to investigate the effect of this click ligation linker on the hybridization 
properties of the extended PNA sequences using click reaction.  
Practically, before the incorporation of the novel Fmoc-protected 1,2,3-triazole 
functionalised thymine PNA monomer 121 into the PNA oligomers, certain 
characteristics needed investigating. The first potential challenge was determining if 
this modified monomer will be stable, and whether it can be activated and coupled 
into PNA oligomers using the conditions used for oligomerisation of the Fmoc/Bhoc 
protected AEG PNA monomers. In the first attempt for synthesising PNA oligomer 
132, the modified Fmoc protected monomer 121 was coupled to the growing PNA 
chain by in situ activation with HATU in the presence of DIPEA and lutidine in NMP 
for one hour similar to oligomerisation of AEG Fmoc/Bhoc protected PNA oligomers. 
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After the cleavage reaction, the crude PNA oligomer was analysed by RP-HPLC and 
characterised by mass spectrometry. The HPLC analysis showed that the target PNA 
oligomer 132 was obtained, however in a relatively low yield. Our investigations into 
why this PNA oligomer resulted in a low yield, it revealed that this monomer has a 
low solubility in NMP that was used as a solvent for the activation and coupling 
reactions during the synthesis cycle. Our first attempt to overcome this issue 
involved replacing the NMP with DMF for dissolving monomer 121. Conveniently, 
this led to the target PNA oligomer 132 being obtained in an improved yield.  
As mentioned early, PNA oligomers require the attachment of an ionic side chain, 
preferably at both N- and C-terminals of their oligomeric chain, to enhance their 
water solubility and to reduce their self-aggregation. For this purpose, the most 
commonly used is the commercially available amino acid lysine. In this case, once 
the PNA sequence is extended via copper (I) catalysed azide-alkyne cycloaddition 
reaction, the lysine moiety is expected to be neighbouring the ligation linker. To 
study the effect of this case on the binding properties, such as binding affinity and 
thermal stability of PNA-nucleic acids complexes, and for comparison with lysine-
lacking modified PNA oligomer 132 (Figure 3.5), a new modified PNA oligomer 133
(Figure 3.6) was designed. Synthesis of PNA oligomer 133 was achieved by 
incorporating a single monomeric unit of Fmoc/Boc-protected lysine amino acid into 
the structure of the modified PNA oligomer 132 (Figure 3.5) adjacent to the 
monomeric unit 121.
Figure 3.6: Structure of PNA oligomer 133. 
After cleavage reaction, the crude PNA oligomers 132 and 133 were purified by RP-
Chapter Three: Synthesis of modified PNA oligomers: Results and Discussion 
88 
HPLC and characterized by LC-MS. Mass spectrometric analysis showed that there 
were peaks for various multiply-charged species of the target PNA oligomers 132 
(Appendix 2) and 133 (Appendix 3). 
3.3.1.2 Solid phase PNA synthesis with incorporation of monomer 123 
An alkyne function can be introduced at the N-terminus of PNA oligomers by 
coupling of the commercially available 4-pentynoic acid during the solid phase 
peptide synthesis. This opens the possibility to construct a new modified 
monomeric unit, as a linkage along PNA structure, which can be ligated via the click 
(CuAAC) reaction. To investigate the effect of this linker on the properties of PNA 
oligomers, and to make a comparison with novel monomeric unit 121, a novel 
monomer 123 was designed. This can be used as a model for general ligation 
linkages of this type and is synthesised as described in Chapter 2. 
In order to investigate the effect of this novel compound 123 on the binding 
properties of PNA oligomers, a single monomeric unit was incorporated at the 
central position of the unmodified sequence of PNA oligomer 131 (Figure 3.4).
However, incorporation of this independent monomeric unit 123 led to synthesis of 
a new modified 9-mer PNA oligomer 134 (Figure 3.7) which is longer than the 
unmodified PNA oligomers 131, although they have a same number and sequence 
of the nucleobases.  
Figure 3.7: Structure of PNA oligomer 134. 
Our key for incorporation of novel monomer 123 into the PNA sequence is the 
manual solid phase PNA synthesis following the standard Fmoc strategy that was 
described in Section 3.2.1. For the same reasons that were described for the 
synthesis of the modified PNA oligomer 133 (Figure 3.6), PNA oligomer 135 (Figure 
3.8) was designed as a model to investigate the effect of the monomeric unit 123
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adjusting to the lysine moiety.  
Figure 3.8: Structure of PNA oligomer 135. 
For synthesising the target modified PNA oligomer 135, a single unit of lysine amino 
acid was incorporated into the PNA oligomer 134 (Figure 3.7) adjacent to the 
monomeric unit 123 during Fmoc solid phase synthesis strategy that was described 
in section 3.2.1. Synthetically, incorporation of the Fmoc-protected monomer 123 
and Fmoc/Boc protected lysine amino acid into PNA oligomers 134 and 135 was 
achieved under the standard conditions that were employed for oligomerization of 
Fmoc/Bhoc PNA monomers without any problem observed.  
HPLC analysis and mass spectra showed that the novel 1,2,3-triazole functionalized 
monomer 123 was incorporated successfully into the target PNA oligomers 134 and 
135. The crude PNA oligomers 134 and 135 were purified by RP-HPLC and 
characterized by LC-MS. Mass spectrometric analysis showed that there were peaks 
for various multiply-charged species of the target PNA oligomers 134 (Appendix 4) 
and 135 (Appendix 5). 
3.3.1.3 Solid phase PNA synthesis with incorporation of monomer 126
Further investigations into the 1,2,3-triazole functionalised PNA oligomers were 
performed by incorporating the novel Fmoc/Boc-protected triazole functionalised 
monomer 126 into 8-mer PNA oligomer 131 (Figure 3.4) to generate a new 9-mer 
modified PNA oligomer 136 as shown in Figure 3.9.  
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Figure 3.9: Structure of PNA oligomer 136. 
As was mentioned in chapter two, our interest in incorporating this monomeric unit 
is to model the ligation linker that can be seen in the PNA structures that have been 
ligated via click reaction. This click ligation linker can be formed when the 
synthesised compound 125 was used introduce an alkyne function to the N-
terminus of PNA oligomers during oligomerization. Comparing to the novel 
monomers 121 and 123, this novel monomeric unit 126 introduces a secondary 
amino function to the PNA oligomers in addition to the 1,2,3-triazole moiety. Thus, 
to investigate if this secondary amine enhances their binding affinity and thermal 
stability of PNA/DNA or PNA/RNA duplexes compared to monomer 123 that does 
not contain this secondary amino function, the modified PNA oligomer 136 was 
designed. 
Like monomer 123, a single unit of monomer 126 was incorporated at the central 
position of the unmodified PNA sequence 131 (Figure 3.4) to produce also a new 
modified 9-mer PNA oligomer 136 (Figure 3.9). This novel monomeric unit 126 was 
incorporated successfully into PNA oligomer 136 following the manual Fmoc solid 
phase peptide synthesis methodology that was described in section 3.2.1. The 
standard conditions used for oligomerisation the Fmoc/Bhoc protected AEG PNA 
monomers were used without any problem observed. After cleavage form the resin, 
the crude PNA oligomer was purified by RP-HPLC and characterised by LC-MS. Mass 
spectrometric analysis showed that there were peaks for various multiply-charged 
species of the target PNA sequence 136 (Appendix 6). 
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3.3.2 Rationale for synthesis of azide-alkyne functionalised PNA oligomers 
Peptide nucleic acid oligomers (PNAs) can hybridise to the natural oligonucleotides 
following Watson-Crick or Hoogsteen base pairing rules, thereby being promising 
tools for antisense and antigene applications. However, in specific applications, 
easily synthetically accessible PNA is much shorter in length than the target 
sequences of nucleic acids. For example, a long sequence of PNA is required for 
blocking the complementary sequence of HAS2-AS effectively, as in the aim of this 
study. 
Because the solid phase synthesis of PNAs is unable to assemble sequences longer 
than 20 nucleobases in length,169 the alternative approach to the chemical synthesis 
of long PNA oligomers is to join PNA oligomers together by native chemical ligation 
methods (NCL). Native chemical ligation is an efficient method for the convergent 
synthesis of proteins and peptides that has been reported to overcome this problem 
or to conjugate peptide with nucleic acids.170 NCL allows two peptide fragments to 
be joined in a covalent peptide bond at the site of ligation and ligation only occurs 
at the C-terminal thiol-ester and N-terminal cysteine.  
For NCL applications in the PNA field, Mattes et al.115,171 and Ficht et al.172 showed 
the first applications of a protocol for native chemical ligation (NCL) in templated 
reactions of PNA oligomers. They designed PNA oligomers, which contained a C-
terminal glycine thioester, to react with a PNA bearing an N-terminal cysteine 
residue. However, the solid-phase synthesis of PNA-thioesters presents a challenge 
because C-terminus PNA-thioester oligomers cannot be prepared easily by SPPS and 
they are subject to cyclization reactions which furnish six-membered lactams.113
Furthermore, as we are interested in ligation of three PNA oligomers, the expected 
PNA sequence will have two residues of cysteine which is one of the most reactive
residues that can possibly influence the proper folding of PNA sequences or can 
distort and influence the proper folding of PNA by formation of disulfide bonds 
between each other. 
Currently, the copper (I) azide- alkyne cycloaddition reaction (CuAAC) could be 
represented as a promising method to facilitate ligation of PNA oligomers via 
formation of triazole ring as a biocompatible chemical linkage, which mimics the 
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normal amide bond in PNA structure. Herein, we are interested in ligation of three 
10-mer mixed purine-pyrimidine PNA oligomers through CuAAC reaction to prepare 
a long sequence of PNA, specifically for preventing a duplex formation between 
mRNA of HAS2 and its natural antisense HAS2-AS through blocking HAS2-AS 
sequences.  
This type of approaches for ligation of PNA is required the synthesis of PNA 
oligomers functionalized with azide and alkyne groups, and then these PNA 
oligomers can be joined by splint mediated ligation to produce a triazole linkage at 
the ligation site. To do this, the azide and alkyne functions were chosen to be 
installed during the solid phase PNA synthesis at the N/C termini of the target 
sequences through a linkage that should be stable towards solid phase conditions 
employed for the deprotection and cleavage of the PNA oligomers from the solid 
support. Furthermore, all three PNA sequences that were designed to be tested in 
the click ligation will have a lysine residue at the C-terminus in order to enhance 
their solubility in water. 
3.3.2.1 Solid phase synthesis of azide-functionalized PNA oligomer 137 
Our first attempt to synthesise the azide/alkyne functionalized PNA oligomers 
started with synthesis of the designed azide functionalized PNA oligomer 137 
(Figure 3.10). Synthesis of the new PNA oligomer 137 was carried out smoothly 
following the standard procedure of the Fmoc strategy using the commercially 
available the Fmoc/Bhoc AEG PNA monomers that was described in Section 3.2.1. 
The particular Fmoc-protected Azido Nova Tag resin was used as a solid support for  
the synthesis of this PNA oligomer. This resin will introduce the required azido 
function as a 2-aminoethyl group attached at the C-terminus of the target PNA 
oligomer 137 as shown in Figure 3.10. 
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Figure 3.10: Structure of azide-functionalized PNA oligomer 137. 
After cleavage from the resin, the crude PNA oligomer 137 was purified by RP-HPLC 
and characterized by LC-MS. Mass spectrometric analysis showed that there were 
peaks for various multiply-charged species of the target sequence 137 (Appendix 7). 
3.3.2.2 Solid phase synthesis of azide-alkyne functionalized PNA oligomer 138 
As we are interested in ligation of three PNA sequences, one of them should be 
designed to accommodate two click ligation linkages. For this purpose, the new PNA 
oligomer 138 was designed to be functionalized with azide function at the C-
terminus and alkyne function at the N-terminus. Similar to the azide functionalized 
PNA oligomer 137 (Figure 3.10), PNA oligomer 138 was synthesised on the Azido 
Nova Tag resin following the standard Fmoc solid phase strategy using the 
Fmoc/Bhoc protected AEG PNA monomers that was described in Section 3.2.1. 
However, the last coupling of synthesis this PNA oligomer 138 was achieved by 
using our novel alkyne functionalized PNA monomer 115 rather than the Fmoc-
protected AEG thymine PNA monomer. This modified PNA monomer 115 will 
introduce an alkyne function at the N-terminus of the target PNA oligomer 138 as 
shown in Figure 3.11.      
Figure 3.11: Structure of azide-alkyne functionalised PNA oligomer 138. 
Our novel monomer 115 was incorporated successfully at the N-terminus of PNA 
oligomer 138 under the same conditions that were used for oligomerisation of the 
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Fmoc/Bhoc AEG PNA monomers with no issue observed. After cleavage from the 
resin, the crude PNA oligomer 138 was purified by reverse phase HPLC and 
characterized by LC-MS. Mass spectrometric analysis showed that there were peaks 
for various multiply-charged species of the target sequence 138 (Appendix 8). 
3.3.2.3 Solid phase synthesis of alkyne-functionalized PNA oligomer 139 
The third target PNA sequence that was chosen to be ligated by the click ‘’CuAAC’’ 
reaction is the alkyne functionalised PNA oligomer 139 as shown in Figure 3.12.  
Figure 3.12: Structure of an alkyne functionalized PNA oligomer 139.
This new PNA oligomer was synthesised on the Rink Amide MBHA resin using the 
Fmoc/Bhoc AEG protected PNA monomers as described in Section 3.2.1. In order to 
introduce an alkyne function at the N-terminus of the PNA oligomer 139, the last 
coupling reaction was achieved smoothly with our novel alkyne functionalised 
thymine PNA monomer 115. This modified monomer was also coupled instead of 
the Fmoc-protected AEG thymine PNA monomer under the same conditions that 
were used for oligomerization the Fmoc/Bhoc-protected AEG PNA monomers. After 
cleavage from the resin, the crude PNA oligomer 139 was purified by reverse phase 
HPLC and characterized by LC-MS. Mass spectrometric analysis showed that there 
were peaks for various multiply-charged species of the target sequence 139 
(Appendix 9).  
3.3.3 Preliminary attempt to ligate PNAs via click reaction 
Having made the target azide and alkyne functionalized PNA oligomers 137, 138 and 
139, we turned our attention to trying to ligate them through copper (I)-catalysed 
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azide-alkyne cycloaddition reaction ‘’click reaction’’ which is a concept that was 
developed to join an azide and alkyne functionalized organic molecules under mild 
conditions.  
Principally, to enhance the ligation reaction and to ligate the target sequences in the 
correct order, a templated method is required. In other words, a sequence specific 
template should bind to the PNA sequences and align the functional groups such 
that a reaction is facilitated. Furthermore, templates will enhance the proximity of 
the azide and alkyne functions of the PNA oligomers. Therefore, this preliminary 
attempt involved a templated two-step methodology for the ligation of the 
synthesised PNA oligomers 137, 138 and 139 as shown in Scheme 3.6.
Scheme 3.6: Proposed synthetic route for the ligation of PNA oligomers. 
The first step of our method involved hybridising the target PNA oligomers 137, 138 
and 139 with a complementary sequence of DNA as a template. In this study, both 
antiparallel and parallel complementary sequences were separately used as 
templates. This hybridization was achieved by mixing the PNA oligomers 137, 138 
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and 139 with a DNA sequence as a template (Table 3.1) in 10 mM phosphate buffer 
solution containing 10 mM NaCl at pH 7.2. The sample was heated up to 90 °C in a 
heat block over one hour followed by slow cooling to 4 °C. In the second step, an 
aqueous solution containing copper (I) in the presence of an excess of sodium 
ascorbate as reducing agent to keep producing Cu (I) in situ during the click ligation 
reaction. An excess of THPTA was used as a ligand to prevent degradation of the 
DNA template. Click (CuAAC) ligation was performed using different concentrations 
of the PNA oligomers, DNA templates, copper source and sodium ascorbate as 
shown in table 3.1.   
Table 3.1: Concentrations used in the copper-catalysed cycloadditions reactions.  
No.
Exp.
Azido-
PNA
Azido-
alknyoic
PNA 
Alkyne-
PNA
DNA
template
Cu
Source
Na-
ascorbate 
THPTA
1 50.0 nM 50.0 nM 50.0 nM 50.0 nM CuSO4 
1.0 eq.
5.0 eq. 10.0
eq.
2 50.0 nM 50.0 nM 50.0 nM 60.0 nM CuSO4
10.0 eq.
50.0 eq. 25.0 
eq.
3 50.0 nM 50.0 nM 50.0 nM 50.0 nM Cu OAc. 
5.0 eq.
0.0 eq. 50.0 
eq.
4 50.0 nM 50.0 nM 50.0 nM 60.0 nM Cu Ac.
20 eq.
100.0 eq. 100.0 
eq.
The reactions were kept at room temperature for different times such as 2, 4, 8 and 
24 hours before being worked up. The crude reaction mixtures were first analysed 
RP-HPLC and mass spectrometry. Although the HPLC chromatograms and mass 
spectrometric analysis showed a disappearance of the peaks belonging to the PNA 
starting material, they did not show any significant peaks. Therefore, many methods 
for reverse phase HPLC analysis were set up in an attempt to get the desired 
product. However, all peaks that were collected by HPLC analysis and checked by 
mass spectrometry did not show matches with the calculated mass of the expected 
product or the starting material. Due to the expected product being composed of 30 
nucleobases in length, it was believed this long PNA oligomer was still binding to the 
DNA template tightly by hydrogen bonding and the resultant duplex cannot be 
denatured under HPLC analysis conditions. An attempt to denature this PNA/DNA 
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hybridization by addition of TFA was also unsuccessful in making significant changes 
in HPLC analysis or mass spectra.  
A parallel PNA/DNA duplex was considered for further investigation as this is less 
stable than their corresponding antiparallel duplex and may be denatured easily 
compared to antiparallel duplex. A parallel complementary DNA sequence was used 
as a template under the same conditions that were used with antiparallel 
hybridization for click ligation. However, this attempt also failed to provide the 
target product.  
For further investigations to verify if the target product was still binding to DNA 
template, two short complementary parallel 8-mer DNA sequences were designed 
to hybridise with PNA by the ends bearing the azide and alkyne functions. 
Unfortunately, this attempt was unsuccessful in giving the PNA target sequence. On 
the other hand, all mass spectra that were run for the crude click ligation reactions 
did not indicate peaks belonging to the PNA oligomers starting materials and the 
expected product.  
Many efforts and a long time were exerted to optimise this method, as if successful, 
it would represent a novel and relatively simple method for the ligation of three or 
more PNA oligonucleotides. Unfortunately, we have been unsuccessful to obtain the 
target product. However, at this point, we really can not specify if this reaction has 
failed or not because there is no evidence that confirms which the case is. However, 
the future work might be led to significant results. 
Chapter Four 
Biophysical Studies of PNA/DNA and 
PNA/RNA duplexes 
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4.1 Introduction 
As described previously, peptide nucleic acids (PNAs) are synthetic DNA mimics, in 
which the negatively charged phosphate-sugar backbone of DNA is replaced by an 
uncharged achiral poly N-(2-aminoethyl) glycine backbone which is connected to a 
nucleobase via a methylene carbonyl linker. This backbone structure is a key feature 
of PNAs compared to other DNA analogues. One impressive feature of PNA 
sequences is their ability to recognize and bind with high affinity and sequence 
selectivity to complementary sequences of DNA and RNA through Watson-Crick 
and/or Hoogsteen base pairing. This is predominantly due to the lack of 
electrostatic repulsion between the neutral PNA strand and the negatively charged 
nucleic acid strand. Even more interestingly, the formed PNA/DNA and PNA/RNA 
complexes exhibit a higher thermal stability than their corresponding traditional 
duplexes and the antiparallel complexes always display much higher thermal 
stability than parallel hybridization. Moreover, PNA/RNA duplex is more stable than 
PNA/DNA duplex. An additional consequence of the uncharged nature of polyamide 
PNA backbone structure is that the thermal stability of PNA/DNA and PNA/RNA 
complexes are virtually independent of the salt concentration and pH in the 
hybridization solution. On other words, these thermal stabilities are not significantly 
affected by changes in the ionic strength.   
As a general rule, the melting temperature (Tm) of a PNA/DNA duplex is 1°C on 
average higher per base pair relative to that of the corresponding DNA/DNA 
duplex.173,174 On the other hand, the thermal stability of PNA hybrids is significantly 
affected by the presence of any mismatching sections.175,176 Such presence of 
mismatches in a PNA/DNA duplex is much more destabilising than a mismatch in 
their corresponding natural nucleic acid complexes. For example, a single base 
mismatch results in a drop of 15 °C and 11 °C in the Tm of a 15-mer PNA/DNA and 
DNA/DNA duplex respectively.136 Specifically, this feature of PNA is responsible for 
the remarkable discrimination between perfect matches and mismatches offered by 
PNA probes, and makes PNA sequences so attractive as oligonucleotide recognition 
tools in biosensor technology. Although, the unique characteristics of PNAs have led 
to the development of a wide range of important applications, PNAs are not yet a 
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fully developed tool with some issues still being outstanding. The most problematic 
of these are their low water solubility, poor cell permeability and a limit to the 
length of sequences that can be prepared by solid phase peptide synthesis 
strategies. Thus, in order to overcome these limitation, there is ongoing research on 
developing and incorporating new monomers into PNA oligomers’ structure. In 
addition to looking for new methods to extend PNA lengths for applications that 
require long PNA sequences. As the thermal stability of PNA complexes is crucial for 
their application, it is necessary that all the target modifications improve or 
maintain the same thermal stability of the modified duplexes, compared to the 
unmodified duplexes. In general, these complexes mediate the antigene and 
antisense effects of PNAs via the steric blockade of enzyme complexes responsible 
for DNA transcription and RNA translation. The binding affinity of PNA oligomers 
toward nucleic acids and thermal stability of their PNA/DNA and PNA/RNA 
complexes can be assessed by several different biophysical techniques. The most 
frequently used of these being temperature dependent UV-spectroscopy (UV-Tm),50
Circular Dichroism (CD)50,177 and Differential Scanning Calorimetry (DSC).178
4.2 UV-Spectroscopic study of biophysical properties of PNA complexes 
The measurement of the UV absorbance as a function of the temperature (UV-Tm) 
is the standard approach to investigate the hybridization properties of PNA 
oligomers. In DNA/DNA, RNA/RNA and PNA/DNA complexes, the nucleobases can 
interact with each other, via their π electron clouds, when the nucleobases in the 
complex are stacked together when dissolved in water. Because the UV absorbance 
of the bases is a consequence of π electron transitions, the magnitude of these 
transitions is highly affected by this base stacking. For this reason, monitoring the 
UV absorption at 260 nm as a function of temperature has been extensively used to 
study the thermal stability of PNA/DNA and PNA/RNA duplexes.  
Practically, an increase in the temperature induces denaturation of the PNA/DNA or 
PNA/RNA complexes into their separate individual strands. This occurs because of 
the diminishing stacking interaction between adjacent bases, and disruption of 
hydrogen bonds between base pairs, leading to a complete loss of secondary 
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structure. Consequently, the UV absorbance that is recorded at 260 nm will increase 
with the temperature, in an effect termed as “hyperchromicity”.179 The process is 
co-operative, and the plot of the absorbance values at 260 nm vs. temperature is 
sigmoidal (Figure 4.1). Having the sigmoidal curves indicates the presence of a 
binding affinity between PNA and nucleic acids, and the midpoint of this sigmoidal 
transition represents the melting temperature of the formed duplex. This is in turn 
termed Tm, and is defined as the temperature at which 50% of the complexes have 
been dissociated.  
Figure 4.1: The sigmoidal graph of UV-Tm.
The sigmoidal nature of the transition suggests that at any temperature, nucleic 
acids exist in two states, as duplexes or as single strands, and at varying 
temperatures the relative proportions of the two states change. A non-sigmoidal 
(e.g. sloping linear) transition, with low hyperchromicity, is a consequence of non-
complementary hybridisation. This chapter addresses the biophysical studies of 
various modified PNA oligomers, and their hybrids formed with complementary 
sequences of DNA and RNA, using temperature-dependent UV spectroscopy. The 
biophysical studies have been carried out on a series of the designed PNA 
sequences, explored in earlier chapters. The resulting data has allowed us to 
investigate the effect of the incorporated novel monomeric units on the binding 
affinity to target nucleic acids, and the resulting duplex stability.  
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4.3 Results and Discussion
As shown in previous chapters, it is now possible for PNA to be extended by a click 
(CuAAC) reaction through 1,2,3-triazole formation as the ligation linker. 
Consequently, based on the structure of the azide and alkyne group precursors, 
different ligation linkages will be constructed in the structure of the extended PNA 
sequence. These modified PNA sequence is therefore being longer than the 
standard AEG PNA sequence and the target nucleic acids sequences despite having 
the same number of nucleobases. In general, most of the PNA modifications 
explored resulted in a lower thermal stability compared to their corresponding 
unmodified complexes.180 The incorporation of PNA monomers with an extended 
backbone, into standard PNA oligomers, reduced the thermal stability of the 
modified PNA/DNA duplexes compared to the corresponding unmodified 
duplexes.93 Thus, one challenge to be investigated is that the click reaction will 
result in an extended monomeric unit in the structure of the extended PNA 
sequence. For this reason, we are interested in investigating the effect of these click 
reaction linkages on the binding properties of PNA oligomers. This was achieved by 
incorporation of a single of monomeric unit of 121, 123 and 126 (Figure 4.2), at the 
central position of a specific 8-mer mixed pyrimidine-purine PNA sequence, during 
the Fmoc solid phase peptide synthesis strategy as described in Chapter three. 
Thus, a series of modified 1,2,3-tiazole functionalised PNA oligomers were 
synthesised as models, mimicking the products of the click ligation.  
Figure 4.2: Structure of novel monomers 121, 123 and 126. 
4.3.1 UV-Tm studies of the modified PNA oligomers with DNA  
For potential antigene applications, the ability of the target triazole-containing PNA 
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oligomers to form duplexes was studied with two complementary antiparallel 
sequences of DNA, an 8-mer (DNA1, Tm= 15 °C) and a 9-mer (DNA2, Tm=19 °C).  As 
the thermal stability of PNA/DNA duplexes is considerably lowered by the presence 
of mismatches, the 9-mer sequence was designed with a mismatch nucleobase 
relative to the target PNA sequences that were prepared as models to investigate 
the effect of novel monomeric units. This base is located at the centre of DNA2
sequence to correspond the site of these modified monomeric units in the modified 
PNA strand during PNA/DNA duplex formation. In the present study, the cytosine 
deoxynucleotide monomer was chosen for this purpose.  
This binding affinity of the modified PNA oligomer and their complexes’ stability 
were  evaluated by temperature dependent changes in their UV-absorbance which 
resulted in distinct melting curves. The absorbance at 260 nm was plotted as a 
function of the temperature. The Tm values were obtained from an average of the 
mid-points of the three sigmoidal thermal stability curves for each duplex with the 
standard deviation for these measurements. The binding properties of all modified 
PNA/DNA duplexes were analysed compared to their corresponding unmodified 
131/DNA1 duplex (Tm= 26.0 ±0.9 °C) and 131/DNA2 (Tm= 28.0 ±0.8 °C)  
4.3.1.1 UV-Tm studies of PNA/DNA duplexes modified with monomer 121 
In order to investigate the effect of the novel thymine PNA monomer 121 on the 
binding properties of the corresponding PNA/DNA duplexes, the modified PNA 
oligomers 132 and 133, each containing a single monomeric unit of 121, were first 
hybridised with an antiparallel complementary 8-mer sequence of DNA (DNA1). 
PNA oligomer 133 containing a single unit of lysine was incorporated adjusting to 
the monomer 121 as described in Chapter 3. The resulting 132/DNA1 and 
133/DNA1 duplexes were subsequently studied by Tm-dependent UV-absorbance 
experiments (Figure 4.3).  
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Figure 4.3: Comparison of the UV-melting curves of the duplex formed between 
DNA1 and (A) unmodified PNA oligomer (131), (B) modified PNA 
oligomer 132 and (C) modified PNA oligomer 133. Performed in a buffer 
of 10 mM potassium phosphate and 10 mM NaCl at pH 7.0. 
By the sigmoidal shape of the curves (Figures 4.3) that resulted from UV-melting 
experiments, it could be concluded that our novel thymine PNA monomer 121 does 
not prevent the corresponding PNA oligomer 132 from binding to the antiparallel 
complementary 8-mer sequence of DNA (DNA1). Even with the presence of the 
lysine moiety beside monomer 121, the corresponding PNA oligomer 133 still 
displayed an ability to bind to the target DNA sequence. One more item of note can 
be taken from the shape of the curves belonging to the modified 132/DNA1 and 
133/DNA1 duplexes. These curves are slightly different compared to the 
unmodified 131/DNA1 duplex that resulted in the standard sigmoidal shape. This 
difference can be attributed to the incorporation of modified PNA monomer 121
which consists of an extended backbone. Consequently, this led to PNA sequences 
being synthesised that is longer than the unmodified PNA sequence as described in 
Chapter 3. This, along with the geometry of monomer 121, results in a strand which 
may not be as compatible with the duplex formation geometry compared to the 
AEG PNA monomers.  
The Tm values that are given in Table 4.1 indicate that the incorporation of a single 
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monomeric unit of the novel thymine PNA monomer 121 into PNA oligomer 132 
slightly decreased the thermal stability the corresponding modified 132/DNA1 
compared to the corresponding unmodified duplex 131/DNA1. Whereas,
incorporation of lysine moiety into the PNA oligomer 133 reduced the thermal 
stability of the corresponding 133/DNA1 duplex compared to the modified 
132/DNA1 and unmodified 131/DNA1 duplexes.   
Table 4.1: Tm values of antiparallel PNA/DNA1 duplexes modified with the 
monomeric PNA unit 121 (X). ΔTm indicates the difference in Tm with the control 
unmodified 131/DNA1. 
PNA code PNA sequence
N-terminus       C-terminus
DNA1: 3' C-T-G-A-A-A-G-A 5'
UV-Tm °C (ΔTm) °C
131 G-A-C-T-T-T-C-T 26.0 ± 0.9 -
132 G-A-C-T-X-T-C-T 24.6 ± 0.8 -1.4
133 G-A-C-T-lys-X-T-C-T 23.0 ± 0.8 -3.0
For further investigation, the effect of monomer 121 was also verified in the 
presence of a mismatch base in the DNA sequence. This was achieved by 
hybridization of the corresponding PNA oligomers 132 and 133 with antiparallel 9-
mer complementary sequence of DNA (DNA2). From the shape of the curves (Figure 
4.4) that resulted from Tm-dependent UV-absorbance experiments, an important 
conclusion was reached. The modified 132/DNA2, 133/DNA2 and even unmodified 
131/DNA2 have all given distorted curves, compared to the standard sigmoidal 
shape. This expected distortion could be attributed to fact that the DNA2 sequence 
is longer than the PNA oligomers 131, 132 and 133. This difference in the length 
may be preventing the matching bases from pairing, resulting in slight mismatch 
character and loss of cooperativity. However, both modified PNA oligomers 132 and
133 also still showed some binding affinity with antiparallel complementary 9-mer 
DNA sequence (DNA2).  
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Figure 4.4: Comparison of the UV-melting curves of the duplex formed between   
DNA2 and (A) unmodified PNA oligomer 131, (B) modified PNA oligomer 
132 and (C) modified PNA oligomer 133. Performed in a buffer of 10 mM 
potassium phosphate and 10 mM NaCl at pH 7.0. 
The Tm values (Table 4.2) revealed that the incorporation of a single modified PNA 
monomer 121 almost kept the same thermal stability of the 132/DNA2 duplex that 
was resulted for the unmodified 131/DNA2. However, incorporation of lysine 
moiety associated with monomer 121 reduced the thermal stability of the 
corresponding 133/DNA2 duplex compared to both the modified 132/DNA2 and 
unmodified 131/DNA2 duplexes.  
Table 4.2: Tm values of antiparallel PNA/DNA2 duplexes modified with monomeric 
PNA unit 121 (X), ΔTm indicates the difference in Tm with the control unmodified 
131/DNA2 duplex. 
PNA code PNA sequence
N-terminus       C-terminus
DNA2: 3' C-T-G-A-C-A-A-G-A 5'
UV-Tm °C (ΔTm) °C
PNA 131 G-A-C-T-T-T-C-T 28.0 ± 0.9 -
PNA 132 G-A-C-T-X-T-C-T 28.7 ± 0.3 +0.7
PNA 133 G-A-C-T-lys-X-T-C-T 25.0 ± 0.9 -3.0
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4.3.1.2 UV-Tm studies of PNA/DNA duplexes modified with monomer 123 
As was mentioned in Chapter 3, the novel monomer 123 was incorporated as 
independent monomer into the model PNA sequence to mimic a new click ligation 
linker type that can be seen in the structure of the extended PNA sequences. 
Specifically, 4-pentynoic acid was used to introduce the alkyne function at the N-
terminus of PNA oligomers. Structurally, unlike monomer 121, monomeric unit 123
does not contain a nucleobase, thereby this monomeric unit acts as a spacer with 
no complementarity.  
In order to investigate the effect of this type of click ligation, the hybridisation 
properties of the corresponding modified 9-mer PNA oligomers 134 and 135 were 
first tested with the antiparallel complementary 8-mer DNA sequence (DNA1), and 
evaluated by temperature dependent UV spectroscopy (Figure 4.5).  
Figure 4.5: Comparison of the UV-melting curves of the duplex formed between 
DNA1 and (A) unmodified PNA oligomer 131, (B) modified PNA oligomer 
134 and (C) modified PNA oligomer 135. Performed in a buffer of 10 mM 
potassium phosphate and 10 mM NaCl at pH 7.0. 
The thermal curves, which are shown in Figure 4.5, demonstrated that although the 
modified 9-mer PNA oligomer 134 is longer, with one extended monomeric unit 123
than the target 8-mer DNA sequence (DNA1), it still has some affinity towards the 
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duplex formation. However, the incorporation of both the lysine moiety associated 
with monomer 123 into PNA oligomer 135 reduced the binding affinity towards the 
DNA target and gave a non-sigmoidal plot. This lack affinity of PNA oligomers 135
can be imputed to that this PNA oligomer is considered the longest of the PNA 
sequences due to incorporation of both modifications. 
Furthermore, the Tm values are listed in Table 4.3 showed that incorporation of a 
single novel monomeric unit of 123 decreased the thermal stability of the modified 
134/DNA1 duplex compared to the unmodified 131/DNA1 duplex  
Table 4.3: Tm values of antiparallel PNA/DNA1 duplexes that are modified with 
monomeric PNA unit 121 (X), ΔTm indicates the difference in Tm with the control 
unmodified 131/DNA1. 
PNA code PNA sequence
N-terminus       C-terminus
DNA1: 3' C-T-G-A-A-A-G-A 5'
UV-Tm °C (ΔTm) °C
PNA 131 G-A-C-T-T-T-C-T 26.0 ± 0.9 -
PNA 134 G-A-C-T-X-T-T-C-T 21.7 ± 0.8 -4.3
PNA 135 G-A-C-T-lys-X-T-T-C-T No duplex -
Again, to further investigate the effect of this independent monomeric unit 123 on 
the binding properties of PNA which contain it, the corresponding modified PNA 
oligomers 134 and 135 were investigated with antiparallel complementary 9-mer 
DNA2 sequence.  From the general appearance of the shape of the curves (Figure 
4.6), it could be concluded that both modified oligomers 134 and 135, have 
displayed an improved binding affinity with the DNA2 sequence compared to their 
binding affinity with the DNA1 sequence that was described in Figure 4.5. A 
reasonable explanation for this is that the difference in the length between these 
modified PNA oligomers and DNA2 is less than with DNA1. 
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Figure 4.6: Comparison of the UV-melting curves of the duplex formed between 
DNA2 and (A) unmodified PNA oligomer 131, (B) modified PNA oligomer 
134 and (C) modified PNA oligomer 135. Performed in a buffer of 10 mM 
potassium phosphate and 10m M NaCl at pH 7.0. 
The Tm values that are given in Table 4.4 have shown that the incorporation of 123
slightly destabilised the 134/DNA2 and 135/DNA2 duplexes compared to the 
corresponding unmodified 131/DNA2. In a general conclusion, incorporation of 
monomer 123 displayed less thermal stability than monomer 121 for both 
PNA/DNA1 and PNA/DNA2 duplexes.  
Table 4.4: Tm values of antiparallel PNA/DNA2 duplexes modified with monomeric 
unit 123 (X), ΔTm indicates the difference in Tm with control unmodified 131/DNA2. 
PNA code PNA sequence
N-terminus       C-terminus
DNA2: 3' C-T-G-A-C-A-A-G-A 5' 
UV-Tm °C (ΔTm) °C
131 G-A-C-T-T-T-C-T 28.0 ± 0.8 -
134 G-A-C-T-X-T-T-C-T 27.0 ± 0.8 -1.0
135 G-A-C-T-lys-X-T-T-C-T 25.6 ± 0.9 -2.4
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4.3.1.3 UV-Tm studies of PNA/DNA duplexes modified with monomer 126 
As described for the above monomeric units, 121 and 123, the novel monomeric 
unit 126 was studied as a potential click ligation linker of the extended PNA 
sequence. Specifically, once compound 124 was used to introduce the alkyne 
function at the N-terminus of PNA oligomers. Structurally, like monomer 123, this 
monomer does not contain a nucleobase that was attached in monomer 121, but it 
contains a secondary amino group that cannot be seen in either 121 or 123. Thus, 
to study the effect of including monomeric unit 126 in PNA oligomers on its binding 
properties, the corresponding PNA oligomer 136 that contains a single monomeric 
unit of 126 was first hybridised to the complementary antiparallel DNA1 (Figure 
4.7).  
Figure 4.7: Comparison of the UV-melting curves of the duplex formed between 
DNA1 and (A) unmodified PNA oligomer 131, (B) modified PNA oligomer 
136. Performed in a buffer of 10 mM potassium phosphate and 10 mM 
NaCl 10 at pH 7.0. 
From the shape of the curves that are shown in Figure 4.7, it is observed that the 
incorporation of a single monomeric unit 126 benefitted the binding affinity of the 
modified PNA oligomers 136. However, like PNA oligomer 134 the modified PNA 
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oligomer 136 has an independent extra monomeric unit therefore being longer 
compared to the DNA1 sequence. For this reason, the corresponding duplex 
136/DNA1 has resulted in a distorted curve which is associated with a slightly 
decreased thermal stability as given in Table 4.5. 
Table 4.5: Tm values of antiparallel PNA/DNA1 duplexes that are modified with 
monomeric PNA unit 126 (X), ΔTm indicates the difference in Tm with control 
unmodified 131/DNA1 duplex. 
PNA code PNA sequence
N-terminus       C-terminus
DNA1: 3' C-T-G-A-A-A-G-A 5'
UV-Tm °C (ΔTm)
PNA 131 G-A-C-T-T-T-C-T 26.0 ± 0.9 -
PNA 136 G-A-C-T-X-T-T-C-T 24.0 ± 0.9 -2.0
As described for others PNA oligomers, the biophysical properties of the PNA 
oligomer 136 was also studied by hybridising with the 9-mer DNA sequence DNA2, 
to investigate whether this secondary amine group of this monomeric unit 126 can 
support this monomer to make a hydrogen bond with the spacer cytosine base on 
the DNA2 sequence. This was also performed using Tm-dependent UV absorbance 
experiments. The shape of the curve, belonging to the 136/DNA2 hybrid (Figure 
4.8), allows us to conclude that the modified oligomer 136 has displayed an 
improved sigmoidal shape over the previous corresponding 136/DNA1. This result 
also can once again be ascribed to the reduction in the difference in a length 
between the 136 and DNA2 sequence, compared to 136 and DNA1. 
The Tm values that are given in Table 4.6 have shown that incorporation of a single 
monomeric unit of compound 126 almost maintained the thermal stability of the 
modified 136/DNA compared to the corresponding unmodified 131/DNA2. 
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Figure 4.8: Comparison of the UV-melting curves of the duplex formed between 
DNA2 and (A) unmodified PNA oligomer 131, (B) modified PNA oligomer 
136. Performed in a buffer of 10 mM potassium phosphate and 10 mM 
NaCl at pH 7.0. 
Table 4.6: Tm values of antiparallel PNA: DNA2 duplexes modified with monomeric 
PNA unit 126 (X), ΔTm indicates the difference in Tm with control unmodified 
131/DNA2 duplex. 
PNA code PNA sequence
N-terminus       C-terminus
DNA2: 3' C-T-G-A-C-A-A-G-A 5'
UV-Tm °C (ΔTm) °C
131 G-A-C-T-T-T-C-T 28.0 ±0.9 -
136 G-A-C-T-X-T-T-C-T 28.6 ±0.9 +0.6
4.3.2 UV- Tm studies of modified PNA oligomers with RNA 
This section describes the hybridisation properties of the modified PNA oligomers 
with a complementary antiparallel RNA sequence (5’ AGAAAGUC 3’), therefore 
displaying any differences in property enhancement between the DNA/PNA hybrids 
and the RNA/PNA hybrids.  
As mentioned previously RNA/PNA hybrids tend to show more affinity towards each 
other and increased stability over their DNA counterparts, however it is important 
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to see how modifying the PNA monomers affects this observation. The binding 
properties of all modified PNA/RNA duplexes were analysed to their corresponding 
unmodified 131/RNA duplex (Tm= 37 ±0.8 °C). As described for modified PNA/DNA1 
duplexes, the modified PNA/RNA duplexes displayed distorted curves compared to 
the standard sigmoidal shape. Again, this distortion could be attributed to fact that 
the modified PNA sequences are longer than RNA sequences. This difference in the 
length may be preventing the matching bases from pairing, resulting in slight 
mismatch character and loss of cooperativity. Consequently, this may be leading to 
a change in the conformation of PNA/RNA duplexes thereby resulting in a 
decreased thermal stability.  
4.3.2.1 UV- Tm studies of PNA/RNA duplexes modified with monomer 121 
The modified PNA oligomers 132 and 133 that are containing a single unit of 
monomer 121 were hybridized to a complementary antiparallel RNA sequence to 
form PNA/RNA duplexes. Thus, this will use as a model to investigate the effect of 
the novel thymine PNA monomer 121 on the binding properties of potential RNA 
antisense PNA oligomers. The hybridisation properties were studied by Tm-
dependent UV absorbance experiments. From the sigmoidal shape of the curves 
shown in Figure 4.9, it can be concluded that both modified PNA oligomers 132 and 
133 still displayed the ability to bind with the antiparallel RNA sequence.  
The melting profiles of PNA/RNA duplexes that have been derived from PNA 
oligomers 132 and 133 are listed in Table 4.7. However, these results showed that 
incorporating the monomeric unit 121 significantly destabilised the 132/RNA 
duplex by (-13.8 °C) and 133/RNA duplex by (-11.1 °C) compared to the unmodified 
131/RNA duplex. 
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Figure 4.9: Comparison of the UV-melting curves of the duplex formed between 
RNA and (A) unmodified PNA oligomer 131, (B) modified PNA oligomer 
132 and (C) modified PNA oligomer 133 in a buffer of 10 mM potassium 
phosphate and 10 mM NaCl at pH 7.0. 
Table 4.7: Tm values of antiparallel PNA/RNA duplexes modified with monomeric 
unit 121 (X), ΔTm indicates the difference in Tm compared with control unmodified 
131/RNA. 
PNA code PNA sequence
N-terminus       C-terminus
RNA: 3' C-U-G-A-A-A-G-A 5'  
UV-Tm °C (ΔTm)
131 G-A-C-T-T-T-C-T 37.0 ± 0.8 -
132 G-A-C-T-X-T-C-T 23.2 ± 0.9 -13.8
133 G-A-C-T-lys-X-T-C-T 25.9 ± 0.9 -11.1
4.4.2.2 UV- Tm studies of PNA/RNA duplexes modified with monomer 123 
To investigate the effect of novel monomeric 123 on the potential RNA antisense 
PNA, the corresponding modified PNA oligomers 134 and 135 were hybridised as 
well with an antiparallel complementary RNA sequence. The hybridisation 
properties were also studied by Tm-dependent UV absorbance (Figure 4.10). To a 
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certain extent, the shape of thermal curves indicates that the modified PNA 
oligomers 134 and 135 still have an affinity towards binding the antiparallel 
complementary RNA sequence.   
Figure 4.10: Comparison of the UV-melting curves of the duplex formed between 
RNA and (A) unmodified PNA oligomer 131, (B) modified PNA oligomer 
134 and (C) modified PNA oligomer 135. Performed in a buffer of 10 mM 
potassium phosphate and 10 mM NaCl at pH 7.0. 
However, the Tm values (Table 4.8) showed that the inclusion of novel monomeric 
123 extremely reduced the thermal stability of the PNA/RNA duplexes, which 
resulted from the use of PNA oligomers 134 and 135, by -15.7 °C and -16.0 °C 
respectively. These are significant reductions compared to the use of the 
unmodified 131/RNA duplex. 
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Table 4.8: Tm values of antiparallel PNA/RNA duplexes modified with monomeric   
PNA unit 123 (X), ΔTm indicates the difference in Tm compared with the control 
unmodified 131/RNA hybrid. 
PNA code PNA sequence
N-terminus       C-terminus
RNA: 3' C-U-G-A-A-A-G-A 5'  
UV-Tm °C (ΔTm) °C
131 G-A-C-T-T-T-C-T 37.0 ± 0.8 -
134 G-A-C-T-X-T-T-C-T 21.3 ± 0.9 -15.7
135 G-A-C-T-lys- X-T-T-C-T 21.0 ± 0.8 -16.0
4.4.2.3 UV -Tm studies of PNA/RNA duplexes modified with monomer 126 
The modified PNA oligomer 136 was used as a model to investigate the effect of 
another expected click ligation linker, which can also be seen in the structure of an 
extended PNA sequence for potential antisense application. This linkage was 
modelled by incorporation of a single monomeric unit of monomer 126 at a specific 
position. The hybridisation properties of the modified PNA oligomer 136 were 
investigated by testing its ability to hybridise with a complementary antiparallel 
RNA sequence. The hybridisation properties were studied by Tm-dependent UV 
absorbance (Figure 4.11). Judging by the shape of the curves shown in Figure 4.11, 
the modified oligomer 136 still has an affinity towards binding the antiparallel 
complementary RNA sequence.  
The Tm values that are given in Table 4.9 have shown that introduction of this 
independent monomeric unit 126 into PNA oligomer 136 reduced the thermal 
stability of the corresponding 136/RNA duplex by -11.5 °C compared to the 
corresponding unmodified  131/RNA duplex.  
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Figure 4.11: Comparison of the UV-melting curves of the duplex formed between 
RNA with (A) unmodified PNA oligomer 131, (B) modified PNA oligomer 
136. Performed in a buffer of 10 mM potassium phosphate and 10 mM 
NaCl at pH 7.0. 
Table 4.9: Tm values of antiparallel PNA/RNA duplexes modified with monomeric 
PNA unit 126 (X), ΔTm indicates the difference in Tm compared with the control 
unmodified 131/RNA hybrid. 
PNA code PNA sequence
N-terminus       C-terminus
RNA: 3'C-U-G-A-A-A-G-A 5'  
UV-Tm °C (ΔTm)
131 G-A-C-T-T-T-C-T 37.0 ± 0.8 -
136 G-A-C-T-X- T-T-C-T 25.5 ± 0.9 - 11.5 °C
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5.1 Conclusions
The work that is described in this thesis mainly deals with the synthesis of two 
classes of novel PNA monomers as well as their application as building blocks in the 
Fmoc solid phase PNA synthesis strategy for modified PNA oligomers that will be 
used in specific applications.   
Since PNA is being considered as a substrate for the copper (I) catalysed azide-
alkyne cycloaddition for different applications, the alkyne group required for the 
reaction would be at the N/C-terminus of the PNA oligomers. A new and efficient 
synthetic route was consequently developed to synthesise novel N-alkyne 
functionalized PNA monomers bearing thymine, Bhoc-protected cytosine, Bhoc-
protected adenine, and Bhoc-protected guanine. These monomers are used to 
introduce an alkyne group at the N-terminus of PNA oligomers.  
An N-propargyl PNA monomer bearing thymine base 115 was incorporated 
successfully into PNA oligomers 138 and 139 under the same conditions that were 
used for oligomerisation of the AEG PNA monomers following the Fmoc solid phase 
synthesis strategy. Whereas the incorporation of N-alkyne PNA monomers of 
cytosine, adenine and guanine was not attempted because it was deemed that 
these monomers were not required at this stage of our initial investigations.  
As an application for ligation PNA by click reaction, we tried to use the CuAAC 
reaction to implement a novel DNA-templated method to ligate three azide and 
alkyne functionalized mixed pyrimidine-purine PNA oligomers. Antiparallel and 
parallel complementary DNA sequences were used as templates.  
Many attempts at click ligation were made involving the use of Cu (II) or Cu (I) salts 
in the presence of an excess of Na-ascorbate to keep producing Cu (I) by reducing 
Cu (II) that was used as a starting material or produced in situ from oxidation of Cu 
(I). Furthermore, an excess of THPTA was used to avoid the DNA template 
degrading. All attempts were unsuccessful in achieving this aim. Although HPLC 
chromatograms and mass spectra that were run for click reaction mixture did not 
show the peaks that are belonging to the desired product or PNA oligomers starting 
materials, we really can not specify if this reaction failed or not. 
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We have successfully used Cu (I) catalysed azide-alkyne cycloaddition to synthesise 
three novel 1,2,3-triazole functionalized monomeric suitable for Fmoc solid phase 
peptide synthesis. Our strategy involved investigating new conditions to connect 
the N-alkyne PNA monomer bearing thymine base 115 PNA monomer to the 
synthesised Fmoc-protected 2-aminoethyl azide 120 to afford novel 1,2,3-triazole 
functionalised thymine PNA monomer 121. Compound 120 was then clicked with 
the commercially available 4-pentynoic 122 and the synthesised N-propargyl-N-Boc 
glycine acid 125 to give the novel monomeric units 123 and 126 respectively.  
These modified 1,2,3-triazole functionalised monomers have shown an ability to be 
incorporated into PNA sequences that were used as models in the evaluation of 
their effect on the binding properties of the potential antisense and antigene PNA 
agents. The incorporation of these monomers into PNA oligomers was done easily 
under the same conditions that are used for oligomerization of the Fmoc/Bhoc PNA 
monomers without any significant issue observed.  
The thermodynamic profiles of hybridization studies that was studied by Tm-
dependent UV spectroscopy indicate that all the novel 1,2,3-tiazole functionalised 
121, 123 and 126 monomers have unevenly maintained the binding affinity and 
slightly reduced thermal stability of their oligomers towards both antiparallel 
complementary DNA sequences 8-mer (DNA1) and 9-mer (DNA2). Also, it was 
demonstrated that the incorporation of a lysine moiety beside monomer 121
reduced the thermal stability of the corresponding 133/DNA1 and 133/DNA2 
duplexes. Whereas, the introduction of a lysine moiety beside monomer 123
prevents the corresponding PNA oligomer from binding the 8-mer DNA sequence 
(DNA1) and reduced the thermal stability of the corresponding 135/DNA2 duplex. 
For antisense investigations, all the modified 1,2,3-triazole functionalised PNA 
oligomers have displayed an ability to bind an antiparallel complementary 8-mer 
RNA sequence. However, their duplexes resulted in a reduced thermal stability 
compared to the corresponding unmodified PNA/RNA duplex. 
However, we think these changes in the binding affinity and thermal stability maybe 
are not going to be a problematic issue for click ligation because if the click ligation 
was successful, then it would have a longer PNA sequence. So, any detrimental 
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effect resulting from a click linker would be more than compensated by the 
increases in the number of nucleobases.   
The encouraging results of novel Fmoc-protected 1,2,3-triazole functionalised 
thymine PNA monomer 121 lead us to believe that our novel alkyne monomers 115,
116, 117 and 118 will be suitable to introduce an alkyne function at the N-terminus 
for ligation of PNA by click reaction. This will lead to construction of ligation linkages 
that are maybe are capable of maintaining the binding affinity and thermal stability 
of extended PNA sequences compared to the other linkages that do not contain 
nucleobase. 
5.2 Future work
As PNA/DNA duplexes have resulted in encouraging binding properties, future 
investigation for biological applications can be achieved for the novel 1,2,3-triazole 
functionalised thymine PNA monomer 121, for instance, by studying its effect on 
the cellular uptake of the corresponding PNA oligomers further to investigate if this 
modified monomer has a metabolic stability.  
Future work could be utilising the tert-butyloxycarbonyl group (Boc) that has proven 
a stability toward click reaction conditions to protect the exocyclic amino function 
of cytosine, adenine and guanine bases of the N-alkyne PNA monomers. This 
protection will help to overcome the deprotection issue of Bhoc group to yield 
novel 1,2,3-triazole functionalised PNA monomers suitable for Fmoc solid phase 
PNA synthesis strategy and could be used to develop a new analogue of PNA.  
For the future, the effect of the 1,2,3-triazole functionalised monomeric units 121, 
121 and 126 on the on the conformation of PNA/DNA and PNA/RNA duplexes can 
be studied by CD spectroscopy. In addition, this technique can be used as a 
complementary tool to Tm-dependent UV spectroscopy to evaluate the effect of 
these monomeric units on thermal stability of their corresponding PNA/DNA and 
PNA/RNA duplexes.  
For ligation of PNAs by click reaction, continued research could involve more studies 
to understand what happened with this reaction. Firstly, what happened to the PNA 
oligomers starting material if the click ligation of PNA oligomers is not going toward 
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the desired product. If it is believed that there is a product still binding to the DNA 
template, then an efficient method should be devised to denature PNA/DNA-
template hybrid and remove the DNA template. 
Further investigations could include the effect of proximity of the azide and alkyne 
terminus of PNA oligomers that are hybridising with a DNA template. That can be 
achieved by introducing a long chain containing an azide or alkyne group into PNA 
sequences.  
Furthermore, a new strategy such as performing the ligation of PNA sequences on 
the solid support may be led to better results.    
Finally, an alternative approach based on the bio-orthogonal chemistry can be 
useful for ligation of PNA oligomer in cells in a copper-free reaction where a 
cyclooctyne is used as an alkyne terminus. That would avoid any toxicity problems 
with the copper salt.      
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6.0 Experimental  
6.1 Synthesis of PNA monomers 
Chemicals and solvents   
All solvents including anhydrous DMF were purchased from commercial suppliers 
and used without further purification. Anhydrous THF and MeCN were collected 
from a solvent purification system. Chemicals were purchased from Acros, Aldrich, 
Fluka, Molekula, Alfa Aesar and Novabiochem and were used without further 
purification. 
Melting Points
Melting points were determined on a Gallenkamp melting point apparatus fitted 
with a mercury thermometer and are uncorrected. 
NMR Spectroscopy 
All 1H NMR and 13C NMR spectra were recorded on a Bruker DPX 400 (400 MHz for 
1H NMR and 100 MHz for 13C NMR) or a Bruker 500 (500 MHz, for 1H NMR and 125 
MHz for 13C NMR). Chemical shifts are given in parts per million, where all spectra 
were calibrated using chemical shifts reported relative to the residual deuterated 
solvent signals in CDCl3 [7.26 ppm for 1H (singlet) and 77.0 for 13C (central line of 
triplet)], DMSO-d6 [2.50 ppm for 1H (central signal of quintuplet) and 39.7 ppm for 
13C (central line of septuplet)]. Coupling constants (J) values are quoted in Hertz 
(Hz).
Mass Spectrometry
Mass spectrometry was performed at the Cardiff University, UK, by the analytical 
services team.  
IR Spectroscopy
Infrared spectra were recorded at Cardiff University, UK, on an FT/IR–660 plus 
spectrometer operating from 4000 – 500 cm-1 as a thin film or as KBr disc. 
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Procedures 
Synthesis of ethyl glycinate 98
To a stirred suspension of glycine 96 (7.5 g, 100 mmol) in ethanol (100 ml) at room 
temperature, TMSCl (25 ml, 200 mmol) was slowly added. The resulting mixture 
reaction was then stirred for 24 h at room temperature. The reaction mixture was 
then concentrated on a rotary evaporator to dryness. The solid product was dried 
under high vacuum for 2 hours to yield the desired compound ethyl glycinate 
hydrochloride 97 (14.9 g, 99.9 %) as white crystals.  
Triethylamine (7.5 ml, 71.7 mmol) was slowly added to a stirred suspension of ethyl 
glycinate hydrochloride 97 (10.0 g, 71.6 mmol) in dichloromethane (100 ml) at 25 
°C. The resulting solution was then stirred for 20 min at the same temperature. The 
solvent was evaporated on a rotary evaporator, and the residue was dissolved in 
ethyl acetate (25 ml). The resulting solution was filtered to remove 
triethylammonium chloride, washed with brine (2 × 25 ml). The organic phase was 
dried over Na2SO4 and concentrated to obtain the target product 98 (6.2 g, 84%) as 
pale green oil.
1H NMR (400 MHz, CDCl3); δ= 4.15 (q, J= 8.0 Hz, 2H, OCH2CH3), 3.38 (s, 2H, 
NCH2CO), 1.45 (s, 2H, NH2), 1.23 (t, J= 8.0 Hz, 3H, CH2CH3). 
13C NMR (100 MHz, CDCl3); δ= 174.11, 60.55, 43.62, 13.99. 
LRMS-ES+ (m/z): Calc. for C4H10NO2 [M+H]+= 104.1, found 104.01. 
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Synthesis of ethyl N-propargyl glycinate 99 183
To a stirred solution of ethyl glycinate 98 (5.0 g, 48.5 mmol) dissolved in dry CH3CN 
containing K2CO3 (9.0 g, 65.2 mmol), a solution of 3-bromopropyne (80% w/v in 
toluene), (3.0 ml, 33.6 mmol) was added in one portion. The reaction mixture was 
then stirred for 8 hours at room temperature. The solvent was evaporated on a 
rotary evaporator. The paste residue was dissolved in ethyl acetate (50 ml), filtered, 
washed with water (2 × 25 ml) and brine (2 × 25 ml). The organic phase was dried 
over anhydrous Na2SO4 and concentrated to give the desired product 99 (5.4 g, 
78%) as pale yellow oil.  
1H NMR (400 MHz, CDCl3): δ = 4.17 (q, J= 7.01 Hz, 2H, OCH2CH3), 3.47 (s, 2H, 
NCH2COO), 3.44 (d, J= 2.30 Hz, 2H, CH2C≡CH), 2.20 (t, J= 2.30 Hz, 1H C≡CH), 1.84 (s,
br, 1H, NH), 1.25 (t, J= 7.01 Hz, 3H, CH2CH3).  
13C NMR (100 MHz, CDCl3): δ= 171.72, 81.11, 71.94, 60.63, 48.99, 37.4, 14.04. 
HRMS-APCl+ (m/z): calc. for C7H12NO2 [M+H]+ =142.0868, found= 142.0863. 
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Synthesis of thymin-1-yl acetic acid 100 156
To a stirred aqueous solution of KOH (7.0 g, 124.8 mmol) dissolved in water (30 ml) 
was added thymine 2 (5.0 g, 39.6 mmol). The resulting solution was then heated to 
40 °C before addition a solution of bromoacetic acid (8.3 g, 59.7 mmol) dissolved in 
water (15 ml) dropwise over 20 min. The reaction mixture was stirred for a further 
30 minutes at this temperature. The reaction mixture was cooled to room 
temperature and acidified with a concentrated solution of hydrochloric acid until pH 
5.5. The resulting solution was then kept in a fridge for two hours. The precipitate 
formed (unreacted thymine) was removed by filtration. The filtrate was then 
acidified with a concentrated solution of hydrochloric acid until pH 2.0 and placed in 
a freezer for 2 hours. The resultant white precipitate was collected by filtration and 
dried under high vacuum to give the titled compound 100 (6.3 g, 86%) as white 
crystals; melting point (mp): 252-254 °C [lit.181 mp: 252-253 °C]. 
1H NMR (400 MHz, DMSO-d6): δ = 11. 35 (s, 1H, NH), 7.51 (s, 1H, CH=C), 4.37 (s, 2H, 
NCH2COOH), 1.75 (s, 3H, CH3).  
13C NMR (100 MHz, DMSO-d6): δ = 170.15, 164.84, 151.45, 142.22, 108.87, 48.89, 
12.31. 
LRMS-ES+ (m/z): calc. for C7H9N2O2 [M+H]+ =185.10, found= 185.07. 
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Synthesis of benzyl cytosin-1-yl acetate 10191
A suspended solution of cytosine 3 (5.0 g, 45.0 mmol) and potassium carbonate 
(12.0 g, 86.8 mmol) in anhydrous DMF (40 ml) was stirred at 100 °C for two hours. 
The reaction mixture was then cooled in an ice-water bath and benzyl 
bromoacetate (7.5 ml, 47.3 mmol) was added in one portion. The reaction mixture 
was then stirred for a further one hour before being removed from the ice-water 
bath. The reaction mixture was stirred at room temperature for 12 hours. The 
solvent was evaporated by a rotary evaporator. The paste residue was triturated 
with water (50 ml) and stirred for 10 minutes. The precipitate was collected by 
filtration and dried under high vacuum to give the titled compound 101 (8.2 g, 70%) 
as a pale white solid, melting point (mp): 242-245 °C. 
1H NMR (400 MHz, DMSO-d6); δ= 7.58 (d, J = 7.5 Hz, 1H, Cyt-C6), 7.35-7.39 (m, 5H, 
Ar-H), 7.16 (br, 1H, NH), 5.69 (d, J= 7.5 Hz, 1H, Cyt-C5), 5.16 (s, 2H, OCH2Ph), 4.51 (s, 
2H, NCH2COO).  
13C NMR (100 MHz, DMSO-d6); δ= 168.9, 166.6, 156.03, 146.51, 135.96, 128.66, 
128.33, 128.1, 93.82, 566.30, 50.24.  
HRMS-EI+ (m/z): calc. for C13H14N3O3 [M+H] + = 260.0957, found= 260.0959. 
The spectroscopic data are in agreement with the literature.182
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Synthesis of benzyl (N4-(benzhydryloxycarbonyl) cytosine-1-yl acetate 102 91
To a stirred solution of compound 101 (5.0 g, 19.3 mmol) dissolved in anhydrous 
DMF (30 ml) was added 1,1-carbonyldiimidazole (6.0 g, 37.0 mmol) in one portion. 
The reaction mixture was stirred at 60 °C for two hours before addition of 
benzhydrol (5.0 g, 27.1 mmol). The reaction mixture was then stirred for 12 hours at 
the same temperature. The solvent was evaporated on a rotary evaporator. To the 
residue was added water (100 ml) and the resulting solution was stirred for 30 
minutes. The white precipitate that formed was collected by filtration, washed with 
diethyl ether (2 × 50) and dried under high vacuum to give the desired compound 
102 (7.0 g, 78%) as a white solid, melting point (mp): 182-185 °C. 
1H NMR (400 MHz, DMSO-d6); δ= 11.07 (br., 1H, NH), 8.65 (d, J= 8.0 Hz, 1H, 
Cytosinyl C(6)-H), 7.48-7.27 (m, 15H, Ar-H), 6.98 (d, J=8.0 Hz, 1H, CH, Cytosinyl C(5)-
H), 6.80 (s, 1H, Ph2CHOCO), 5.18 (s, 2H, COOCH2Ph), 4.69 (s, 2H, NCH2COO). 
13C NMR (100 MHz, DMSO-d6); δ= 168.14, 163.68, 155.24, 152.57, 150.63, 140.56, 
135.76, 128.78, 128.67, 128.40, 128.15, 128.10, 126.70, 94.25, 77.57, 66.44, 50.71. 
HRMS-ES+ (m/z): Calc. for C27H23N3O5Na [M+Na]+ = 492.1535, found= 492.1551. 
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Synthesis of N4-(benzhydryloxycarbonyl) cytosin-1-yl acetic acid 103 91
Benzyl (N4-(benzhydryloxycarbonyl) cytosin-1-yl acetate 102 (6.0 g, 12.8 mmol) was 
dissolved in a mixture of acetonitrile, methanol, ethanol and water (78 ml, 2:2:1:1). 
To the resulting solution was added a solution of anhydrous lithium hydroxide (5.2 
g, 217.0 mmol) dissolved in water (40 ml). The resulting reaction mixture was 
stirred at room temperature for 15 minutes. The reaction mixture was cooled in an 
ice bath before being treated with a solution of citric acid (15.0 g, 78.1 mmol) 
dissolved in water (65 ml). The resulting solution was stirred for further 10 minutes 
before collecting the precipitate by vacuum filtration. The precipitate was washed 
several times with water and dried under high vacuum to afford the titled product 
103 (4.4 g, 92%) as a white powder, melting point (mp): 320-323 °C. 
1H NMR (400 MHz, DMSO-d6); δ= 11.03 (s (br), 1H, NH), 8.01 (d, J= 7.2 Hz, 1H, CH, 
Cytosinyl C(6)-H), 7.47-7.27 (m, 10H, Ar-H), 6.945 (d, J= 7.20 Hz, 1H, CH, Cytosinyl 
C(5)-H), 6.79 (s, 1H, CHOCO), 4.51 (s, 2H, NCH2COOH). 
13C NMR (100 MHz, DMSO-d6); δ= 170.06, 163.86, 155.79, 153.00, 151.21, 140.94, 
128.80, 128.12, 126.43, 94.26, 77.80, 59.97. 
HRMS-ES-ve (m/z): calc. for C20H16N3O5 [M-H]- = 378.109, found= 378.109. 
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Synthesis of ethyl adenin-9-yl acetate 104 91
Potassium carbonate (10.0 g, 72.4 mmol) and adenine 6 (5.0 g, 37.0 mmol) were 
suspended in anhydrous DMF (50 ml). The resulting suspension was stirred at 100 
°C for 30 minutes. The reaction mixture was then cooled in an ice bath and ethyl 
bromoacetate (4.1 ml, 37.0 mmol) was added via syringe over 5 minutes. The 
stirred reaction mixture was maintained for a further one hour at the same 
temperature. The reaction mixture was then allowed to stir at the ambient 
temperature for four hours. The solvent was evaporated by a rotary evaporator to 
dryness. The solid residue was triturated with water (50 ml) and stirred for 15 
minutes. The precipitate was collected by filtration under vacuum and dried under 
high vacuum to obtain the desired compound 104 (7.8 g, 96%) as a pale white solid, 
melting point (mp): 217-220 °C. 
1H NMR (400 MHz, DMSO-d6); δ= 8.2 (s, 1H, adeninyl-C(2)-H), 8.1 (s, 1H, adeninyl-
C(8)-H), 7.27 (s, 2H, NH2), 5.06 (s, 2H, NCH2COO), 4.14 (q, J= 7.2 Hz, 2H, OCH2CH3), 
1.18 (t, J= 7.2 Hz, 3H, CH2CH3).  
13C NMR (100 MHz, DMSO-d6); δ= 168.12, 156.02, 152.89, 149.73, 141.32, 118.46 
61.39, 43.96, 14.02. 
HRMS-EI+ (m/z): calc. for C9H11N5O2 = 221.0913, found= 221.0135. 
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Ethyl (N6-benzhydryloxycarbonyl) adenin-9-yl acetate 105 91
To a stirred solution of ethyl adenin-9-yl acetate 104 (5.0 g, 22.6 mmol) dissolved in 
anhydrous DMF (30 ml) was added 1,1-carbonyldiimidazole (5.9 g, 36.2 mmol) in 
one portion. The reaction mixture was heated to 100 °C and then maintained at this 
temperature for two hours. The temperature was reduced to 60 °C, and benzhydrol 
(6.2 g, 33.9 mmol) was added in one portion. The resulting reaction mixture was 
then stirred at 60 °C overnight. The reaction mixture was cooled to the ambient 
temperature and water (200 ml) was added. The resulting reaction mixture was 
then stirred for 30 minutes, and the precipitate was collected by filtration under 
vacuum, washed with cold diethyl ether and dried under high vacuum to give the 
desired compound 105 (9.1 g, 93%) as a white solid, melting point (mp): 109-112 °C. 
1H NMR (400 MHz, DMSO-d6); δ=10.98 (s, 1H, NH), 8.6 (s, 1H, adeninyl-C(2)-H), 
8.45 (s, 1H, adeninyl-C(8)-H), 7.52-7.27 (m, 10H, Ar-H), 6.83 (s, 1H, Ph2CHOCO), 5.20 
(s, 2H, NCH2COO) 4.175 (q, J= 7.1 Hz, 2H, OCH2CH3), 1.21 (t, J= 7.1 Hz, 3H, OCH2CH3). 
13C NMR (100 MHz, DMSO-d6); δ=167.77, 152.14, 151.87, 151.22, 149.96, 144.8, 
141.32, 128.54, 127.77, 126.57, 122.66, 77.41, 61.60, 44.29, 14.00. 
HRMS ES+ (m/z): calc. for C23H22N5O4 [M+H] + = 432.1672, found= 432.1689. 
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Synthesis of (N6-benzhydryloxycarbonyl) adenin-9-yl acetic acid 106 91
To a stirred solution of ethyl (N6-benzhydryloxycarbonyl) adenine-9-yl acetate 105 
(5.0 g, 11.6 mmol) dissolved in a mixture of ethanol and acetonitrile (30 ml, 1:1) was 
added a solution of anhydrous lithium hydroxide (4.8 g, 200.0 mmol) dissolved in 
water (50 ml). The reaction mixture was then stirred for exactly 10 minutes at room 
temperature, followed by addition of water (10 ml). The stirred reaction mixture 
was then cooled in an ice-water bath before being treated with a solution of citric 
acid (30 g, 183 mmol) dissolved in water (80 ml). The precipitate was collected by 
filtration under vacuum, washed with water several times and dried under high 
vacuum to give the desired compound 106 (6.0 g, 92%) as a white solid, melting 
point (mp): 282-285 °C. 
1H NMR (400 MHz, DMSO-d6); δ= 10.95 (s, 1H, NH), 8.61 (s, 1H, adeninyl-C(2)-H), 
8.44 (s, 1H, adeninyl-C(8)-H), 7.53-7.25 (m, 10H, Ar-H), 6.82 (s, 1H, Ph2CHOCO), 5.06 
(s, 2H, NHCH2COO).  
13C NMR (100 MHz, DMSO-d6); δ= 169.63, 152.52, 152.11, 151.61, 149.73, 146.07, 
141.24, 128.96, 128.19, 126.91, 122.96, 77.82, 45.0. 
HRMS ES+ (m/z): calc. for C21H18N5O4 [M+H]+ = 404.1359, found= 404.1349. 
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Synthesis of benzyl 2-amino-6-chloropurin-9-yl acetate 108 91
2-Amino-6-chloro purine 107 (4.5 g, 26.54 mmol) and potassium carbonate (5.5 g, 
37.8 mmol) were suspended in an anhydrous DMF (50 ml). The stirred suspension 
solution was heated to 100 °C for 30 minutes. The mixture reaction was then cooled 
in an ice bath to less than 10 °C, followed by addition of benzyl bromoacetate (4.2 
ml, 26.6 mmol) in one portion. The reaction mixture was then stirred for further 
four hours at room temperature. Water (200 ml) was then added. The resulting 
solution was cooled in an ice bath and stirred for further one hour. The precipitate 
was collected by vacuum filtration and dried under high vacuum to give the desired 
compound 108 (7.8 g, 89%) as a white solid, melting point (mp): 169-172 °C. 
1H NMR (400 MHz, DMSO-d6); δ= 8.12 (s, 1H, guaninyl-C(8)-H), 7.42-7.43 (m, 5H, 
Ar-H), 7.01 (s, 2H, NH2), 5.20 (s, 2H, COOCH2Ph), 5.07 (s, 2H, NCH2COO).  
13C NMR (100 MHz, DMSO-d6); δ= 167.62, 159.99, 154.28, 149.58, 143.44, 135.47, 
128.47, 128.37, 128.06, 123.01, 66.81, 44.23. 
HRMS-ES+ (m/z): calc. for C14H12N5O2 NaCl [M+Na]+ = 340.0577, found= 340.0590. 
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Synthesis of benzyl N2-(benzhydryloxycarbonyl)-6-chloropurin-9-yl acetate 109 91
To a stirred solution of benzyl 2-amino-6-chloropurine-9-yl acetate, 108 (5.0 g, 15.7 
mmol) dissolved in dry tetrahydrofuran (50 ml) at 0 °C was added triphosgene (1.8 
g, 6.0 mmol) in one portion. The reaction mixture was maintained at the same 
temperature for one hour before addition of DIPEA (7.0 ml, 40.2 mmol) over 30 
minutes. The temperature of the reaction was then allowed to rise to the room 
temperature, followed by addition of benzhydrol (3.5 g, 19.0 mmol). The resulting 
reaction mixture was stirred for 8 hours. The solvent was evaporated by a rotary 
evaporator. The residue was dissolved in CH2Cl2 (50 ml), washed with water (3 × 50 
ml), dried over Na2SO4 and concentrated to dryness. The paste residue was 
triturated with diethyl ether and stirred for one hour. The formed precipitate was 
collected by filtration and dried under high vacuum to yield the desired compound 
109 (5.2 g, 63%) as a pale yellow solid, melting point (mp): 70-75 °C. 
1H NMR (400 MHz, DMSO-d6); δ= 11.02 (s, 1H, NH), 8.51 (s, 1H, guaninyl-C(8)-H), 
7.36-719 (m, 15H, Ar-H), 6.81 (s, 1H, Ph2CHOCO), 5.21(s, 2H, COOCH2Ph), 5.18 (s, 
2H, NCH2COO). 
13C NMR (100 MHz, DMSO-d6); δ= 168.43, 153.61, 152.80, 151.42, 149.72, 147.21, 
141.32, 135.77, 128.97, 128.76, 128.50, 128.46, 127.27, 127.16, 126.94, 126.70, 
77.56, 67.39, 44.96. 
HRMS-ES+ (m/z): calc. for C28H23N5O4Cl [M+H]+ = 528.1439, found= 528.1443. 
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Synthesis of N2-(benzhydryloxycarbonyl) guanin-9-yl acetic acid 110 91
A stirred suspension of sodium hydride (60% in oil, 1.84 g, 46.0 mmol) in dry THF 
(50 ml) was cooled in a dry ice/acetone bath for 20 minutes, followed by addition of                    
3-hydroxypropionitrile (3.1 ml, 46.0 mmol) in one portion. The resulting solution 
was then stirred at 0 °C for two hours before addition of compound 109 (5.0 g, 9.5 
mmol). The resulting reaction mixture was stirred for 12 hours at room 
temperature. The solvent was removed under vacuum, and the residue was 
dissolved in water (50 ml). The resulting solution was acidified with an aqueous 
solution of citric acid (20% w/v) until pH 3. The formed precipitate was collected by 
filtration, washed with diethyl ether and dried under high vacuum to give the titled 
compound 110 (3.5 g, 90%) as a pale white solid melting point (mp): 220-224 °C. 
1H NMR (400 MHz DMSO-d6); δ = 11.71 (s, 1H, COOH), 11.24 (s, 1H, NH), 7.94 (s, 
1H, guaninyl-C(8)-H), 7.47-7.30 (m, 10H, Ar-H), 6.86 (s, 1H, Ph2CHOCO), 4.88 (s, 2H, 
NHCH2COOH).  
13C NMR (100 MHz, DMSO-d6); δ = 169.35, 155.38, 153.93, 149.49, 147.41, 140.55, 
140.17, 128.82, 128.22, 126.63, 119.79, 78.38, 44.80. 
HRMS-ES+ (m/z): Calc. for C21H23N5O5 [M+H]+ = 420.1308, Found= 420.1304. 
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Synthesis of ethyl N-propargyl-N-(thymin-1-yl acetyl) glycinate 111 162
Ethyl N-propargyl glycinate 99 (2.0 g, 14.2 mmol), thymin-1-yl acetic acid 100 (2.6 g, 
14.0 mmol), DCC (3.0 g, 14.5 mmol) and HOBt·H2O (2.2 g, 14.4 mmol) were 
dissolved in anhydrous DMF (25 ml). The resulting mixture was then stirred for 12 
hours at room temperature. The reaction mixture was filtered to remove the 
formed DCU, and DMF was removed by a rotary evaporator. The residue was 
dissolved in dichloromethane (50 mL), washed with aqueous solutions of Na2HCO3
(1 M, 25 ml), KHSO4 (1 M, 25 ml), and brine (2 × 25 ml). The organic phase was dried 
over anhydrous (MgSO4) and the solvent was removed under reduced pressure to 
yield a pale orange foam which was purified by column chromatography 
(EtOAc/MeOH, 10:1) to give the title compound 111 (3.2 g, 74%) as pale yellow 
foam. 
1H NMR (400 MHz; CDCl3) (two rotational isomers observed); δ= 8.70 (s, 1H,
thyminyl N(3)-H) 7.00 and 6.96 (s, 1H, thyminyl (C6)-H), 4.67 and 4.45 (s, 2H, 
NCH2CON), 4.30-4.17 (m, 6H, C≡CCH2NCH2COOCH2), 2.30 and 2.48 (t, 1H, J= 2.4 Hz, 
C≡CH), 1.7 (s, 3H, thyminyl C(5)-CH3), 1.30 and 1.25 (3H, J= 6.8 Hz, OCH2CH3).  
13C NMR (100 MHz; CDCl3) (two rotational isomers observed); δ= 168.9 and 168.5, 
167.1 and 166.5, 151.3, 141.1, 110.3, 77.1 and 76.6, 74.6 and 73.8, 62.3 and 61.7, 
48.1 and 48.0, 47.7, 38.0 and 36.3, 14.0 and 14.1, 12.2. 
HRMS-ES+ (m/z): calc. for C14H18N3O5 [M+H]+ = 308.1246, found = 308.1256. 
FT-IR (CDCl3 film, cm−1): 3242 (str. C-H, C≡CH), 2920 and 2832 (str. aliphatic CH), 
2100 (str. C≡C), 1712 (str. C=O amide, 1678 (str. C=C), 1653 (str. C=O).  
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Synthesis of ethyl N-propargyl-N-[(N4-benzhydryloxycarbonyl) cytosin-1-yl 
acetyl] glycinate 112 
Ethyl N-propargyl glycinate (2.8 g, 19.8 mmol) 99, N4-(benzhydryloxycarbonyl) 
cytosin-1-yl acetic acid 103 (5.0 g, 13.2 mmol), DCC (2.78 g, 13.5 mmol) and 
HOBt·H2O (2.0 g, 13.2 mmol) were sequentially were added in DMF (50 ml). The 
reaction mixture was stirred at 25 °C for overnight. The reaction mixture was 
filtered to remove the formed DCU, and the solvent was removed under vacuum. 
The residue was dissolved in DCM (50 ml), filtered and washed with water (2 × 25 
ml), brine (2 × 25 ml), dried over Na2SO4. The solvent was removed on a rotary 
evaporator. The formed foam was purified by column chromatography 
(EtOAc/MeOH, 9:1) to yield target compound 112 (5.0 g, 76%) a pale white foam. 
1H NMR (400 MHz, CDCl3) (two rotational isomers observed); δ= 7.80 (b, 1H, NH), 
7.62 and 7.56 (d, J = 7.74, 1H, Cytosinyl-C(6)-H), 7.26-7.37 (m, 10H, Ph2CHO), 7.19 
and 7.20 (d, J = 7.74, 1H, Cytosinyl-C(5)-H), 6.82 (s, 1H Ph2CHO), 4.84 and 4.60 (s, 2H 
NCOCH2N), 4.38 and 4.28 (d, J= 2.44 Hz, 2H, NCH2C≡C), 4.34 and 4.16 (s, 2H, 
NCH2CO), 4.24 and 4.5 (q, J= 7.1 Hz, 2H, OCH2CH3), 2.34 and 2.20 (t,  J= 2.44 Hz, 1H, 
C≡CH), 1.16 and 1.22 (t, J= 7.1 Hz, 3H, OCH2CH3). 
13C NMR (100 MHz, CDCl3) (two rotational isomers were observed); δ= 168.99 and 
168.56, 167.02 and 166.87, 162.87, 155.74, 151.66, 149.73 and 149.56, 139.29, 
128.68, 128.29, 127.02, 95.25, 79.12, 77.3 and 77.2, 74.48 and 73.76, 62.16 and 
61.59, 49.41 and 49.16, 48.12 and 47.61, 36.39 and 33.96, 14.14 and 14.12. 
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HRMS-ES+ (m/z): calc. for = C27H26N4O6Na [M+Na]+: 525.1750, found= 525.1730. 
FT-IR max (CHCl3 film, cm-1); 3270 (str. C≡C-H), 2980 and 2880 (str. CH, aliphatic), 
2130 (str. C≡C), 1744 (str. CO ester), 1678 (str. C=C aromatic), 1629 (str. C=O).  
Synthesis of ethyl N-(propargyl)-N-[N6-(benzhydryloxycarbonyl) adenine-9-
acetyl] glycinate 113 
To a stirred solution of N6-(benzhydryloxycarbonyl) adeninyl-9-yl acetic acid 106 
(3.0 g, 7.4 mmol) in DMF (50 ml), DCC (1.6 g, 7.8 mmol), HOBt·H2O (1.2 g, 7.5 mmol) 
and ethyl N-propargyl glycinate (1.2 g, 8.5 mmol) were added sequentially. The 
resulting reaction mixture was stirred at 25 °C for overnight. The reaction mixture 
was filtered to remove the formed DCU after which the solvent was removed under 
vacuum. The crude residue was dissolved in acetonitrile and filtered. The solvent 
evaporated on rotary evaporator to dryness. The formed foam was purified by 
column chromatography (EtOAc/MeOH, 9:1) to yield target compound 113 (3.2 g, 
82%) as a pale white solid, melting point (mp): 125-128 °C
1H NMR (400 MHz; CDCl3) (two rotational isomers were observed); δ= 8.72 and 8.70 
(s, 1H, adeninyl (C2)-H), 8.45 (br s, 1H, NH), 8.07 and 8.06 (s, 1H, adeninyl C(8)-H), 
7.42-7.24 (5H, m, Ph), 6.98 (s, 1H, Ph2CHO), 5.20 and 5.00 (s, 2H, NCOCH2N), 4.32 
and 4.31 (d, J= 2.4 Hz, 2H, NCH2C≡), 4.38 and 4.45 (s, 2H, NCH2CO), 4.15 and 4.10 (q, 
J= 7.1 Hz, 2H, OCH2CH3), 2.29 and 2.44 (t, 1H, J= 2.4 Hz, CH≡C), 1.24 and 1.31 (t, 3H, 
J= 7.1 Hz, OCH2CH3). 
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13C NMR (100 MHz; CDCl3) (two rotational isomers were observed); δ= 169.7 and 
168.5, 166.3 and 166.0, 152.78, 151.7 and 151.6, 150.7 and 150.6, 149.4 and 
149.29, 144.3 and 143.9, 139.7, 128.61, 128.17, 128.14, 127.34, 78.7, 74.9 and 
74,06, 61.7 and 61.6, 47.8 and 47.5, 40.06 and 43.39, 37.99 and 36.37, 14.14 and 
14.10. 
HRMS-ESI+ (m/z): calc. for C28H27N6O5 [M+H]+ = 527.2043, found = 527.2035. 
FT-IR max (film CHCl3, cm-1): 3190 (str. C-H of aromatic ring), 2957 (str. C-H of 
aliphatic), 1763 (str. C=O), 1749 (str. C=O), 1680 (str., C=C, Aromatic). 
Synthesis of ethyl N-(propargyl)-N-[N2-(benzhydryloxycarbonyl) guanine-9-
acetyl] glycinate 114 
Ethyl N-propargyl glycinate 99 (1.2 g, 8.5 mmol), N2-(benzhydroloxycarbonyl) 
guanin-9-yl acetic acid 110 (3.0 g, 7.153 mmol), DCC (1.6 g, 7.8 mmol) and HOBt·H2O 
(1.2 g, 7.8 mmol) were dissolved in DMF (50 m). The reaction mixture was stirred 
for overnight at 25 °C then filtered to remove DCU after which the solvent was 
removed under vacuum. The residue was dissolved in dichloromethane (50 ml), 
filtered and concentrated. The residue was re-dissolved in acetonitrile (50 ml) to 
remove remaining DCC after which the solvent was evaporated until dryness. The 
formed foam was purified by column chromatography (EtOAc/MeOH, 9:1) to yield 
target compound 114 (3.5 g, 76%) a pale-yellow powder, melting point (mp): 145-
148 °C. 
1H NMR (400 MHz, CDCl3) (two rotational isomers observed); δ= 11.28 (br. 1H, NH), 
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7.53 (m, 1H, guaniniyl C(9)-H), 7.35-7.27 (m, 10H, Ar), 6.80 (s, 1H, Ph2CHOCO), 4.94 
and 4.47 (s, 2H, NCH2COO), 4.34-3.8 (m, 6H, OCH2, CH2C≡C, NCH2CON), 2.44 and 
2.34 (t, J= 2.5 Hz, 1H, C≡CH), 1.21 and 1.17 and (t, J= 7.1 Hz, 3H, CH3). 
13C NMR (100 MHz, CDCl3) (two rotational isomers observed); δ= 168.87 and 
168.75, 166.47 and 166.40, 156.0, 153.22, 149.19, 147.06, 140.19, 139.06 and 
138.89, 128.17, 128.42, 127.09, 79.69, 77.2, 74.65 and 73.81, 61.66 and 61.42, 
47.70 and 47.36, 44.20 and 41.52, 37.99 and 36.23, 14.14 and 14.09. 
HRMS-ES+ (m/z): calc. for C28H27N6O6 [M+H]+= 543.1992, found= 543.1993. 
FT-IR (film CHCl3, cm-1); 2984 (str. CH, aliphatic), 1744 (str. C=O ester), 1678 (str. 
C=C aromatic), 1629 (str. C=O). 
Synthesis of N-propargyl-N-(thymin-1-yl acetyl) glycine 115 
To a stirred solution of ethyl N-propargyl N-(thymin-1-yl acetyl) glycinate 111 (2.0 g, 
6.5 mmol) dissolved in 1,2-dioxane (10 ml) at room temperature was added an 
aqueous solution of NaOH (10 ml, 24.9 mmol). The mixture reaction was stirred at 
room temperature for 15 minutes. The reaction mixture was acidified with 20% 
aqueous solution of KHSO4 until pH 3. The resulting precipitate was collected and 
dried in high vacuum for 3 hours to give the desired compound 115 (1.3 g, 70%) as a 
pale white solid, melting point (m.p.): 138-140 °C. 
1H NMR (400 MHz, DMSO-d6) (two rotational isomers observed); δ= 12.91 (br, 1H, 
COOH), 11.31 (s, 1H, thyminyl N(3)-H), 7.34 and 7.34 (s, 1H, thyminyl C(6)-H), 4.71 
and 4.53 (s, 2H, NCOCH2N), 4.33 and 4.26 (s, 2H, ≡CCH2N), 4.17 and 4.04 (s, 2H, 
NCH2CO), 3.44 and 3.26 (s, 1H, C≡CH), 1.7 (s, 3H, CH3). 
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13C NMR (100 MHz, DMSO-d6) (two rotational isomers observed); δ= 170.51 and 
170.2, 167.76 and 167.29, 164.84, 151.40, 142.61, 108.82, 79.39 and 78.59, 76.26 
and 75.49, 48.05, 46.96 and 47.59, 12.41. 
HRMS-ES- (m/z): calc. for C12H12N3O5 [M-H]- = 278.0777, found= 278.0781. 
FT-IR (cm−1): 3277 (str. C-H, C≡CH), 2990 and 2832 (str. aliphatic CH), 2200 (str. 
C≡C), 1737 (str. C=O amide, 1678 (str. C=O), 1653 (str. C=O).
Synthesis of N-propargyl-N-[N4-(benzhydryloxycarbonyl) cytosin-1-acetyl] 
glycine 116 
To a stirred solution of ethyl N-propargyl-N-[N4-(benzhydryloxycarbonyl) cytosin-1-
acetyl] glycinate 112 (4.0 g, 8.0 mmol) in 1,4-dioxane (8 ml) at room temperature 
was added an aqueous solution of NaOH (15 ml, 30.0 mmol). The resulting reaction 
mixture was stirred for exactly 10 minutes then the reaction was quenched by 
addition a solution of citric acid (20% w/v) until pH 3. The precipitate formed was 
stirred for further 5 minutes before collecting by filtration under vacuum. The 
precipitate was dried under high vacuum for three hours to afford the novel PNA 
monomer 116 (3.3 g, 89%) as a white solid, melting point (mp): 125-127 °C. 
1H NMR (400 MHz, DMSO-d6) (two rotational isomers observed); δ= 8.56 (br., 1H, 
NH), 7.96 (m, 1H, Cytosinyl-C(6)-H), 7.48- 7.25 (m, 10H, Ar), 6.94 (m, 1H, Cytosinyl-
C(5)-H, 6.79 (s, 1H, Ph2CHO), 4.88 and 4.68 (s, 2H, NCH2COO), 3.5-4.5 (m, 4H, 
C≡CCH2N, NCH2CO), 2.45 and 2.26 (t, J= 2.62 Hz, 1H, C≡CH).
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13C NMR (100 MHz, DMSO-d6) (two rotational isomers observed); δ= 170.83 and 
171.42, 170.43 and 169.61, 169.61, 155.74, 151.66, 149.73 and 149.56, 139.29, 
128.68, 128.29, 127.02, 95.25, 79.12, 77.3 and 77.2, 74.48 and 73.76, 49.41 and 
49.16, 48.12 and 47.61, 36.39 and 33.96.
HRMS-ES+ (m/z): calc. for C25H24N4O6Na [M+Na]+ = 497.1437, found= 497.1441. 
FT-IR max (cm-1); 3270 (str. CH, C≡C-H), 2980 and 2880 (str. CH, aliphatic), 2230 (str. 
C≡C), 1744 (str. C=O), 1678 (str. C=C aromatic), 1629 (str. C=O), 1558.
Synthesis of N-propargyl-N-[N6-(benzhydryloxycarbonyl) adenin-9-acetyl] 
glycine 117 
To a stirred solution of ethyl N-propargyl-N-[N6-(benzhydryloxycarbonyl) adenin-9-
acetyl] glycinate 113 (2.0 g, 3.8 mmol) in 1,4-dioxane (10 ml) at room temperature, 
an aqueous solution of NaOH (10 ml, 20mmol) was added. The reaction mixture was 
stirred at room temperature for 20 minutes. After this time, the reaction was 
acidified with an aqueous solution of citric acid (20% w/v) until pH 3. The formed 
precipitate was collected by filtration under vacuum. The wet precipitate was dried 
in high vacuum for 3 hours to give the novel PNA monomer 117 (1.7 g, 90%) as a 
pale white powder, melting point (mp): 155-158 °C. 
1H NMR (400 MHz, DMSO-d6) (two rotational isomers observed); δ= 10.96 (br, 1H, 
NH), 8.62 and 8.61 (s, 1H, adeninyl-C(2)-H), 8.40 and 8.39 (s, 1H, adeninyl-C(8)-H), 
7.55-7.25 (m, 10H, Ar), 6.86 (s, 1H, Ph2CHO), 5.43 and 5.25 (s, 2H, NCH2CON), 4.49 
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and 4.20 (d, J= 2.45 Hz, 2H, CH2C≡CH), 4.42 and 4.07 (s, 2H, NCH2COO), 3.35 and 
3.30 (t, J= 2.45 Hz, 1H, C≡CH). 
13C NMR (100 MHz, DMSO-d6) (two rotational isomers observed); δ= 171.8 and 
171.4, 170.7 and 170.4, 169.61, 151.7 and 151.6, 150.7 and 150.6, 149.7 and 
149.29, 144.3 and 143.9, 139.7, 128.61, 128.17, 128.14, 127.34, 78.7, 74.9 and 
74.06, 47.8 and 47.5, 40.06 and 43.39, 37.99 and 36.37. 
HRMS-ESI+ (m/z): calc. for C26H23N6O5 [M+H]+ = 499.1730, found= 499.1729. 
FT-IR max (cm-1): 3190 (str. C-H of aromatic ring), 2957 (str. C-H of aliphatic), 2270 
(str. C≡C), 1724 (str. C=O), 1670 (str.C=C), 1616 (str., C=C, Aromatic).
Synthesis of N-propargyl-N-[N2-(benzhydryloxycarbonyl) gunain-9-acetyl] 
glycine 118
To a stirred solution of ethyl N-propargyl-N-[4-N-(benzhydryloxycarbonyl) guanine-
9-acetyl] glycinate 114 (1.0 g, 1.8 mmol) dissolved in 1,4-dioxane (10 ml), was added 
in one portion an aqueous solution of NaOH (10 ml, 20.0 mmol). The reaction 
mixture was stirred at room temperature for 20 minutes. After this time, the 
reaction mixture was cooled with an ice-water bath and stirred for further five 
minutes and then was acidified with an aqueous solution of citric acid (20% w/v) 
until pH=3. The resulting precipitate was stirred for a further five minutes and 
collected by filtration under vacuum and dried under high vacuum for 3 hours to 
give the desired novel PNA monomer 118 (0.81, 84%) as a pure white powder, 
melting point (mp): 195-198 °C.  
1H NMR (400 MHz, DMSO-d6) (two rotational isomers observed); δ= 11.78 (br. 1H, 
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OH), 11.26 (br., 1H, NH), 7.91 (m, 1H, gauninyl-C(8)-H), 7.50-7.28 (m, 10, Ar), 6.87 (s, 
1H, Ph2CHO), 5.21 and 5.64 (s, 2H, NCH2CON), 4.45 and 4.38 (s, 2H, NCH2COOH), 
4.20 and 407 (s, 2H, CH2C≡CH), 3.53 and 3.30 (s, 1H, CH≡C).
13C NMR (100 MHz, DMSO-d6) (two rotational isomers observed); δ = 170.84 and 
170.6, 167.47 and 166.9, 156.0, 153.22, 149.19, 147.5, 141.1, 139.06 and 138.89, 
129.05, 128.9, 128.4, 126.88, 79.05, 78.4, 74.65 and 73.81, 61.66 and 61.42, 47.70 
and 47.36, 44.20 and 43.52, 36.0 and 33.8.
HRMS-ES+ (m/z): calc. for C26H23N6O6 [M+H]+= 515.1679, found= 515.1680. 
FT-IR (CHCl3 film, cm-1): 3251 (str. C≡C-H), 2983 (str. aliphatic CH), 1681 (str. C=O), 
1612 (str. C=O), 1571 (str. C=C). 
Synthesis of 2-(N-Fmoc amino) ethyl azide 120
2-Bromoethylamine hydrobromide 119 (5.0 g, 24.4 mmol) and sodium azide (4.0 g, 
61.5 mmol) were dissolved in water (100 ml). The resulting solution was stirred and 
heated up 80 °C for 20 hours. The reaction mixture was cooled to room 
temperature followed by addition NaOH (2.0 g, 50.0 mmol). The resulting solution 
was stirred for further 15 minutes before being extracted with DCM (4 × 50 ml). The 
combined organic layer was dried over MgSO4 and concentrated to about 60 ml. To 
this solution, Fmoc succinimide ester (3 g, 8.9 mmol) and triethylamine (2.5 ml, 17.8 
mmol) were added. The reaction mixture was stirred for two hours at room 
temperature. The reaction mixture was then washed with water (5 × 50 ml), brine 
(3 × 50 ml). The organic phase was dried over MgSO4 and concentrated under 
vacuum. The residue was cooled in an ice bath to give the target compound 120 
(2.2 g, 80%) a white solid product, melting point (mp): 85-88 °C. 
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1H NMR (400 MHz, CDCl3); δ= 7.75 (d, J= 8.93 Hz, 2H, Ar-CH), 7.57 (d, J= 8.93 Hz, 2H, 
Ar-CH), 7.39 7.30 (m, 4H, Ar-CH), 5.03 (bs, 1H, NH), 4.41(d, J= 6.29 Hz, 2H, CHCH2O), 
4.21 (t, J= 6.29 Hz, 1H, CHCH2O), 3.43 (t, J= 3.5 Hz, 2H, NHCH2), 3.5 (t, J= 3.55 Hz, 2H, 
CH2N3). 
13C NMR (100 MHz, CDCl3); δ= 156.44, 143.9, 141.39, 127.83, 127.16, 125.11, 
120.11, 69.89, 51.14, 47.26, 40.54. 
HRMS-ESI+ (m/z): Calc. for C17H16N4O2 [M+H] + = 309.1352, found= 309.1347. 
FT-IR (CHCl3 film, cm-1): 2988 and 2875 (str. aliphatic CH), 2100 (str. azide group), 
1681 (str. C=O), 1543 (str. C=C). 
Synthesis of N-[(1-(2-Fmoc-aminoethyl)-1H-1,2,3-triazol-4-yl) methyl]-N-
(thyminyl-1-yl acetyl) glycine 121 
To a stirred solution of CuSO4·5H2O (40 mg, 0.16 mmol) in water (0.5 ml) was added 
a solution of sodium ascorbate (60 mg, 0.3 mmol) dissolved in water (0.5 ml), 
followed by addition of tert-butanol:water (20 ml 2:1). N-propargyl N-(thymin-1-yl 
acetyl) glycine 115 (0.3 g, 3.1 mmol) and compound 120 (0.95 g, 3.1 mml) were 
sequentially added. The reaction mixture was heated to 40 °C and stirred for 22 
hours. The precipitate formed was collected by filtration, washed with ethyl acetate 
and dried under high vacuum to obtain the target compound 121 (1.5 g, 75%) as a 
pale white powder, melting point (mp): 197-200 °C. 
1H NMR (500 MHz, DMSO-d6); δ= 11.30 (br. 1H, NH-thyminyl), 7.96 (s, 1H, C=CH-
triazolyl), 7.88 (d, J= 5.0 Hz, 2H, Ar-CH), 7.65 (d, J= 5.0 Hz, 2H, Ar-CH), 7.55 (br, 1H, 
CONH), 7.5-7.25 (m, 5H, C=CH-thyminyl, Ar-H), 4.80 and 4.66 (s, 2H, NCH2CON), 4.5- 
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3.25 (m, 9H, CHCH2O, NCH2CH2NCH2), 1.71 (s, 3H, CH3).
13C NMR (125 MHz, DMSO-d6); δ= 167.84, 164.61, 156.61, 151.0, 144.26, 142.0, 
140.50, 135.83, 128.24, 124.4, 125.0, 120.5, 108.0, 66.56, 49.66, 48.7, 48.02, 46.2, 
42.0, 12.25. 
HRMS-ESI+ (m/z): calc. for C29H30N7O7 [M+H]+ = 588.2207, found = 588.2197 
FT-IR (Disc KBr, cm-1): 3311 (s, amide NH), 2962 and 2885 (str., CH, aliphatic), 1690 
(str. C=O), 1664 (str. C=O), 1544 (str. C=C aromatic). 
Synthesis of 3-[1-(2-Fmoc-aminoethyl)-1H-1,2,3-triazol-4-yl] propionic acid 
123 
A solution of sodium ascorbate (100 mg, 0.50 mmol) dissolved in water (0.5 ml) was 
added to a stirred solution of CuSO4·5H2O (65.0 mg, 0.30 mmol) dissolved in water 
(0.5 mL), followed by addition a mixture of tert-butanol:water (10 ml, 2:1). To the 
resulting solution were sequentially added compound 120 (1.5 g, 4.9 mml) and 4-
pentynoic acid 122 (0.5 g, 5.1 mmol). The reaction mixture was stirred at room 
temperature for overnight. The residue was dissolved in ethyl acetate (25 ml), and 
washed with water (2 × 25 ml) and brine (2 × 25 ml). The organic phase was dried 
over Na2SO4, filtered and concentrated. The crude product was purified by column 
chromatography to give the titled compound 126 (1.2 g, 80%) as pale yellow solid, 
melting point (mp):164-166 °C. 
1H NMR (400 MHz, DMSO-d6); δ= 12.14 (s, 1H, COOH), 7.9 (d, J= 7.02 Hz, 2H, Ar-
CH), 7.77 (s, 1H, CH=C) 7.66 (d, J= 7.02 Hz, 2H, Ar-CH), 7.50 (br, 1H, NH), 7.4 (t, J= 
7.9 Hz, 2H, Ar-CH), 7.34 (t, J= 7.9 Hz, 2H, Ar-CH), 4.36 (t, J= 5.94 Hz, 2H, CH2-N-
triazole), 4.31 (d, J= 6.3 Hz, 2H, CHCH2O), 4.21 (t, J= 6.3 Hz, 1H, CHCH2O), 3.40 (q, J= 
5.3 Hz, 2H, CONHCH2), 2.82 (t, J= 7.2 Hz, 2H, CH2CH2COOH), 2.56 (t, J= 7.2 Hz, 2H, 
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CH2COOH). 
13C NMR (100 MHz, DMSO-d6); δ= 173.77, 156.63, 146.11, 144.33, 141.24, 128.10, 
127.55, 125.63, 122.76, 120.58, 66.89, 49.19, 47.18, 41.06, 39.0, 21.27. 
HRMS-ESI+ (m/z): calc. for C22H22N4O4 [M+H]+ = 407.1719, found = 407.1722. 
FT-IR (Disc KBr, cm-1): 3311 (s, amide NH), 3100 (str. C-H, Aromatic) 2962 and 2885 
(str., CH, aliphatic), 1734 (str. C=O, COOH), 1695 (str. C=O, OCON), 1544 (str. C=C 
aromatic). 
Synthesis of N-tert-butoxycarbonyl-glycine 124 166
To a stirred solution of glycine 96 (1.5 g, 20.0 mmol) in an aqueous solution of NaOH 
(40 ml, 1N) was added in portions a solution of di-tert-butyl carbonate (5.5 g, 25.2 
mmol) dissolved in isopropanol (30 ml). The resulting solution was stirred at room 
temperature for two hrs and then washed with light petroleum ether (b.p 40-60 °C) 
(2 × 50 ml). The aqueous phase was acidified to pH 3 with a solution of H2SO4 (2 N) 
and was then extracted with chloroform (3 × 50 ml). The combined organic layer 
was dried over anhydrous Na2SO4 and evaporated on the rotary evaporator to give 
the desired compound 124 (3.1 g, 88%) as white crystals, melting point (mp): 89-92 
°C, [lit.166 mp: 93 °C]. 
1H NMR (400 MHz, CDCl3); δ= 12.46 (br, 1H, OH), 7.10 (br, 1H, NH), 3.56 (d, J= 8.0 
Hz, 2H, NCH2CO), 1.37 (s, 9H, (CH3)3).  
13C NMR (100 MHz, CDCl3); δ= 173.56, 156.14, 80.09, 41.7, 28.27. 
HRMS-ESI- (m/z): calc. for C7H12NO4 [M-H]- = 174.076, found = 174.0760. 
FT-IR (Disc KBr cm-1): 3292-3488 (br, OH), 3133 (NH str, amide), 2927 and 2850 (str. 
aliphatic C-H), 1737 (str. C=O of COOH), 1635 (str. C=O of amide). 
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Synthesise of N-(tert-butoxycarbonyl)-N-(prop-2-yn-1-yl) glycine 125 165
To a stirred solution of N-Boc-protected glycine, 124 (1.5 g, 8.6 mmole) dissolved in 
dry THF (100 ml) was added a solution of propargyl bromide 80% w/v in toluene 
(6.0 ml, 66.0 mmol). The resulting reaction mixture was cooled in an ice-water bath 
and kept under nitrogen atmosphere, and sodium hydride (60% in mineral oil, 0.175 
g, 24.0 mmol) was added in portions. The resulting mixture reaction was stirred for 
a further two hours at 0 °C, and then the ice-water bath was removed. The reaction 
mixture was stirred at room temperature for overnight. The solvent was evaporated 
on a rotary evaporator and the residue was dissolved in water (50 ml) and washed 
with diethyl ether (20 ml). The aqueous phase was acidified to pH 2 with a solution 
of hydrochloric acid (1.0 N). The resulting solution was extracted with ethyl acetate 
(3 × 50 ml). The combined organic layer was dried over anhydrous MgSO4, filtered 
and evaporated to give the desired product 125 (1.42 g, 78%), melting point (mp): 
98-100 °C. 
1H NMR (400 MHz, CDCl3) (two rotational isomers observed); δ= 10.37 (br, 1H, 
COOH), 4.22 and 4.18 (s, 2H, NCH2COO), 4.15 and 4.11 (s, 2H, NCH2C≡), 2.27 (s, 1H, 
C≡CH), 1.48 and 1.44 (s, 9H, C (CH3)3). 
13C NMR (100 MHz, CDCl3) (two rotational isomers observed); δ= 175.2 and 174.01, 
155.3 and 154.7, 82.1 and 81.9, 79.0 and 78.75, 73.44 and 72.18, 47.4 and 47.0, 
37.6 and 37.0, 28.56 and 28.5. 
HRMS-ESI- (m/z): calc. for C10H15NO4 [M-H]- = 212.0923, found = 212.0916. 
FT-IR (CDCl3 film, cm-1): 3311 (s, C≡H), 2981 and 2927 (str., aliphatic CH), 2300 (str. 
C≡C) 1740 (str. C=O, COOH), 1650 (str. C=O, OCON). 
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Synthesis of N-[(1-(2-Fmoc-aminoethyl)-1H-1,2,3-triazol-4-yl) methyl]-N-
(tert-butoxycarbonyl) glycine 126 
To a stirred solution of CuSO4·5H2O (50 mg, 0.20 mmol) dissolved in water (0.5 ml) 
was added a solution of sodium ascorbate (90 mg, 0.45 mmol) dissolved in water 
(0.5 mL). To the resulting solution, a mixture of tert-butanol:water (9 ml, 6:3) was 
added, followed by addition of N-propargyl-N-tert-butyloxycarbonyl glycine 125 (0.5 
g, 2.3 mmol) and the azide component 120 (0.95 g, 3.1 mmol) sequentially. The 
mixture was then stirred at 40 °C overnight. The solvents were removed under 
vacuum. The residue was dissolved in ethyl acetate (25 ml), and washed with water 
(2 × 25 ml) and brine (2 × 25 ml). The organic phase was dried over Na2SO4, filtered 
and concentrated to give a yellow foam which was purified by column 
chromatography to give the titled compound 126 (1.2 g, 75%) as pale yellow solid, 
melting point (mp): 78-80 °C. 
1H NMR (400 MHz, Acetone-d6); δ 7.74 (s, 1H, C=CH, triazolyl), 7.88 (d, J= 8.0 Hz, 
2H, Ar-CH), 7.65 (d, J= 8.0 Hz, 2H, Ar-CH), 7.39-7.31 (m, 4H, Ar-CH), 4.46-4.36 (m, 
4H, CH2CH2-triazole, CH2OCON), 4.28 (t, J= 8.2 Hz, 1H CHCH2OCON), 4.21 (t, J= 7.5 
Hz, 2H, CONHCH2), 4.1 and 3.95 (s, 2H, NCH2COO), 3.64 (s, 2H, CH2NCO), 1.30 and 
1.28 (s, 9H, (CH3)3). 
13C NMR (100 MHz, CDCl3); δ = 173.12, 157.03, 155.76, 144.12, 141.63, 128.13, 
127.47, 125.49, 125.05, 124.26, 120.38, 81.46, 67.22, 50.45, 47.49, 43.22, 41.30, 
28.76 and 28.58. 
HRMS-ESI+ (m/z): calc. for C27H31N5O6 [M+H]+ = 522.2353, found= 522.2352. 
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FT-IR (CDCl3 film, cm-1): 2962 and 2885 (str., aliphatic C-H), 1734 (str. C=O, COOH), 
1695 (str. C=O, OCON), 1525 (str. C=C aromatic). 
Synthesis of tert-Butyl (2-aminoethyl) carbamate 33 87
To a stirred solution of 1,2-diaminoethane (20 ml, 299 mmol) dissolved in THF 
(40 ml) at room temperature, a solution of Boc-anhydride (3.3 g, 15.114 mmol) 
dissolved in tetrahydrofuran (50 ml) was slowly added. The reaction mixture was 
stirred at room temperature for 12 hours. After this time, the solvent was 
evaporated on a rotary evaporator and the residue was dissolved in ethyl acetate 
(50 ml) and washed with brine (2 × 25 ml), and water (2 × 25 ml). The organic phase 
was dried over Na2SO4 and concentrated to give the desired product (2.0 g, 80%) as 
a pale-yellow oil. 
1H NMR (400 MHz, CDCl3); δ = 5.05 (br, 1H, NH), 3.10 (q, J= 8.0 Hz, 2H, NHCH2CH2), 
2.27 (t, J= 8.0 Hz, 2H, CH2NH2), 1.41 (s, 9H, (CH3)3). 
13C NMR (100 MHz, CDCl3); δ = 156.13, 78.26, 43.12, 41.53, 28.07. 
LRMS-ES+ (m/z): calc. for C7H16N2O2= 160.1, found = 160.104.  
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Synthesis of benzyl (2-((tert-butoxycarbonyl) amino) ethyl) glycinate 127 87
To a stirred solution of tert-butyl (2-aminoethyl) carbamate 33 (2.0 g, 12.517 
mmol), triethylamine (1.8 ml, 12.917 mmol) and benzyl bromoacetate (1.4 ml, 
12.658 mmol) were dissolved in acetonitrile. The reaction mixture was stirred at 
room temperature for 2 hours and then filtered. The solvent was removed under 
vacuum, and the residue was dissolved in ethyl acetate (50 ml), washed with brine 
(2 × 25 ml), water (2 × 25 ml). The organic phase was dried over Na2SO4, filtered, 
and concentrated to give the titled compound 127 (2.5 g, 83%) as a pale red oil. 
1H NMR (400 MHz, CDCl3); δ = 7.2-7.35 (m, 5H, Ar), 5.1 (s, 2H, OCH2Ar), 5.05 (br, 1H, 
NH), 3.39 (s, 2H, NCH2COO), 3.15(q, J= 5.7 Hz, 2H, NHCH2), 2.79 (t, J= 5.7 Hz, 2H, 
CH2NH), 1.78 (br, 1H, NH), (s, 9H, (CH3)3).
13C NMR (100 MHz, CDCl3); δ= 172.62, 156.26, 135.6, 128.7, 128.58, 128.50, 77.69, 
50.56, 48.89, 40.26, 28.53.  
LRMS-ES+ (m/z):  calc. for C16H25N2O4 [M+H]+ = 309.2, found= 309.204. 
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Synthesis of benzyl N-(2-Fmoc-aminoethyl) glycinate 128 87
To a stirred solution of benzyl 2-((2-((tert-butoxycarbonyl) amino) ethyl) amino) 
acetate 127 (2.0 g, 8.120 mmol) dissolved in DCM (20 ml) in an ice-water bath was 
added TFA (15 ml) in one portion. The resulting reaction mixture was stirred for 15 
min at room temperature. The solvent was removed under vacuum and the residue 
was washed with chloroform (25 ml) and then decanted. DCM (25 ml), 
triethylamine (2.5 ml, 17.924 mmole), Fmoc-OSu (2.7 g, 8.120 mmol) were added 
and the reaction mixture was stirred for further two hours at room temperature. 
The reaction mixture was washed with water (3 × 50 mL), brine (3 × 25 ml) dried 
over Na2SO4, filtered, and concentrated to give the target compound 128 (2.1 g, 
76%) a red oil. 
1H NMR (400 MHz, CDCl3); δ 7.61 (d, J= 7.4 Hz, 2H, Ar-CH), 7.49 (d, J= 7.4 Hz, 2H, Ar-
CH), 7.42–7.28 (m, 9H, Ar-CH), 5.68 (br, 1H, NH), 5.1 (s, 2H, COOCH2Ph), 4.3 (d, J= 
7.0 Hz, 2H, CHCH2O), 4.22 (t, J= 7.0 Hz, 1H, CHCH2O), 3.25 (s, 2H, NHCH2COO), 3.19 
(q, J= 5.4 Hz, 2H, NHCH2), 2.58 (t, J= 5.4 Hz, 2H, CH2NH), 1.76 (br, 1H).  
13C NMR (100 MHz, CDCl3); δ= 172.52, 156.66, 144.18, 141.3, 135.6, 127.28, 125.0, 
120.0, 66.5, 50.44, 48.67, 48.2, 40.0. 
LRMS-ES+ (m/z): calc. for C26H26N2O4 [M+H]+ = 430.5 found = 430.52.
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Synthesis of benzyl N-(2-Fmoc-aminoethyl)-N-(thymin-1-yl acetyl) glycinate 
129 86 
To a stirred solution of compound 128 (1.99 g, 5.428 mmol) dissolved in DMF (25 
ml), DCC (1.1 g, 5.428 mmol), and HOBt.H2O (0.765 g, 5.0 mmol) and thymine acetic 
acid derivative 100 (1.0 g, 5.428 mmol) were sequentially added. The reaction 
mixture was stirred at room temperature overnight. The formed DCU was removed 
by filtration, and the solvent was then evaporated under vacuum to dryness. The 
residue was dissolved in DCM (50 ml), filtered and washed sequentially with 
NaHCO3 5% w/v (2 × 50 ml), KHSO4 1 M aqueous (2 × 50 ml) and brine (2 × 50 ml). 
The organic phase was dried over Na2SO4 and concentrated. The resulting foam was 
triturated with a mixture of THF/ hexane (25 ml, 5:20). The precipitate that formed 
was collected by filtration and dried under high vacuum to give the titled compound 
129 (2.1 g, 72%) as a foam. 
1H NMR (400 MHz, CDCl3) (two rotational isomers); δ= 7.88 (d, J=7.3 Hz, 2H, Ar-CH), 
7.68 (d, J=7.3 Hz, 2H, Ar-CH), 7.48-7.25 (m, 11H, Ar-H, thymin-C(6)-H), [5.22 (s, min) 
and 5.13 (s, maj) 2H, OCH2Ph], [4.69 (s, maj) and 4.51 (s, min), 2H, NHCH2CO], 4.10-
4.40 (m, 5H, CHCH2OCO, NCH2COO), 3.0-3.50 (m, 5H, NHCH2CH2)), 1.76 (s, 3H, CH3)
13C NMR (100 MHz, CDCl3); δ= 169.6, 167.8, 164.8, 156.7, 151.3, 144.2, 141.1, 
136.1, 128.8, 128.6, 1285, 128, 4, 128.2, 127.9, 127.4, 125.4, 120.4, 67.0, 66.3, 48.3, 
12.3.   
LRMS-ES+ (m/z):  calc. for C33H33N4O7 [M+H]+ = 597.2, found 597.21. 
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Synthesis of N-(2-Fmoc-aminoethyl)-N-(thymin-1-yl acetyl) glycine 130 86 
Compound 129 (0.5 g, 1.0 mmol) was dissolved in the minimal amount of an 
acetone:MeOH solution (1:1, v/v). To the resulting solution was added Pd/C (100 
mg) and the reaction flask was placed under an atmosphere of H2 at 0 °C for 1 hour. 
The suspension was stirred at room temperature for a further 2 h. The solvent was 
removed and the residue suspended in MeOH (100 ml). The suspension was filtered 
through celite, and the solvent removed by rotary evaporator to yield the tilted 
compound 130 (0.22, 90%) as white solid, melting point ( mp)= 215-218 °C  [lit.86
mp: 216-219 °C]. 
1H NMR (400 MHz, CDCl3) (two rotational isomers observed); δ= 11.2 (s, 1 H), 7.9 (d, 
J=7.3 Hz, 2H Ar-H), 7.68 (d, J=7.3 Hz, 2H, Ar-H), 7.20-7.48 (m, 5H, Ar-H and thyminy-
C(6)-H), [4.69 (s, maj.) and 4.51(s, min), 2H, NCH2COO] 4.4-4.10 (m, 5H, CHCH2OCO, 
NCH2CON), 3.5-3.1(m, 5H, NHCH2CH2), 1.76 and 174 (s, 3H, CH3).
13C NMR (100 MHz, DMSO-d6) (two rotational isomers observed); δ= 168.1 and 
167.7, 164.9, 156.8 and 156.5, 151.5, 144.3, 142.6, 141.15, 128.1, 127.5, 125.7, 
120.5, 108.58, 65.98, 48.2 and 47.1, 12.38 and 12.33. 
LRMS-ES+ (m/z):  calc. for C26H26N4O7 [M+H]+ = 506.2, found 506.205. 
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6.2 Solid phase PNA synthesis
Monomers and reagents for solid phase PNA synthesis  
Standard Fmoc/Bhoc protected PNA monomers were purchased from Link 
Technologies. Fmoc-Lys (Boc)-OH, HATU and NMP reagent were purchased from 
Novabiochem. 2,6-Lutidine, DIPEA (N,N-diisopropylethylamine), acetic anhydride 
were obtained from Sigma-Aldrich. Piperidine, m-cresol and TFA were purchased 
from Fisher scientific. 
Reversed-phase high-performance liquid chromatography (RP-HPLC) 
RP-HPLC chromatograms was recorded on a Merck-Hitachi La Chrom D-7000 series 
instrument with a Merck reverse phase C18 E column (4.6 × 100 mm) and a UV 
diode array detector which was set at 260 nm. The column was set at 30 °C with 
flow rate 0.5 ml/min. The analysis was performed on the mobile phase consisting of 
H2O (A) and MeCN (B) acidified with 0.1 % TFA. Gradient elution from 95% to 5% 
water in 30 minutes. 
Ultra-high performance liquid chromatography-mass spectrometry  (UPLC-MS)  
Mass spectra of the synthesised PNA oligomers were recorded at the Cardiff 
University, UK using positive ESI mode on a Waters Synapt G2-Si spectrometer with 
Acquity UPLC and an Acquity UPLC BEH C18 column (50 × 2.1 mm; 1.7 μm). 
General Procedure for Synthesis of PNA oligomers
Resins preparation 
In the current study, two different Fmoc-protected resins Rink Amide MBHA resin 
(Substitution 0.34 mmole/g) and Azido-Nova Tag (Substitution 0.35 mmole/g) were 
used in the synthesis of the target modified PNA oligomers. The appropriate resin 
was added to a fritted plastic vessel. The outlet of the syringe was connected to a 
membrane pump via a collecting tank. NMP was added for resin swelling and left at 
least two hours before the solvent was removed by vacuum filtration. 
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Fmoc-deprotection/Coupling-activation/Capping cycle  
For Fmoc removal, a solution of piperidine in NMP (20% v/v) was added and shaken 
for 10 min at room temperature. The solvent was removed by vacuum filtration, 
and this step was repeated. The resin was then washed with NMP (3 × 2 min). To a 
solution containing the required monomer (4 eq.) and HATU (4.5 eq.) in NMP was 
added a solution of DIPEA (10 eq.) and 2,6-lutidine (10 eq.). The resulting solution 
was mixed for five min. before being added to the reaction vessel containing the 
resin bound free amino function. The resulting solution was shaken for 60 min at 25 
°C. The solvent was removed by vacuum filtration, and the resin beads were washed 
with NMP. Followed by addition of a solution of a mixture of acetic anhydride (5 
µL), lutidine (6 µL) and NMP (85 µl). The resulting solution was shaken for 10 min. at 
room temperature, filtered and washed efficiently with NMP. This 
deprotection/coupling/capping cycle was repeated for all building blocks until the 
required PNA sequence was synthesised. 
Finally, for removal of the N-terminal Fmoc group and drying the resin-bound PNA 
oligomers, a solution of piperidine in NMP (20% v/v) was added and shaken for 10 
min. at room temperature. The solvent was removed by vacuum filtration, and this 
step was repeated. The resin was the washed three times with each of NMP, 
chloroform methanol and diethyl ether and finally dried in vacuo. 
Cleavage of the PNA oligomer from resin and deprotection of side chains  
To the resin-bound PNA oligomer was added a solution (1 ml) of a mixture of TFA 
(95%), water (2.5%) and m-cresol (2.5%). The resulting mixture reaction was shaken 
for two hours at room temperature. The filtrate was then collected, and the resin 
was washed with TFA (200 µl). All cleavage solutions were combined and 
concentrated to about the 0.5 ml under a stream of nitrogen gas. Diethyl ether (1.5 
ml) was added to induce the precipitation of the PNA oligomers. The sample was 
centrifuged at 4 °C for 10 minutes at 11000 rcf.  The ether was carefully decanted 
without removing any precipitated PNA. The precipitate was re-suspended in 
diethyl ether and centrifuged three more times. The PNA oligomers were dried 
under vacuum and then dissolved in 1 ml of a mixture of H2O/ACN (1:1). All the 
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crude samples were purified by HPLC and characterised by mass spectrometry. 
Purifications of the synthesised PNA oligomers 
The crude PNA oligomers were purified by RP- HPLC with UV detection at 260 nm. 
Semi-prep column C18 (5 µm, 250 × 10 mm, Jupiter Phenomenex, 300 Å) was 
utilized, eluting with water + 0.01% TFA (eluent A) and acetonitrile + 0.01% TFA 
(eluent B); elution gradient: from 95% A to 95% B in 25, flow: 1 ml/min. The 
resulting pure PNA oligomers were characterized by LCMS-ESI with gave positive 
ions consistent with the final products. 
PNA oligomer 131 
Chemical Formula: C86H111N41O27, Exact Mass: 2149.9, Molecular Weight: 2151.1 
RP-HPLC, retention time: 8.71 min 
ESI-MS: m/z = found 1076.0 (calc. 1075.95; [M+2H]2+), found 717.9 (calc. 717.6; 
[M+3H]3+), found 538.7 (calc. 538.475; [M+4H]4+), found 431.1 (calc. 430.98; 
[M+5H]5+). 
PNA oligomer 132 
Chemical Formula: C89H114N44O27, Exact Mass: 2230.9, Molecular Weight: 2232.2 
RPHPLC retention time: 9.33 
ESI-MS: m/z = found 1116.9 (calc. 1116.45; [M+2H]2+), found 744.8 (calc. 744.6; 
[M+3H]3+), found 559.0 (calc. 558.7; [M+4H]4+). 
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PNA oligomer 133 
Chemical Formula: C95H126N46O28, Exact Mass: 2359.0, Molecular Weight: 2360.3 
RPHPLC retention time: 8.63 
ESI-MS: m/z = found 1180.5 (calc. 1180.5; [M+2H]2+), found 787.6 (calc. 786.3; 
[M+3H]3+), found 591.0 (calc. 590.75; [M+4H]4+), found 473.0 (calc. 472.8; 
[M+5H]5+). 
PNA oligomer 134 
Chemical Formula: C93H121N45O28, Exact Mass: 2315.9, Molecular Weight: 2317.3 
RPHPLC retention time= 13.12 
ESI-MS: m/z = found 1159.8 (calc. 1158.95; [M+2H]2+), found 773.4 (calc. 772.96; 
[M+3H]3+), found 580.3 (calc. 579.97; [M+4H]4+), found 462.8 (calc. 464.1; 
[M+5H]5+). 
PNA oligomer 135 
Chemical Formula: C99H133N47O29, Exact Mass: 2444.0, Molecular Weight: 2445.5 
RPHPLC retention time: 12.61 
ESI-MS: m/z = found 1223.5 (calc. 1223.0; [M+2H]2+), found 816.3 (calc. 815.6; 
[M+3H]3+), found 612.2 (calc. 612.0; [M+4H]4+). 
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PNA oligomer 136
Chemical Formula: C93H122N46O28, Exact Mass: 2331.0, Molecular Weight: 2332.3 
RPHPLC: Retention time = 9.09  
ESI-MS: m/z = found 1167.0 (calc. 1166.5; [M+2H]2+), found 778.4 (calc. 778.0; 
[M+3H]3+), found 584.1 (calc. 583.75; [M+4H]4+). 
Azide functionalised PNA oligomer 137 
Chemical Formula: C115H149N67O28; Exact Mass: 2916.2; Molecular Weight: 2917.9 
RPHPLC: Retention time = 9.28  
ESI-MS: m/z = found 1459.3 (calc. 1459.1; [M+2H]2+), found 973.4 (calc. 973.06; 
[M+3H]3+), found 730.3 (calc. 730.1; [M+4H]4+), found 584.5 (calc. 584.24; 
[M+5H]5+), found 487.2 (calc. 487.03; [M+6H]6+), found 417.8 (calc. 417.6; 
[M+7H]7+). 
Azide-alkyne functionalised PNA oligomer 138  
Chemical Formula: C116H150N54O36, Exact Mass: 2875.2, Molecular Weight: 2876.8 
RPHPLC: Retention time = 9.9  
ESI-MS: m/z = found 1438.8.0 (calc. 1438.6; [M+2H]2+), found 959.8 (calc. 959.4; 
[M+3H]3+), found 720.0 (calc. 719.8; [M+4H]4+), found 576.3 (calc. 576.04; 
[M+5H]5+), found 480.1 (calc. 480.2; [M+6H]6+). 
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Alkyne functionalized PNA oligomer 139 
Chemical Formula: C115H146N56O34, Exact Mass: 2855.1, Molecular Weight: 2856.8 
RPHPLC: Retention time = 10.51  
ESI-MS: m/z = found 1429.0 (calc. 1428.55; [M+2H]2+), found 953.1 (calc. 952.7; 
[M+3H]3+), found 715.1 (calc. 715.77; [M+4H]4+), found 572.4 (calc. 572.02; 
[M+5H]5+), found 477.2 (calc. 476.85; [M+6H]6+). 
6.3 UV-Tm measurements
Samples preparation 
DNA and RNA sequences were purchased from Sigma-Aldrich Company (Table 6.1). 
Table 6.1: Physical data of nucleic acids that were used in the Tm -UV spectroscopy 
experiments.  
Oligo 
name 
Sequences 
(5’-3’)
Pur Mw Tm µg nmol µl for 
100 
µM
DNA1 AGAAAGTC HPLC 2443 15.0 87.5 35.8 358
DNA2 AGAACAGTC HPLC 2732 19.0 34.1 12.7 125
RNA AGAAAGUC HPLC 2557 8.9 255.1 99.7 997
PNA oligomers were prepared in our lab. Stock solutions of PNA oligomers, DNA and 
RNA, were prepared in distilled water, and their concentrations were determined 
on the basis of absorbance from the molar extinction coefficient of corresponding 
nucleobases i.e. C = 6.6, T = 8.6, A = 13.7 and G = 11.7 [(mmol)-1 cm-1] following Beer 
Lambert’s Law (A = εcl).  Phosphate buffer was prepared by mixing both potassium 
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phosphate monobasic (KH2PO4), sodium phosphate dibasic (K2HPO4) buffers and 0.1 
mM NaCl in amounts appropriate for the desired pH= 7.0. PNA complexes with the 
antiparallel complementary nucleic acid oligomers were prepared by mixing 
stoichiometric quantities (1:1) of the involved oligomers with the DNA or RNA 
sample in 1 ml buffer of 10 mM sodium phosphate and 10 mM NaCl, at pH 7.0. The 
samples were annealed at 90 °C in a heat block for 5 min followed by slow cooling 
to 4 °C slowly over one hour and then were transferred to quartz cuvette, sealed 
with a Teflon stopper.  
All UV melting experiments were performed on Shimadzu UV-2600 UV-Visible 
Spectrophotometer equipped with a heat controller. The absorbance at 260 nm was 
recorded in steps from 5-65 °C. Nitrogen gas was purged through the cuvette 
chamber below 20 °C to prevent the condensation of moisture on the cuvette walls. 
All measurements were recorded three times. Cuvette of 1.0 cm path length and 
1.0 ml volume was used for all experiments.   
The absorbance at 260 nm was plotted as a function of the temperature. The Tm
values were obtained from average of the mid-points of the three sigmoidal 
thermal stability curves for each duplex with calculated the standard deviation for 
these measurements. 
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Appendix 1: HPLC Chromatogram and mass spectrum of PNA oligomer 131 
Finger 1: HPLC chromatogram of PNA oligomer 131. 
Figure 2: Mass spectrum of PNA oligomer 131. 
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Appendix 2: HPLC Chromatogram and mass spectrum of PNA oligomer 132
Figure 3: HPLC chromatogram of PNA oligomer 132. 
Figure 4: Mass spectrum of PNA oligomer 132.
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Appendix 3: HPLC Chromatogram and mass spectrum of PNA oligomer 133 
Figure 5: HPLC chromatogram of PNA oligomer 133. 
Figure 6: Mass spectrum of PNA oligomer 133. 
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Appendix 4: HPLC Chromatogram and mass spectrum of PNA oligomer 134 
Figure 7: HPLC chromatogram of PNA oligomer 134. 
Figure 8: Mass spectrum of PNA oligomer 134. 
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Appendix 5: HPLC Chromatogram and mass spectrum of PNA oligomer 135 
Figure 9: HPLC chromatogram of PNA oligomer 135. 
Figure 10: Mass spectrum of PNA oligomer 135. 
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Appendix 6: HPLC Chromatogram and mass spectrum of PNA oligomer 136 
Figure 11: HPLC chromatogram of PNA oligomer 136. 
Figure 12: Mass spectrum of PNA oligomer 136. 
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Appendix 7: HPLC Chromatogram and mass spectrum of PNA oligomer 137 
Figure 13: HPLC chromatogram of PNA oligomer 137. 
Figure 14: Mass spectrum of PNA oligomer 137. 
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Appendix 8: HPLC Chromatogram and mass spectrum of PNA oligomer 138 
Figure 15: HPLC chromatogram of PNA oligomer 138. 
Figure 16: Mass spectrum of PNA oligomer 138.
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Appendix 9: HPLC Chromatogram and mass spectrum of PNA oligomer 139 
Figure 17: HPLC chromatogram of PNA oligomer 139. 
Figure 18: Mass spectrum of PNA oligomer 139.
